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“Words are the source of misunderstandings.”
A. de Saint-Exupéry, The Little Prince
Chapter 1
12
INTRODUCTION
This thesis is a burden of illness study that will focus on the overall problem statement 
‘What is the individual, interpersonal and societal impact of Attention Deficit 
Hyperactivity Disorder (ADHD) in terms of quality of life and societal costs related 
to response to treatment?’. This introduction will explain what ADHD is and how 
ADHD is linked to children’s general development. Following, treatment options for 
ADHD will be discussed with a focus on treatment compliance and accompanied 
functioning of the child. The introduction will further describe the concepts quality 
of life (QoL) and societal cost calculation. 
1.1 HISTORY OF ADHD AND DIAGNOSTIC CRITERIA
ADHD is a neurodevelopmental disorder in children and adolescents and is highly persistent into adult age 1,2. As with virtually all psychiatric disorders, no single diagnostic test is available to establish the diagnosis 3. The knowledge of the neurobiological and genetic factors that are assumed to contribute to ADHD has increased rapidly over the last decades, but using neurobiology for diagnosis or 
classification of ADHD is not (yet) possible 4,5. The diagnosis of ADHD is based on 
a combination of behavioral signs and symptoms. One of the first descriptions of ADHD-like behavior dates back to 1865 in a poem by the German physician Heinrich Hoffman 1. One of his poems based on observations in clinical practice is called ‘Fidgety Phil’ and describes a young boy with hyperactive symptoms 1. Most scientific credit for being the first to publish on behavioral conditions that most closely relate to current ADHD symptoms is awarded to the British physician Briton George Still in 1902 6. His descriptions refered to problems with among others sustained attention, a proneness to accidental injuries, and greater incidence in males. 
 During the sixties, almost fourty different names were circulating throughout the world to describe the current ADHD diagnosis 7. This changed when the third Diagnostic and Statistical Manual for Mental Disorders (DSM-III) was introduced in 1980 by the American Psychiatric Association (APA). DSM and DSM-II were practically unused outside the United States (US), but DSM-III was accepted 
worldwide. A second classification system is the International Classification of 
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Disease (ICD) of the World Health Organisation (WHO) with the first issue including morbidity in 1948 8. ICD presented its newest version, ICD-11, in June 2015 9,10. 
However, the most commonly used classification system for mental disorders in 
Europe is DSM due to the specific focus on mental health and the level of detail. Table 1 provides an overview on DSM criteria for ADHD over time. DSM is not the perfect instrument and subject to regular changes due to new insights, but it does offer uniformity and clarity in discussion on a combination of symptoms 11.  Until 2013, the revised fourth edition of the DSM (DSM-IV-TR) was the leading diagnostic manual for ADHD and therefore was the leading manual while conducting this study 12. Table 2 shows the DSM-IV-TR criteria for ADHD. In 2013, 
the fifth edition of the DSM was published (DSM-5). For ADHD specifically there were minor changes. The 18 ADHD symptoms were nearly unchanged, but for 
all criteria examples were provided of these symptoms at different ages. Age of 
onset of the first ADHD symptoms and impairment was changed from seven to twelve years, since there was no thorough evidence for a cut-off at age seven. The threshold for meeting the diagnostic criteria for ADHD has been lowered slightly 
from six to five symptoms to improve the diagnosis of older adolescents and 
adults based on findings of impaired functioning in adults when four symptoms are present 13. Also, the three subtypes inattention, hyperactivity and impulsivity turned out to be unstable over time. The subtypes were changed to presentations of ADHD but the presentations do refer to the former subtypes 14,15. A fourth ADHD 
presentation (restrictive inattentive presentation) was added referring to explicit 
inattentiveness (at least six symptoms of inattentiveness and no more than two hyperactive/impulsive symptoms). 
1.1.1 Epidemiology, aetiology and comorbidity
The worldwide-pooled prevalence of ADHD in children and adolescents (≤18) is 5.3%; a recent meta-analysis concluded that the predominantly inattentive subtype is the most common 2,16-18. Age and gender are significantly associated with prevalence rates, with higher incidence in school-age children and males 17. Evidence suggests symptoms to decline with age in 65% of the affected individuals, but only 15% of children with ADHD show full remission in early adulthood. The prevalence of ADHD in adults ranges between 2.5% and 4.4% depending on inclusion criteria for meta-regression 19-21. A prospective sample of twin pairs 
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indicated a sharp linear decrease of hyperactive/impulsive symptoms between 
eight and sixteen years, but the linear decrease in inattentive symptoms was less pronounced 22. Studies have identified a robust genetic contribution to the disorder with heritability between 70% and 80% 1,23-27. Approximately 40% of this heritability can be ascribed to several common genetic variants 28. Environmental risk factors that are associated with ADHD are maternal smoking and alcohol use, 
premature birth, low birth weight and exposure to toxins 29,30. Studies on cognition 
and brain mechanisms in ADHD show that ADHD is characterized by deficits in multiple, independent cognitive domains and by abnormalities of multiple 
neural structures and functions. For example, neuroimaging studies show various brain volumetric alterations in ADHD patients 24,31,32. However, the effects of the individual genetic and environmental risk factors are small and gene-environment interactions might be the main aetiological mechanism underlying ADHD 33.
 Comorbidity is often present, in particular with oppositional defiant disorder 
(ODD), conduct disorder (CD), learning disability (LD, e.g. dyslexia and dyscalculia), 
autism spectrum disorder (ASD), mood/anxiety disorder, and substance use disorder (SUD) 34-39. Also, a recent meta-analysis provides evidence for a significant association between ADHD and obesity 40. The explanation for these comorbidities 
lies in shared genetic influences among these disorders based on family and twin studies 33. 
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Table 1. DSM criteria for ADHD over time
 
DSM VERSION CRITERIADSM 1952 41 * No reference to ADHD-like behavior. 
DSM-II 1968 42 * Inclusion of the concept ‘Hyperkinetic reaction of childhood’.* Definition: The disorder is characterized by overactivity, restlessness, distractibility, and short attention span, especially in young children; the behavior usually diminishes by adolescence.
DSM-III 1980 43
* Change to Attention Deficit Disorder (ADD) (with or without hyperactivity).* Predominant focus on hyperactivity was shifted towards the attention deficit.* Three separate symptom lists for inattention, impulsivity, and hyperactivity based on 16 diagnostic items.* Onset before the age of 7.
DSM-III-TR 1987 44
* Change to Attention Deficit Hyperactivity Disorder (ADHD).* The subtype ‘ADD without hyperactivity’ was removed and assigned to a residual category named ‘undifferentiated ADD’.* Characteristics: hyperactivity, impulsivity and attention deficit.* One list of symptoms with a single cutoff score based on 14 diagnostic items.* Onset before the age of 7.
DSM-IV  1994 45 
* Attention Deficit Hyperactivity Disorder (ADHD).* It was recognized that ADHD was not exclusively a childhood disorder: 
inclusion of examples of workplace difficulties in the depiction of symptoms.* Possibility of a diagnosis of a purely inattentive form.* The heterogeneous category of ADHD in DSM-III-R was subdivided into three subtypes: predominantly hyperactive / impulsive, predominantly attention 
deficit, or combined based on 18 diagnostic items.* Onset before the age of 7.* Impairment present in >2 settings (e.g. at school/work and at home). 
DSM-IV-TR 2000 12 * Text revision, no changes vs. DSM-IV.* Criteria for ADHD listed in table 2.
DSM-5  2013 46
* Attention Deficit Hyperactivity Disorder (ADHD). * More examples on presentation of symptoms at different ages.* Three subtypes changed to ‘presentations’ of ADHD based on 18 diagnostic items with a fourth presentation of mainly inattentiveness based on >6 inattentive and <2 hyperactive symptoms.* Impairment in at least two settings replaced by symptoms in at least two settings.* Age of onset changed from 7 to 12 years of age.* Comorbidity with Autism Spectrum Disorder is allowed to be classified.
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Table 2. DSM-IV-TR criteria for ADHD
A. Either 1 or 2: 1. Inattention: six (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level: 
Inattentiona. Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities.b. Often has difficulty sustaining attention in tasks or play activities.c. Often does not seem to listen when spoken to directly. d. Often does not follow through on instructions and fails to finish school work, chores, or duties in the workplace (not due to oppositional behavior or failure to understand instructions). e. Often has difficulty organizing tasks and activities.f. Often avoids, dislikes, or is reluctant to engag  in tasks that require sustained mental effort (such as schoolwork or homework). g. Often loses things necessary for tasks or activities (e.g. toys, school assignments, pencils, books, or tools).h. Is often easily distracted by extraneous stimuli.i. Is often forgetful in daily activities. 2. Hyperactivity-impulsivity: six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity a. Often fidgets with hands or feet or squirms in seat. b. Often leaves seat in classroom or in other situations in which remaining seated is expected. c. Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults may be limited to subjective feelings of restlessness). d. Often has difficulty playing or engaging in leisure activities quietly. e. Is often “on the go” or often acts as if “driven by a motor”. f. Often talks excessively.
Impulsivityg. Often blurts out answers before questions have been completed. h. Often has difficulty awaiting turn. i. Often interrupts or intrudes on others (e.g. butts into conversations or games).
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 years. 
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] and at home). 
D. There must be clear evidence of clinically significant impairment in social, academic, or occupational functioning. 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another mental disorder 
(e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorders, or a Personality Disorder).
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1.1.2 ADHD in today’s societyADHD is often debated in the media. Newspapers publish about ‘the ADHD hype’, TV shows spend broadcasts on the topic, and political parties ask questions in parliament about the rising incidence of ADHD and increased use of ADHD treatment 11,41-49. Although the inattentive subtype is the most common, the general focus lies on the hyperactive and impulsive behavior and trouble that children with ADHD cause 1-3,11. Furthermore, annoyance is expressed regarding the medicalisation of society and many suggestions have been put forward for the increase of medication use which is pronounced as undesirable 6,11. One opinion is that ADHD behaviour (hyperactive, easy to distract, acting impulsively) is just part of being a young child. 
However, simply stating that ADHD is non-existing does no justice to children with ADHD and their parents and will only contribute to stigma 1. On the other hand, the number of ADHD diagnoses and ADHD medication prescriptions are rising 11. 
Several explanations exist for the apparent increase in the prevalence of ADHD and the increase in the use of medication. First of all, the awareness of ADHD has increased over the last decades. Clinicians are trained to recognize the symptoms of ADHD and initiate treatment. Also an increasing number of parents and teachers 
are aware of the burden of ADHD and the beneficial effects of treatment. ADHD 
has a significant effect on a child’s life and it is now recognized as a disorder which causes severe problems for children, adolescents and adults that suffer from ADHD symptoms, as well as their peers, family and society as a whole. As a result, the increased prevalence is most likely to be an increase in the administrative prevalence, caused by improved diagnostic procedures and increased awareness amongst health care professionals. Yet, the public debate seems to distract attention from the actual public health and societal implications of ADHD. 
1.2 CHILDREN’S DEVELOPMENT AND ADHD
ADHD is a risk factor for the steady development of a child 11. Irrespective of ADHD, 
every individual develops in a complex environment of relationships. Different 
models exist on children’s biologic, social and cognitive development. 
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1.2.1 Development according to BronfenbrennerA model linking biologic and environmental levels of development is the ecological systems theory from Urie Bronfenbrenner 50. Bronfenbrenner’s theory explains how multiple interpersonal factors affect a child’s development and presents elements that can either curb or speed up this development (Figure 1) 50. 
Figure 1. Bronfenbrenner’s ecological systems theory 50
As depicted by the ecological systems theory, the relation between a child’s development and the environment is multifactorial in any case. When linking ADHD to this model it shows that all systems of the model are affected and/or 
influenced by ADHD: school, family, neighbours and peer interaction are involved, 
and mass media is involved putting pressure on parents that can influence the 
child in turn. Scientific studies on ADHD paint the same picture over time: ADHD impacts the child’s development and is related to a large burden in his or her environmental systems. 
1.2.2 Impact of ADHDTable 2 highlighted the DSM-IV-TR criteria for ADHD. Many studies have been performed on the further impact of ADHD and based on the current available 
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evidence figure 2 is contructed. Figure 2 shows that there are short- and long-term consequences in childhood through adolescence into adulthood and the burden transfers from the personal to a societal level. Comorbidity can be present and can increase the impact of ADHD. 
Figure 2. Impact of ADHD 1,34,35,51-66 
ADHD has an impact on social interaction and relations throughout life and has a 
significant influence on the life of household members, peers and teachers 59,66. The 
economic burden of ADHD is high due to need for extra lessons or special classes and is linked to decreased educational outcomes. In practice, indeed problems in school often bring the child with ADHD to clinical attention 67. As school is an 
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important basis for life, it is relevant to further study the specific factors that are associated with ADHD and decreased educational outcomes. Further economic burden is caused by decreased work opportunities for parents or caregivers (the spillover health effect). Several studies concluded that ADHD is associated with substance abuse, delinquency and a risk for injuries and increased health care visits and more accidents 51-57,62-65. A recent review even highlighted an excess mortality in ADHD mainly driven by deaths due to accidents 58. Later in life, ADHD is a risk factor for domestic violence 60.  The available evidence on ADHD burden is scattered, isolated to single elements and often based on small samples. Also, most studies on the burden 
of ADHD have focused on the directly observable consequences, for example a demanding child that distracts other children in the classroom. However, consequences of ADHD are broad and present at the short- and long-term at 
several levels as shown in figure 2 1,3,61. There is a need for a broad view on the burden of ADHD to provide a comprehensive overview of the burden. Especially in case of health policy making and health care provision it is essential to understand the overall burden of ADHD based on a societal perspective to be able to provide appropriate interventions. QoL and societal costs are essential parts in order to study the ADHD burden. These concepts will be further discussed in paragraph 1.5.
1.3 TREATMENT OPTIONS FOR ADHD
Although specific treatment goals will always depend on personal circumstances, in general the goal of any treatment is attainment of remission 68,69. Clinical studies on ADHD have focused on symptom reduction as a measure of treatment success. Nevertheless, in clinical practice, ADHD symptom reduction is just one of the goals 
and the next goal would be to improve functioning in important life domains 68. 
This means, the question is to what extent the symptom reduction translates into a functional improvement described as an improvement in the ability to pursue and enjoy the typical activities of daily living 68. A review of thirteen national and international ADHD guidelines published between 2000 and 2011 from ten medical societies targeting various groups of health care professionals reported on a consensus of a combined approach of non-pharmacological and pharmacological interventions 70. 
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1.3.1 Non-pharmacological interventionsEvidence-based non-pharmacological treatments for ADHD include various sorts of behavioral therapies, the most important and studied one is parent management training 71-73. Recent meta-analyses showed however that the effect of behavioral 
treatment on the core ADHD symptoms became non-significant when using blinded raters 74,75. It has been studied whether ADHD is induced by food and if a strictly supervised, individually constructed restricted elimination diet (RED) has an effect on behavioral problems 76. The response on the publication of the effects 
of a RED on ADHD was mixed, mainly highlighting that more evidence is needed before diets can be used on a wider scale 77-80. In general it has been concluded that dietary treatments could play a positive, but limited therapeutic role in ADHD management 81. The interventions EEG-neurofeedback (enabling a patient to train him or herself to self-regulate electric brain activity) and cognitive training 
(learning that thoughts influence how a person feels and acts) require further data collection as well before they can be supported as treatments for core ADHD symptoms 74,82. 
1.3.2 Pharmacological interventionsGuidelines describe the pivotal role of medication in the management of ADHD 70,83-85. Due to the chronic nature of ADHD, patients with ADHD typically require long-term pharmacotherapy. Pharmacological treatments for ADHD include 
stimulants (methylphenidate, dexmethylphenidate, mixed amfetamine salts, 
dextroamphetamine and lisdexamfetamine dimesylate) and non-stimulants 
(atomoxetine, guanfacine, and clonidine) 86. As first-line pharmacotherapy the 
recommendations are unanimous for stimulants, confirmed in meta-analysis 
showing the greatest significant effect size on ADHD outcomes 61,70,87-89. Several 
guidelines recommend atomoxetine as a first-line treatment as well, although 
most often when specific comorbidities are present 83. Methylphenidate is the most often prescribed stimulant which acts by blocking the reuptake of dopamine 87,90,91. Findings of a recent systematic Cochrane review on use of methylphenidate for ADHD suggest that methylphenidate improves some of the core symptoms of ADHD and it might also help to improve the QoL of children with ADHD 89. Methylphenidate is available in different strengths and different formulations (short-acting or immediate-release, intermediate-acting and long-acting). Medication intake may 
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require high effort and impose practical difficulties, for example, on children attending school. Amongst others, the long-acting methylphenidate formula has been developed to overcome the practical problems of medication intake and compliance by using a once-a-day treatment scheme 92. In strictly controlled clinical trials, immediate-release and long-acting methylphenidate were found to be equally effective 84. Real-world evidence however showed that long-acting methylphenidate is associated with better treatment continuity and has proven to result in superior compliance in patients when compared with the short-acting formulation 93-95. This superior compliance was associated with improved outcome measured by symptom reduction and reduced hospitalizations 93,95. With respect to safety, methylphenidate is associated with non-serious adverse events as decreased appetite and sleep problems 89. A cohort study in the US on ADHD medication and serious cardiovascular events in children and adults concluded that there is no evidence for an increased risk 96,97. The long-term effects (up to 1 year) of medication on growth, blood pressure and heart rate are limited and the occurrence of suicidal, psychotic and manic symptoms is rare 86. 
1.3.2.1  Long-term treatment effect of pharmacological interventionsIn general, it is recommended to continue ADHD treatment as long as it remains clinically effective 70. The National Institute of Mental Health (NIMH) in the US funded a multisite, multimodal treatment study of children with ADHD, abbreviated as the MTA study to study the long-term effects of different ADHD treatments. The study included a group of 579 children (age 7-9.9) that were assigned to community care (CC), medication management (MM), behavior treatment (BT) or combined MM and BT 98. The most important finding after fourteen months was the superiority of both MM and the MM/BT groups over the BT and CC conditions 98. After the first fourteen months the intensive treatments by protocol were abandoned and a naturalistic, prospective follow-up study of the sample was conducted, where patients could be treated according to their clinical need and preferences. As a group, all MTA participants did better in terms of symptom 
severity (less severe) and impairment of functioning (less impairment) at six and eight years compared to baseline, but at the same time, they did not bridge the gap that separated them from a normative comparison group 99-102. The MTA study results have been interpreted as showing no long-term effects of MM or BT, but 
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interpretation of the MTA findings after fourteen months is complicated by the switch in design from a randomized trial to an observational study and the lack of an untreated ADHD comparison group 99,101-103. In conclusion, the MTA follow-
up studies neither confirm nor reject the importance of long-term medication or behavioral treatment in ADHD 99,100. 
1.4 TREATMENT COMPLIANCE AND FUNCTIONING
In general, the chances that treatment is effective are increased when they are used in the recommended manner. A review on maintenance of response upon discontinuation across medication treatments in ADHD suggested a clinically 
significant benefit with continued long-term pharmacotherapy 104. Continued and compliant treatment results in improved functioning compared to treatment discontinuation. A systematic review of long-term outcome in ADHD and effects of treatment (pharmacological, non-pharmacological, or multimodal) and non-treatment concluded that without treatment, people with ADHD had poorer long-term outcomes in most life areas compared with people without ADHD, and treatment for ADHD improved long-term outcomes compared with untreated ADHD 61. Next to no treatment at all, the effectiveness of current pharmacological treatments is often reduced, due to low treatment compliance resulting in decreased functioning 61,105,106. Concluding, compliance to treatment is essential for good treatment outcomes in ADHD 95,105,107.
1.4.1 ComplianceDifferent terminology is used when it comes to describing the correct follow-up of medical advice: compliance, adherence and concordance 108. The terminology used 
reflects the changing relationships between patients and health care professionals 108. Compliance is defined as: following a treatment regimen as prescribed by the doctor (correct timing, dosing, and frequency) 108. Both adherence and concordance 
relate to a situation where prescribing is based on partnership and reflecting a range of factors related to compliance. This study will use the term ‘compliance’ since no insight is provided in the reasons of suboptimal medication intake that could 
be reflected in adherence or concordance. Next to the aforementioned decreased 
clinical benefits, poor compliance to ADHD medication has been associated with 
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impairment of the family process as well 109. A population based case registry study from Sweden shows that periods of medication use are associated with diminished delinquent and rule breaking behavior, and non-use of medication is associated with return to illegal activities 110. Irrespective of the negative consequences of non-
compliance, it turns out that being compliant to treatment is difficult for patients in all disease areas and intervention types. Children with psychiatric disorders may be at even greater risk for poor compliance 95. More specifically, the problem of non-compliance has been described as an obstacle in ADHD treatment 95,111. To better understand the theoretical basis of compliance and why being compliant 
to treatment turns out to be so difficult, the Integrated Model for explaining motivational and behavioral change (the I-Change Model) is described. Health behavior as treatment compliance can be described by the I-Change Model 112. The I-Change Model states that behavior is determined 
by a person’s motivation. Information factors (the quality of explanation of the doctor and other channels and sources used) are at the start of the model together with the predisposing factors (an aspect associated with an increased likelihood of (not) following treatment) such as behavioral factors (e.g. irregular life style), psychological factors (e.g. personality) and cultural factors (general opinion on medication use) 112. The main determinant of behavior, a person’s motivation, is built from three factors: Attitude (the perceived 
cognitive and emotional advantages and disadvantages), social influences 
(perception of others) and self-efficacy (perception of the capability to comply).  The I-Change Model assumes that the motivational factors attitude, social 
influences and self-efficacy are influenced by various awareness factors (e.g. knowledge about ADHD and the reason for treatment prescription, or the risk perception of side effects). 
 Studies on the specifics of compliance to medication for ADHD found several predictors of increased and decreased compliance. Related to good compliance were amongst others two-parent families, a good relationship with the doctor, the combined ADHD subtype (Table 2), and use of long-acting formulations 95,105. 
The Canadian guidelines even propose only long-acting strategies as a first-line treatment over the available short-acting interventions 113. Factors related to decreased compliance were a higher age at time of diagnosis, use of short-acting 
formulations, and the experience of side effects 95,105. The overall conclusion is 
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that compliant behavior is related to multiple causes. This study will focus on the impact of non-compliance to ADHD treatment in real-life for children from a broad perspective in order to provide insight in the health problem and accompanied recommendations for health policy. 
1.4.2 Functioning 
The relationship between ADHD symptoms and impaired functioning is complex. Any of the symptoms can lead to decreased functioning whereas a form of functional impairment may be the outcome of several symptoms 69. From a clinical 
perspective, it is expected to first observe improvement in symptoms followed by functional improvement 69. As described above, most clinical studies in ADHD have 
focused on symptom reduction as a measure of efficacy of a specific treatment, 
but the question to what extent the symptom reduction translates into functional improvement is at least as relevant 83,113,115. This functional improvement provides the patient amongst others with the ability to enjoy daily life, achieve good grades and be a pleasant family member. Since inclusion of both short-term and long-term effects is necessary to capture all relevant aspects of the burden of suboptimal 
treatment use, a definition should therefor include a reference to functioning 68. In this study, the concepts of compliance (C) and functioning (F) together were 
defined as ‘response to treatment’. The different chapters will further specify the operationalisation of these concepts.
1.5 HEALTH TECHNOLOGY ASSESSMENT (HTA)
HTA is a method to obtain a systematic and overall insight in a certain health issue and interventions in order to support decision-making and resource allocation 116.  The main purpose of conducting a Health Technology Assessment (HTA) is to inform a policy decision making. HTA came to attention in the 80’s when technologies as heart and liver transplants were introduced. HTA aims to assess epidemiological implications, medical effectiveness, social characteristics, ethical 
implications, and financial/economic aspects in one comprehensive evaluation 116,117. During the years, HTA is increasingly used as a tool to assist in decisions on reimbursement of new medical technologies 118. One part of the HTA that is most often performed and crucial for the outcome of the HTA is the economic evaluation 
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of alternative interventions in a cost-effectiveness analysis (CEA) including QoL and cost data 118,119. To optimize cost-effectiveness analyses, actual and well-defined data on utilities and costs (medical and non-medical) are needed.
1.5.1 Quality of life QoL is considered to be an important measure in public health research and for the (economic) evaluation of medical interventions. Evaluation of QoL has become increasingly important in health care, because it describes the well-being of patients and is an important supplement to traditional or biological measured 
health status. QoL is an elusive concept, and many definitions have been issued 
during the years reflecting that individuals differ in what they find important which might evolve over the years as well 120. Next to QoL, the term health-related QoL was introduced (HRQoL), nevertheless there is not always a clear distinction between health-related and nonhealth-related QoL 121. Moreover, in case of chronic conditions as ADHD all life areas are impacted and therefore become health-related 121. When discussing QoL in this thesis, it refers to all aspects of life and as such refers to health-related QoL as well 121,122. A causal model including the most 
common approaches to assess QoL is shown in figure 3 121. 
Figure 3. Model of Ferrans et al. on quality of life 121 
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The Ferrans’ model is an adapted version of a previous model by Wilson and Cleary and is recommended as the best QoL model available today 123,124. The changes to 
the Wilson and Cleary model are mainly the exclusion of non-medical factors as a separate item as this is included in the other items, a link from individual and 
environmental characteristics to biological function and exclusion of labels on the arrows since they tended to restrict characteristics of the relationship 121. The 
final outcome of the causal model is overall QoL which is defined as how happy or 
satisfied a person is as a whole which is related to all model variables. This model 
further confirms the aforementioned reasoning from symptoms and functioning to overall QoL. Two systematic reviews show that ADHD has a negative impact on QoL of ADHD patients 62,125. The need for further research on QoL in ADHD and the relationship between ADHD and impact on families rather than only patients has been stressed 83,125,126. Several questionnaires to measure QoL are available, and 
the choice of an instrument depends on the study aim, for example to evaluate treatment effect 124,127,128. 
1.5.2 Quality of life measurement 
No specific QoL questionnaire for ADHD exists. Two of the mostly used generic QoL instruments in children are the CHQ (Child Health Questionnaire) and the Paediatric Quality of Life Inventory (PedsQL), both validated 129,130. Generic instruments aim to be applicable to a wide range of conditions and interventions. Although relevant, the short CHQ parent-report questionnaire still consists of 28 items (CHQ-PF28) and the PedsQL has 23 items. A generic QoL instrument that was developed to offer a short questionnaire useful for public health and clinical studies which would help to reduce response burden is KIDSCREEN-10 (KS-10) 131. KS-10 offers the ability to summarize scores into one single value, is useful to detect overall changes in QoL and was assessed to be a valid measure of the general QoL in children and adolescents 132. 
 Child-specific instruments applicable for economic evaluations including preference-based evaluations for health states are the EQ-5D-Youth (EQ-5D-Y) and the Child Health Utility 9D (CHU-9D). However, these instruments were in early stages of development at the start of this study 133,134. A preference based instrument that is able to compare QoL across disease areas is the EuroQol 5-dimension measurement instrument (EQ-5D). Considering the increased use of economic 
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evaluations we aimed to explore this most frequently used QoL instrument in 
HTA studies next to the KS-10, although it was not originally designed for use in children 135-137. The EQ-5D can also be used to evaluate the QoL of the parents. Table 3 provides an overview of the QoL instruments used per group (child or parent) and the dimensions they cover.
 Table 3. QoL measurements for children with ADHD and their parents 131,136
 
CHILD
PAR-
ENT
EQ-5D INSTRUMENT
* Five dimensions with 3 – level response scales.
* Mobility – self-care – usual activities – pain/discomfort – anxiety/depression. Proxy* Proxy*
KIDSCREEN-10 INSTRUMENT
* Ten dimensions using 5 – point response scales.
* physical well-being – psychological wellbeing – mood and emotions – self-perception – autonomy – parent relation and home life – peers and social support – school and environment – 
bullying – financial resources.
X
 
* The parent is asked to answer the questions in such a way that it reflects the rating of the child.
1.5.3 Societal costs and their measurement
Evidence is limited regarding the influence of ADHD treatment response on resource use and economic burden 138. This lack of insight in the health problem is a hindrance for the evaluation of current and future ADHD interventions. In an economic evaluation, different categories of costs can be incorporated in the analysis which is related to the perspective of the analysis. The broadest perspective is the 
societal perspective and is the preferred method and recommended in scientific guidelines 118,139. The societal perspective includes direct and indirect medical costs and direct non-medical costs illustrated in Table 4 118,119.
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Table 4. Costs categories in economic evaluations with the societal perspective 125
INSIDE HEALTHCARE (MEDICAL) OUTSIDE HEALTHCARE (NON-MEDICAL)
Direct costs  E.g. medical consultations or parent training. E.g. remedial teaching after school or diet. Indirect costs * E.g. productivity losses, and special education.
 
* Indirect medical costs are excluded based on general guidelines. This would incorporate all costs of all 
other (unrelated) diseases in life-years gained 145.
1.5.4 Cost-effectiveness analysis (CEA)The economic evaluation CEA includes medical effectiveness, medical safety, costs and QoL 116. The effect measure is often expressed in so-called Quality Adjusted Life-Years, or QALYs. In this case CEA is referred to as cost-utility analysis (CUA). 
A QALY captures both length of life and QoL in a single index 140. According to the Dutch guidelines an economic evaluation should be conducted from a societal 
perspective. In the UK commonly a health care perspective is taken. The exclusion 
of certain cost and benefits will lead to an inefficient allocation of resources and 
might even result in exclusion of new interventions for ADHD that could have a 
societal benefit although it might (slightly) increase direct health care costs. Next, it is arbitrary what costs are included inside healthcare and outside healthcare. A narrow perspective can make it attractive to shift costs to another party and 
therefore excluding it from the economic evaluation 118. The National Institute for 
Health and Care Excellence (NICE) in the UK performed a HTA on methylphenidate, 
atomoxetine and dexamphetamine for ADHD in children and adolescents 141. A review of this HTA concluded amongst others that there remains a need for an evaluation beyond children’s QoL including caregiver burden 142. This conclusion 
fits to the abovementioned view on the need for a broad view on the burden of ADHD. Especially chronic disorders like ADHD request for a broad societal 
perspective, since burden of disease and benefits of treatment could relate to improved QoL beyond the patient. This study adds to current literature on real-life cost and QoL in ADHD patients, which is amongst others of fundamental importance for future cost-effectiveness analyses in order to aid reimbursement decisions.
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1.6 AIM AND OUTLINE OF THE THESISMany studies have been performed to provide insight in isolated components of the burden of ADHD. This study will contribute to a better understanding of the real-life ADHD burden based on a broad societal perspective following the research question: 
 
 
‘What is the individual, interpersonal and societal impact of 
Attention Deficit Hyperactivity Disorder (ADHD) in terms 
of quality of life and societal costs related to response to 
treatment?’ 
With this question, we aim for a screenshot of children diagnosed with ADHD and their parents in a real-world setting (in care as usual) on the association between pharmacological treatment of ADHD and QoL and societal costs. More precisely, we are interested in the effect on QoL and societal costs for children and their parents of either using the medication as prescribed by their physician or not using the medication as prescribed.
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The thesis on the burden of ADHD is divided into three parts, presented in Table 5:
PART I , ‘Quality of life’, explores the validity of two QoL instruments for use in ADHD studies and presents QoL outcomes. 
Chapter 2 specifically focuses on the validity and responsiveness of the generic preference-based EQ-5D and the generic QoL questionnaire KIDSCREEN-10 in children with ADHD considering the increasing use of health economic evaluations of alternative interventions in children and adolescents. 
Chapter 3 presents the association between QoL and treatment response in children with ADHD and their parents in a real-life setting since evidence on the impact of pharmacological treatment on symptoms of ADHD and the QoL of the patient and their family is limited.  
PART II, ‘Societal costs’, describes societal costs related to ADHD and provides insight in factors associated with educational and academic performance in children with ADHD. 
Chapter 4 describes the association between societal costs and treatment response in children and adolescents with ADHD and their parents in a real-life setting. This is relevant since pharmacological treatment is recommended by authoritative 
guidelines, but evidence on its influence on the broader burden of ADHD is limited. 
Chapter 5 focuses on a specific part of ADHD burden. This review tries to identify factors associated with ADHD and educational and academic performance
PART III, ‘Comparison of an ADHD sample and a reference sample’, addresses the question how the data of the real-life ADHD sample as presented in part 1 and 2 relate to a comparison sample out of the general population. 
Chapter 6 provides a comparison of the total ADHD sample compared to population controls to identify the burden of ADHD. 
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Table 5. Outline of the thesisOVERALL RESEARCH QUESTION OF THIS THESIS
 
What is the individual, interpersonal and societal impact of ADHD in terms of quality of life and 
societal costs related to response to treatment?
PART I Quality of life
Chapter 2 An exploration to what extent the EQ-5D and KS-10 are valid instruments for assessment of QoL in children with ADHD and an examination of the compa-rability of the domains captured on the basis of cross-sectional data analysis. 
Chapter 3 A description of the real-life QoL outcomes for children with ADHD and their parents simultaneously and an exploration of the association with response to treatment on the basis of data analysis.PART II Societal costs
Chapter 4 A description of the real-life societal costs for children with ADHD and their parents and the possible association with response to treatment on the basis of data analysis.
Chapter 5 Identification of factors that have been demonstrated to be associated with educational and academic performance in ADHD based on a systematic literature review.PART III Comparison of an ADHD sample and population controls 
Chapter 6 A comparison of retrospective data analysis of a real-life ADHD sample (child and parent) and data of a reference sample reflecting the general public (child and parent).
Chapter 7 Methodological interpretation
Chapter 8 General discussion
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PART I
QUALITY OF LIFE 
“It's not about what it is, it's about what it can become.” Dr. Seuss

Validity and 
responsiveness of 
the EQ-5D and the 
KIDSCREEN-10 in 
children with ADHD
Bouwmans CAM, van der Kolk A, Oppe M, Schawo SJ, Stolk E, van Agthoven M, Buitelaar JK, Hakkaart-van Roijen L. Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD. Eur J Health Econ 2014;9:967-77
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ABSTRACT
Background: The aim of our study is to compare the validity of a generic preference-based Quality of Life (QoL) instrument for adults to that of a generic 
child-specific QoL instrument in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). 
Methods: EQ-5D and KIDSCREEN-10 data were collected using a questionnaire survey performed among parents with a child or adolescent diagnosed with ADHD. The measurements were compared to assess (dis)similarities of the instruments’ constructs and responsiveness to different health states. Principal component 
analysis (PCA) with varimax rotation was used to identify factors underlying the 
constructs of both instruments. Instruments’ index scores of respondents with 
different treatment and comorbidity profiles were compared using Student’s t-tests. Cohen’s effect sizes were calculated for an indirect comparison of the instruments’ responsiveness and discriminating ability. Separate analyses were performed in children aged 8–11 and 12–18 years. 
Results: A strong relation was found between the EQ-5D and KIDSCREEN-10 index scores. However correlations between EQ-5D and KIDSCREEN-10 items were 
moderate or low. The PCA identified five separate factors of quality of life. A physical 
and a mental factor included a combination of three EQ-5D dimensions and six KIDSCREEN-10 items; the remaining EQ-5D and KIDSCREEN-10 items constituted complementary factors without any overlap between the separate instruments. 
Scores of both instruments differed significantly according to respondents’ 
response to treatment and comorbidity profile. Cohen’s effect sizes indicated comparable results of the instruments’ responsiveness and discriminative ability.
Conclusions: The results highlight that the instruments measure different constructs of QoL in children with ADHD. Despite this, the analyses showed comparable responsiveness and discriminative ability of the  instruments. These results suggest that for economic evaluations, the EQ-5D is an appropriate and valid instrument for measuring QoL in children.
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2.1 BACKGROUND
Quality of life (QoL) is considered to be an important measure in public health research and for the (economic) evaluation of alternative medical interventions.  Additionally, the comprehensive assessment of health status or QoL, including physical, psychological and social dimensions, is increasingly required for interpreting clinical outcomes from the perspective of the patient on his/her general functioning. The advantage of the application of generic measures is that they allow comparisons across different disorders, severities of disease, interventions, and demographic groups.  One of the most commonly used generic measures in economic evaluations 
is the EQ-5D, which describes a patient’s health state in terms of five separate QoL domains. Additionally, the evaluation of health states allows combining QoL with gains or losses in quantity of life, to produce quality-adjusted life years (QALYs). However, the instrument was developed for assessing QoL in adults. The current 
debate on the development of child-specific QoL instruments concentrates on the 
appropriate dimensions reflecting the perspective of children and adolescents on their health status. Additionally, due to rapid development changes during childhood, the application of a common set of dimensions suitable for all age groups from infancy through adolescence is challenging 1–3. Currently, a wide-
range of child-specific Qol measurement instruments is available, such as the Child Health Questionnaire (CHQ), the KIDSCREEN, the TNO AZL Children’s Quality of Life (TACQOL), and the Pediatric Quality of Life Inventory (PedsQOL) 4–13. All these instruments aim to be generic, and thus aim to be applicable to a wide range of medical conditions and interventions. As all instruments are relatively new, detailed information on their respective strengths and weaknesses is still scarce. Additionally, these instruments were developed for clinical or epidemiological 
purposes. Child-specific instruments that are applicable for economic evaluations, including preference-based evaluations for health states, such as the EQ-5D-Youth and the Child Health Utility 9D (CHU-9D), are still in early stages of development 14–16. Consequently, in the current situation for QALY estimation in children and adolescents, a practice of opting for application of adult QoL measures in children has not been abandoned yet, as proper alternatives are not available. While this situation seems far from ideal, it does offer the advantage of empirical testing of the 
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psychometric properties of a generic preference-based adult-specific instrument 
against a generic child-specific measurement instrument in specific populations.  Considering the increasing use of health economic evaluations of alternative 
interventions in children and adolescents, we aimed to explore to what extend the EQ-5D is a valid instrument for assessments in these populations. 
 In the current study we examined the comparability of the domains 
captured by the EQ-5D and the KIDSCREEN-10 (KS-10). Additionally, we examined the validity of the EQ-5D in comparison to the KS-10 in a child and adolescent population with ADHD. 
 Attention Deficit Hyperactivity Disorder (ADHD) is a high prevalence mental disorder in youths, characterized by its early onset and chronic character, and patterns of inattention, hyperactivity and impulsivity. ADHD is associated with impairments across a range of QoL domains, i.e. impairments due to academic failure, poor self-esteem, and social functioning 17. Furthermore, ADHD is often 
comorbid with other diseases, such as oppositional defiant disorder (ODD), conduct 
disorder (CD), depression and anxiety 18. Treatment of ADHD is mainly focused on reducing the symptoms that have been shown to be responsive to stimulant medication and/or psychosocial support 19, 20. 
2.2 METHODS
2.2.1 Study design and sample descriptionFor the present study, data were derived from a larger study aimed to assess the burden of illness of children and adolescents with ADHD (not published). The 
burden of a disease may be expressed as cost to society, due to the treatment and the consequences of a disorder. Additionally, the impact of a disease for the 
individual may be expressed in terms of a reduced QoL attributable to the disorder.  A questionnaire survey was performed among parents with a child aged 8–18 years and diagnosed with ADHD, to collect data on costs and QoL. Respondents were recruited via ‘Balans’, the Dutch ADHD parent association. The survey was carried out in 2010. 
 The primary care parent for the child was asked to fill out an online booklet 
of questionnaires, including the proxy version of the EQ-5D and the KS-10, as well as questions on demographics (i.e. child’s age and gender) and comorbidity (i.e. 
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anxiety disorder, mood disorder, learning disorder, oppositional defiant disorder (ODD)/conduct disorder (CD), asthma, tic disorder, mental retardation, autism disorder, epilepsy), and the use of medication for ADHD. Additionally, the parent was asked to report their child’s health condition related to the intake and response to medication treatment, by ticking off the most applicable description of the condition. The description of the condition 'responder' was as follows: ‘Your child uses the prescribed daily dose of medication. Using this treatment, your child’s 
functioning is fine and there are no noteworthy problems at home, at school, with peers or during leisure time’. The description of the condition 'non-responder' was: ‘The daily dose of medication used by your child differs from the dose prescribed. Using this treatment, your child’s functioning is hampered by problems at home, at school, with peers or during leisure time for short periods of time.
2.2.2 QoL instrumentsThe EQ-5D is a preference-based generic instrument for the measurement of 
QoL in adults. The instrument provides descriptives of health states covering five separate dimensions of health: mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression. Scores on each dimension are rated on a three-point scale 
(e.g. no problems, some or moderate problems and extreme problems). A health 
state may be converted into a single summary index by applying a formula that attaches different weights to each of the levels in each dimension. The anchor points of the EQ-5D are 0 (dead) and 1 (perfect health). The formula is based on the evaluation of EQ-5D health states from the Dutch general adult population 21. 
Hence, the summary index scores represent valuations (preferences) adopting a 
societal perspective. In the current study, the EQ-5D proxy version was used to measure the health states of the children and adolescents. The KIDSCREEN instruments aim to measure generic Qol in children and adolescents between the ages of 8 and 18 years.  The KIDSCREEN instruments are demonstrated to be suitable as a screening, monitoring and evaluation tool in representative national and European health surveys, and have been shown to have good psychometric properties 6–8. The instruments were developed simultaneously in 13 European countries, ensuring 
their crosscultural applicability. Literature reviews, expert consultations and children’s focus groups were used to identify dimensions and items of QoL 
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relevant to respondents in all countries. Currently, three versions are available. The KIDSCREEN-52 is the longest version, using 52 items for the measurement of ten separate dimensions of QoL. The KIDSCREEN-27 is the shorter version, merging 
the ten original dimensions into five dimensions. The KS-10  is derived from the 
KIDSCREEN-27, and provides a single index of global QoL using ten items related to physical well-being, psychological wellbeing, autonomy and parent relation, social support and peers, and school environment 8. All items are measured using 
a five-point Likert scale. The items are scored as Rasch scales and summed into a single score. The scores are transformed into standardized values based on data from an international survey sample from twelve European countries, and range from -16.06 to 57.77. Additionally, the KS-10 includes a question for rating the general health of the child. The KIDSCREEN instruments include child versions for 
self-report and parent proxy versions. In the current study, we applied the KS-10 
proxy version. 
2.2.3 Statistical analyses
2.2.3.1 Comparison of constructs 
Comparison of the instruments included an exploration of the distribution of responses on the different dimensions of the EQ-5D and the items of the KS-10. Scores on the separate dimensions and items of each measurement instrument 
are presented as proportions. We explored the data to find (dis)similarities of 
the instruments using the combined correlation matrix of the EQ-5D and the KS-10 items. Given that the assumptions of monotonic relationships were not violated, Spearman’s rank correlations were performed to assess the strengths of the correlations, as the items of the EQ-5D and the KS-10 are measured on 
ordinal scales. Correlation coefficients between 0.1 and 0.3 were considered 
low, from 0.31 to 0.5 were considered moderate, and those exceeding 0.5 were considered strong 22. The next step included an exploratory principle component 
analysis (PCA). The basic idea behind PCA is to explore whether the items of both instruments evident in these data generate information about more general underlying dimensional constructs 23. PCA determines these factors and the way items are associated by analyzing the pattern of correlation. Items with relatively 
high inter-correlations are assumed to reflect the same construct. Consequently, PCA generates a summary of factors identifying underlying constructs of the 
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different items of both instruments. Interpretation of the factors is based on the strength of inter-correlations. To obtain a more interpretable set of factors, PCA 
was followed by varimax rotation. As a rule of thumb, eigenvalues >1 are used to limit the number of factors. Considering the wide age span in our population, PCA was conducted for the overall sample and for two separate age groups (6–11 years and 12–18 years, respectively).
2.2.3.2 ResponsivenessThe performance of the KS-10 and the EQ-5D was evaluated based on the 
responsiveness of the index scores of both instruments to different health states in our study population. We hypothesized that QoL in respondents who were 
responder to treatment would be significantly higher compared to respondents who are non-responder. Also, we assumed decreasing QoL in children with increasing numbers of comorbid conditions. For these analyses, Student’s t-tests were performed. For larger studies, Student’s t-tests are robust even for heavily skewed data 24. For the comparison in smaller subgroups (<200 respondents) Mann–Whitney tests were applied. Additionally, an indirect comparison was performed to assess the instruments’ comparability on responsiveness by calculating Cohen’s effect sizes between subgroups. Finally, KS-10 scores were compared with Dutch norm scores 25. As norm scores for EQ-5D index scores of young children are lacking, the comparison of the EQ-5D scores was limited to respondents aged 15–19 years 26. Responsiveness was evaluated in the overall sample and in two age 
groups (8–11 years and 12–18 years) separately. For all analyses, a significance level of p<0.05 was used. The data were analyzed using SPSS, version 20.0 (SPSS Inc, Chicago, IL, USA).
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Table 1 Characteristics of the study population (n=739) %Age mean (SD) in years 12 (3)Boys   82.1ADHD diagnosed by* Pediatrician  16.3
Child psychiatrist   69
General practitioner   0.4
Other (not specified) 14.4Health condition associated with medication treatment** Responder 59.2
Non responder 25.2
Stopped medication 12.8
Never used medication 2.8Comorbidity Yes 74.0
Learning disorder 39.8 Autistic disorder 27.8
Anxiety disorder 13.6
ODD/CD 12.1
Mood disorder 11.8
Asthma 11.5
Mental retardation/ tic disorder/ epilepsy 7.8
* Percentages do not sum up to 100 due to the application of cut off values. ** Definitions of the health 
conditions associated with medication treatment are presented in the method section. 
ODD: Oppositional Defiant Disorder; CD: Conduct Disorder.
2.3 RESULTS
2.3.1 Study populationData were available from 779 parents with a child aged 8 years and older. Of these, 40 did not complete the KS-10 and/or EQ-5D questionnaire (Table 1).  The mean age of the children was 11.9 years (SD 2.8); 82.1 % were boys. Almost 75 % of the children had a comorbid condition and 84.4 % of the children took medication for ADHD.
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2.3.2 Construct validity
For the evaluation of the instruments’ constructs, data of respondents who filled out both measurement instruments were used. In Table 2, the distribution of answers on the dimensions of the KS-10 and the EQ-5D are presented. Generally, variation within the items of the KS-10 and the dimensions of the EQ-5D was limited. Relatively few respondents gave low scores on the KS-10 items. (See Table 2: never/seldom, respectively, often/always for negative formulated items 3 and 4) On the 
EQ-5D dimensions, ‘extreme problems’ were reported occasionally. Additionally, almost no respondent reported problems on the EQ-5D ‘mobility’ dimension.  Generally, correlations between the EQ-5D domains were low. Moderate correlations were found between the dimensions ‘usual activities’ and ‘self-care’ 
and the dimensions ‘usual activities’ and ‘anxiety/depression’ (rho 0.365 and 0.319, respectively). Strong correlations were found between the following KS-10 items: 
‘felt fit and well’ and ‘felt full of energy’ (rho 0.591); ‘had enough time for him/herself’ and ‘was able to do things he/she wanted to do in free time’ (rho 0.539); and the items ‘went well at school’ and ‘was able to pay attention’ (rho 0.532).  Correlations between the EQ-5D dimensions and the KS-10 items are shown 
in Table 3. Additionally, correlations of the EQ-5D dimensions and the KS-10 index 
score are presented. The correlation between the EQ-5D and KS-10 index scores was strong. However, no strong correlations were found between the separate EQ-5D dimensions and KS-10 items. The strongest correlations were between the 
EQ-5D dimension ‘anxiety/depression’ and the KS-10 items ‘felt fit and well’, ‘felt sad’, and ‘felt lonely’.  The EQ-5D dimension ‘usual activities’ correlated moderately with the KS-10 item ‘got on well at school’. The EQ-5D dimension ‘pain/discomfort’ 
correlated moderately with the KS-10 item ‘felt fit and well’. Overall, the EQ-5D 
dimensions ‘usual activities’ and ‘anxiety/depression’ correlated moderately with 
the KS-10 index score. 
 PCA followed by varimax rotation, using the data of the total study population (8–18 years) on the dimensions of both the EQ-5D and the KS-10 
items, resulted in five separate constructs of QoL that explained 60 % of the total variance in the measurements (see Table 4). The EQ-5D dimension ‘mobility’ had a loading of >0.4 on more than one construct. Additionally, the loadings of the KS-10 item ‘felt treated fairly by parents’ on the constructs two and three had almost equal weights, indicating that this item might represent a separate factor 
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of QoL. Construct one represents a physical factor including the KS-10 items ‘felt 
fit and well’ and ‘felt full of energy’ and the EQ-5D dimensions ‘pain/discomfort’ and ‘mobility’. Construct two can be labeled as a mental factor including the KS-10 items ‘felt sad’, ‘felt lonely’, ‘had fun with friends’ and ‘felt treated fairly by 
his/her parents’, and the EQ-5D dimension ‘anxiety/depression’. The constructs 
three to five did not show an overlap of KS-10 and EQ-5D dimensions. The third and fourth constructs included KS-10 items concerning school and KS-10 items 
of life satisfaction (free time). As expected, none of the EQ-5D dimensions were 
related to these constructs, as these were associated with child-specific items of well-being. Additionally, the EQ-5D dimensions ‘self-care’ and ‘usual activities’ were not captured by any of the KS-10 items. Additionally, separate PCAs were performed in children aged 8–11 and 12–18 years, respectively. Generally, no major differences were found in comparison to the results for the total sample. In the group aged 8–11 years, the KS-10 item ‘had fun with friends’ had a higher factor loading on the life satisfaction construct. In the group aged 12–18 years, 
the KS-10 items ‘felt fit and well’ and ‘felt full of energy’ correlated stronger with KS-10 items associated with school-related functioning. The same goes for the KS-10 item ‘felt treated fairly by parents’.  Overall, the results indicate that three dimensions of the EQ-5D are 
associated with six items of the KS-10. The remaining EQ-5D dimensions and KS-10 items constitute complementary constructs unrelated to the separate instruments.
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Table 2.  Scores (%) on KS-10 and EQ-5D (n=739)
 
KS-10
ITEM Has your child:
Not at all/
never Seldom
On average/
sometimes Often Always1 Felt fit and well 0.7 4.7 33.4 27.9 33.32 Felt full of energy 0.5 3.1 19.8 48.8 28.33* Felt sad 8.3 31.9 49.1 10.4 0.34* Felt lonely 23.1 30.4 37.8 8.0 0.75 Had enough time for him/herself 0.3 1.4 9.7 67.4 21.2
6 Been able to do things that he wants to do in his free time 0.1 1.9 11.5 66.3 20.2
7 Felt that his/her parents treated him fairly 0.3 6.2 20.2 60.5 12.98 Had fun with his friends 1.2 8.1 28.1 45.9 16.69 Got on well at school 2.2 6.9 41.5 31.0 18.410 Been able to pay attention 0.5 5.8 34.5 56.2 3.0
EQ-5D
DIMENSION
No 
problems
Some 
problems
Extreme 
problems1 Mobility 96.2 3.6 0.12 Self-care 67.2 31.9 0.93 Daily activities 28.8 68.6 2.64 Pain/discomfort 79.8 19.4 0.8 5  Depression/anxiety  61.6  36.2  2.2
* Negative formulated items.
Bold values reflect the most frequent answers per item/dimension.
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2.3.3 Responsiveness
In the total study population, the average KS-10 index score was 45.5 (SD 8.8), 
and the average EQ-5D utility score was 0.81 (SD 0.17). The average KS-10 index 
score in the study population was significantly lower in comparison to Dutch norm data (mean 53.85) in children and adolescents. The average EQ-5D utility score of adolescents (15 years and older; n=154) in the study was 0.83, and was 
significantly lower in comparison to the norm score of 0.91 (p<0.001) of their peers (weighted norm score on gender). These results suggest discriminative 
ability of both instruments. Comparable index scores were found between the 
two age groups, with exception of the average EQ-5D score in the group aged 
8–11 years, which was significantly lower in comparison to the score in the older age group (Table 5). 
 The mean KS-10 index scores of children who were responder to treatment (n=417) and children who were non-responder (n=177) were 47.5 and 42.7, 
respectively. Corresponding mean EQ-5D index scores in these groups were 0.84 and 0.75. Student’s t-tests revealed that both instruments showed significantly different mean scores between these groups. Cohen’s d effect sizes based on the KS-10 and the EQ-5D were 0.58 and 0.52, respectively. 
 Comparable differences in EQ-5D and KS-10 index scores between the two subgroups were found in the two age groups. 
 Additionally, both the KS-10 and the EQ-5D index scores showed significantly 
decreasing values with increasing number of comorbidities, confirming that both instruments are responsive to differences in health. The analyses in the 
subgroups showed comparable results. However, no significant differences were found between respondents with one comorbid condition and respondents without 
comorbidity on either the KS-10 index score or the EQ-5D score in the group aged 
12–18 years. Additionally, no significant difference was found on the KS-10 score between respondents with two and three comorbid conditions in the group aged 8–11 years.
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Table 4. Overview of factors underlying the QoL based on the results of the KS-10 items  and EQ-5D dimensions using PCA
CONSTRUCT 1
8-18 YEARS (N=737)
PHYSICAL FACTOR LOADING
8-11 YEARS (N=380 )
PHYSICAL
FACTOR 
LOADING
12-18 YEARS (N=357)
PHYSICAL
FACTOR 
LOADINGKS-10 Felt fit and well    0.711 KS-10 Felt fit and well  0.701KS-10 Felt full of energy    0.702 KS-10 Felt full of energy  0.729EQ-5D Mobility  -0.519 EQ-5D Mobility -0.635 EQ-5D Mobility 0.691EQ-5D Pain/discomfort  -0.592 EQ-5D Pain/discomfort -0.454 EQ-5D Pain/discomfort 0.723
CONSTRUCT 2 MENTAL  MENTAL MENTALKS-10 Felt sad    0.790 KS-10 Felt sad  0.809 KS-10 Felt sad  0.758KS-10 Felt lonely    0.838 KS-10 Felt lonely  0.769 KS-10 Felt lonely  0.837KS-10 Had fun with friends    0.566 KS-10 Had fun with friends*  0.353 KS-10 Had fun with friends  0.602KS-10 Felt treated fairly by parents    0.342 EQ-5D Anxiety/depression 0.534 EQ-5D Anxiety/depression -0.66EQ-5D Anxiety/depression  -0.577 -
CONSTRUCT 3 SCHOOL RELATED FUNCTIONING  SCHOOL RELATED FUNCTIONING SCHOOL RELATED FUNCTIONINGKS-10 Got on well at school    0.796 KS-10 Got on well at school  0.795 KS-10 Got on well at school 0.776KS-10 Was able to pay attention    0.824 KS-10 Was able to pay attention  0.849 KS-10 Was able to pay attention 0.818KS-10 Felt treated fairly by parents*   0.27 KS-10 Felt full of energy  0.517KS-10 Felt treated fairly by parents 0.485KS-10 Felt fit and well 0.534
CONSTRUCT 4 LIFE SATISFACTION  LIFE SATISFACTION LIFE SATISFACTIONKS-10 Had enough time for him/herself    0.849 KS-10 Had enough time for him/herself  0.745 KS-10 Had enough time for him/herself  0.852KS-10 Was able to do things he/she wanted in free time 0.823 KS-10 Was able to do things he/she wanted in free time  0.798 KS-10 Was able to do things he/she wanted in free time  0.843KS-10 Felt treated fairly by parents  0.479KS-10 Had fun with friends  0.428
CONSTRUCT 5 DAILY FUNCTIONING  DAILY FUNCTIONING DAILY FUNCTIONINGEQ-5D Self-care    0.807 EQ-5D Self-care  0.844 EQ-5D Self-care  0.780EQ-5D Usual activities    0.647 EQ-5D Usual activities  0.756 EQ-5D Usual activities  0.658  EQ-5D Mobility*    0.42
Explained variance (%)    60 Explained variance (%)    59.3 Explained variance (%)   62.2
 
Negative values of the factor loadings result from differences between formulations of the EQ-5D and the KS-10 items. 
* Higher loading on different construct.
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2.4 DISCUSSION
During the last decades, the application of QoL as outcome measure has generally been accepted in both clinical and health economic studies. QoL denotes a multidimensional construct covering physical, emotional, social and behavioral components of well-being, as perceived by patients and other observers 27,28. The interest of measuring QoL in children is growing, due to changing epidemiology of childhood disease from acute to chronic and from incurable to curable 29. Research questions regarding the measurement of QoL in children and adolescents involve a number of aspects, such as what dimensions of QoL are relevant for children and adolescents, and how QoL can be properly measured in these populations. Additionally, the question of how to value the QoL of children and adolescents arises 3. The EQ-5D was purposefully designed to generate a weighted health state 
index that can be applied in economic evaluations. It is a standardized, short (five questions) instrument, applicable to a wide range of health conditions, and is the most frequently used instrument for assessing outcomes in economic evaluations 30. 
The EQ-5D provides a description of health states limited to five broad dimensions of physical and psychological functioning. This limitation is due to the feasibility of valuing all possible health states. The EQ-5D was developed for measuring QoL in adult patient populations. 
 The KIDSCREEN is a child-specific instrument for measuring child and adolescent QoL for use in epidemiologic studies, clinical intervention studies and research projects. The KS-10 was derived from the KIDSCREEN-27 and seems to 
be more defined by mental aspects than by physical ones 8. The KS-10 includes ten 
questions regarding the child’s functioning during the preceding week. Index scores of the KS-10 are derived using Rasch techniques, resulting in a one-dimensional QoL measure. 
 Both QoL instruments reflect different theoretical bases, and their content is designed to capture differences on a number of dimensions of health and functioning. A comparison of the EQ-5D and the KS-10 provides information that can help health care professionals and researchers to select a suitable instrument to measure QoL. 
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For reasons of comparability, especially for economic evaluations, there are arguments for the use of the EQ-5D in studies with children and adolescents. However, studies evaluating the psychometric properties of the EQ-5D in 
comparison to child-specific measures are limited 31,32. Willems et al. reported low discriminant power of the EQ-5D, and low to moderate correlations between the EQ-5D utilities and TACQOL scales. They concluded that the EQ- 5D seems most suitable for children with a chronic physical disorder 33. In a study by Klaassen et al. 34, the EQ-5D and the PedsQOL were found to be sensitive to change in children suffering from Hodgkin disease. However, in this study, the application of the EQ-5D was limited to the Visual Analogue Scale. In a recent study, the validity of the EQ-5D was assessed in a pediatric injury population with different severity levels of injury 35. 
 In the current study, we explored similarities and dissimilarities between the QoL constructs of the KS-10 and the EQ-5D, and we assessed the instruments’ responsiveness to different health states. The correlation between the instruments’ 
index scores was high. However, only moderate correlations were found between a 
number of KS-10 items and the EQ-5D dimensions ‘pain/discomfort’ and ‘anxiety/depression’. Overall, relatively small variations were found in the scores on the EQ-5D dimensions in this study population. This may have resulted in relative low correlations with the KS-10 items. Additionally, the correlation of the EQ-5D 
‘mobility’ dimension with the KS-10 index score was very low, suggesting that the combination of this dimension with the KS-10 items and the EQ-5D dimension 
‘pain/discomfort’ may be artificial. This may be attributed to ceiling effects of the EQ-5D. Additionally, in this patient population, the number of children with 
problems related to mobility is expected to be low. Beside the limited variations in data on the EQ-5D dimensions, the three-level scoring system of the EQ-5D may result in relatively low correlations with KS-10 items. 
 The results of the PCA indicated that six items of the KS-10 were associated 
with three EQ-5D dimensions, namely ‘mobility’, ‘pain/discomfort’ and ‘anxiety/depression’. The remaining two EQ-5D dimensions, ‘self-care’ and ‘usual activities’, and the remaining KS-10 items presenting information on performance at school and satisfaction with free time activities, showed to be distinct  constructs of QoL. 
As expected, these results suggest that the KS-10 and the EQ-5D are complementary 
instruments. While the KS-10 questionnaire includes specific items on child’s well-
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being, the instrument lacks elements of disability (like the EQ-5D dimension ‘self-care’) and general participation (like the EQ-5D dimensions ‘usual activities’). It can be argued that the applicability of these dimensions in children may be hampered due to confounding factors related to physical and/or emotional development from childhood to adulthood 36. Additionally, ‘usual activities’ of children are likely to 
have a distinct context compared to the ‘usual activities’ of adults. Apparently, the KS-10 items related to performance at school and satisfaction with activities in free time relate to distinct social role activities of children and adolescents that are not captured by the EQ-5D dimension usual activities. 
 Despite the non-specific child character of the EQ-5D, the performance of the instrument in this population was comparable with that of the KS-10. The EQ-
5D utility scores and the KS-10 index scores were both significantly different in comparison to the scores of their peers from the general population, suggesting that both instruments were able to discriminate between healthy and disabled populations. However, norm scores of EQ-5D in younger populations (< 15 years) 
are lacking. Consequently, more research is necessary to confirm the discriminating 
ability of the EQ-5D in younger children. These general findings of lower QoL in children with ADHD are in line with the study of Danckaerts et al. 37. 
 Remarkably, significant differences were found between the EQ-5D utility scores of the younger children in comparison to the older children. These differences were consistently found between the different subgroups. Generally, percentages of respondents reporting problems on the different EQ-5D dimensions 
in the two age groups were comparable, with the exception of the dimension ‘self-care’. In the younger group, over 42% reported having some problems with washing or dressing her/himself (data not shown). It is not clear whether this higher percentage with problems on this dimension in the younger group can be attributed to the age of the respondents, or whether this can be attributed to the disorder. Consequently, more research is recommended on this.  Overall, the instruments responsiveness to different health conditions within our study sample was comparable. However, in the age group 12–18 
years, no significant differences were found between the KS-10 index scores of respondents without and respondents with one comorbid condition. The same 
goes for the differences in KS-10 index scores between respondents with two and three comorbid conditions in the younger age group. The higher responsiveness of 
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the EQ-5D may be attributed to differences in the index-scores of both instruments. For the valuation of the EQ-5D health states different weights for the separate dimensions of QoL are used. 
 Despite the non-specific child character of the EQ-5D questionnaire, the performance of the instrument in this population was comparable with that of the KS-10.  There are a number of features of this study that merit further discussion. Respondents were recruited via the Dutch ADHD parent association ‘Balans’.Since a golden standard of QoL is lacking, it is desirable to compare the psychometric properties with clinical information regarding the diagnosis and severity of the disorder. Consequently, the results should be interpreted with some caution. The 
validity of the EQ-5D should be compared with a disease-specific instrument. 
Additionally, we used proxy measurements to assess the QoL of the children 
and adolescents. Generally, correlations between child and proxy reports are higher for observable domains, but low in unobservable domains like pain and 
anxiety 38. More research is recommended, including self-report measurements. 
In the current study, the EQ-5D proxy version was derived from the adult version for self-completion. Currently, the EQ-5D-Youth (EQ- 5D-Y) is introduced as a self-report version of the EQ-5D for young respondents 14,15. The original EQ-5D dimensions are considered to be important domains of QoL for adults, as well as for children and adolescents. However, the wording of the questionnaire is 
modified to improve respondents’ comprehension of the questions. Some minor adaptations were performed to clarify the meaning of the dimensions for younger 
respondents and more appropriate examples were added in the ‘usual activities’ dimension. Despite the different wording of the EQ-5D, the results of our study were in line with the results on the EQ-5D Y in the studies of Ravens-Sieberer et al. 14 and Willems et al. 33.  In our study, we applied EQ-5D utility scores that were derived from a general population of adults. It is suggested that valuations of health states of younger patients may differ from those for adult patients 39,40. However, there is still debate whether subgroup preferences are useful or appropriate for economic evaluations 41.  This study contributes to the validity of the EQ-5D for economic evaluations 
of alternative interventions in children and adolescents. It is the first study that 
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compares the EQ-5D and KS-10 in a population of children and adolescents with ADHD. The results provide information about the differences measured by the KS-10 and the EQ- 5D. However, these differences do not impede the merits of either instrument when used for their own purposes. The results demonstrated applicability and appropriateness of the EQ-5D for estimating QALYs in children by comparing instruments’ responsiveness to different health states. These QALY estimates are commonly used in economic evaluations.
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ABSTRACT 
Background: It has been shown that Attention Deficit Hyperactivity Disorder (ADHD) lowers the Quality of Life (QoL) of patients and their families. Medication as part of the treatment has a favourable effect on symptoms as well as functioning. Evidence on the impact of pharmacological treatment on symptoms of ADHD and the QoL of the patient and their family is still limited. There is a need for further research on QoL in ADHD as well as the relationship between ADHD and the impact on families rather than solely on patients. 
Aims of the Study: Measure QoL of children with ADHD and their parents and 
explore the association of QoL with treatment response. 
Methods: A cross-sectional survey was performed using an online questionnaire 
to collect QoL data of children with ADHD (based on proxy reporting of parents) and their parents in a sample of members of an ADHD parent association. QoL was measured by EQ-5D and KIDSCREEN-10. Treatment response was based on 
descriptions by experts, based on compliance and functioning. 
Results: Analyses were based on 618 questionnaires (treatment responder n=428, treatment non-responder n=190). Mean age of the children was 11.8 years (82.4% male). QoL according to EQ-5D utility was 0.83 and 0.74 for responders 
and non-responders, respectively (p<0.001). For KIDSCREEN-10 the index was 42.24 and 40.33 for responders and non-responders, respectively (p<0.001). EQ-5D utility scores of the parents were 0.83 on average; no association with their 
child’s treatment response could be established. A significant positive correlation between EQ-5D utility of the children and EQ-5D utility of the parents (R2=0.207, p<0.001) was found. The association between treatment response and children’s 
QoL was significantly influenced by age category, having a sibling with ADHD, and presence of comorbidity. 
Discussion (with limitations of the study): Strengths of this study are its sample size and the inclusion of QoL of parents, which has not been reported simultaneously before. The facts that data were derived from members of the 
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ADHD parent association, the data for children were based on parents’ report, 
and lack of possibility for confirmation of the clinical diagnosis are the main study limitations. 
Implications for Health Care Provision and Use: QoL of children with ADHD 
was shown to be significantly positively associated with response to treatment and negatively affected by comorbidity. In determining the treatment effects in ADHD, QoL and family overall well-being should be a standard consideration as well as an integrated part of health policy discussions on ADHD. 
Implications for Health Policies: Policymakers in the field of ADHD should focus on QoL of the patient, but also on the broader effects of effective treatment on well-being of the parents. 
Implications for Further Research: Suggestions for further research include the repetition of this study including a control group and obtaining children’s self-report on QoL and clinicians report on diagnosis.
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3.1 INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is a heterogeneous condition characterized by the early onset of age-inappropriate hyperactivity, impulsivity and inattentiveness 1. The worldwide-pooled prevalence of ADHD was estimated to be 5.3% in a meta-analysis that covered the period between 1978 and 20052. ADHD may persist into adulthood 3. Symptom overlap or comorbidity with other 
conditions is the rule rather than the exception, in particular with oppositional 
defiant disorder, conduct disorder, anxiety or depression, autism spectrum disorder, and substance use disorders 4,5.  Two systematic reviews show that ADHD has a negative impact on quality of life (QoL) of ADHD patients 6,7. Treatment by medication has been shown to have a favourable effect on functioning of ADHD patients and is recommended by authoritative treatment guidelines worldwide 8-12. However, evidence on the impact of pharmacological treatment on the impact of ADHD and the QoL of the patient is limited 6. 
 The concept of QoL fits well to the treatment goals in ADHD, and could therefore potentially be used to evaluate treatment effect. According to clinical guidelines in ADHD, the aim of treatment is to reduce symptoms that have been shown to be responsive to stimulant medication and/or psychosocial support 12-14. Symptomatic improvement is required to reach functional improvement 15. Functional improvement can be evaluated well by appropriate QoL measures. The need for further research on QoL in ADHD and the relationship between ADHD and impact on families rather than only patients has been stressed 7,10,16. 
 One of the most commonly used generic QoL instruments in the field of health technology assessment is EQ-5D 17-19. EQ-5D is used to calculate utilities covering physical, psychological and social domains. Utilities are used to calculate Quality Adjusted Life Years (QALYs), which is an outcome measure that is preferred by various health authorities. To our knowledge, only two studies in ADHD using EQ-5D have been performed in relatively small samples both referring to the need for more data on ADHD and EQ-5D 20,21. In studying QoL in children, a measure that has been demonstrated to have complementary value to EQ-5D is KIDSCREEN-10 (KS-10) 22. The advantage of KS-10 is that the results can be assumed to be applicable to and interpreted across a variety of cultures due to 
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the simultaneous development and validation in thirteen countries 23. The aim of this study was to measure QoL according to treatment response of children with ADHD and their parents using EQ-5D and KS-10 in order to contribute to the further understanding of the impact of ADHD on both patients 
and their relatives, and to the role of treatment in that context. To our knowledge, no previous study focused on QoL for children and their parents simultaneously. 
3.2 METHODS
3.2.1 Study designThe present study was part of a larger study on the burden of ADHD. A cross-sectional survey was performed using an online questionnaire with closed-ended questions to collect QoL data on children with ADHD and their parents. The questionnaire was drafted in close collaboration between Janssen-Cilag BV and the institute for Medical Technology Assessment (iMTA). The sample comprised of members of the Dutch ADHD parent association ‘Balans’. Parents and caregivers (hereafter: parents) of children with ADHD were asked via the quarterly magazine of the association to complete the online questionnaire via the temporary website www.adhdonderzoek-imta.nl accessed with a personal login code. The questionnaire was available from 01-09-2010 until 03-10-2010. Parents of children aged 8-18 years diagnosed with ADHD and children themselves were included. Parents were asked to state the date of diagnosis and the type of 
physician who had confirmed the diagnosis. In the current study we focus on children (and their parents) using pharmacological treatment by methylphenidate 
(both short-acting and extended release formulations) or atomoxetin, as these are the most commonly used ADHD drugs in the Netherlands 11.  The study proposal was reviewed by the medical staff of Janssen and Balans reviewed and approved the questionnaires. Janssen-Cilag BV was not referred to as having commissioned the study and in case of questions parents were offered the opportunity to contact the iMTA. The parent taking care of the child most of the day was asked to complete the questionnaires. In case the parent had more than one child with ADHD, he or she was asked to answer the questions for their youngest child. The parents evaluated their children’s QoL, because the questions were considered to be potentially distressing for younger children. Further, it was 
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aimed to collect QoL data on both children and parents. Administering separate QoL questionnaires to children/adolescents and their parents was considered to 
negatively influence the response rate given the higher logistical complexity. It was concluded that according to Dutch regulation no approval of an ethics committee was needed since the study did not interfere with clinical practice. Consequently, with the methodology of this study focused on parents, it was not obligatory to use informed consent forms. Nevertheless, the protocol took into account all privacy aspects. Participants were informed on the purpose of data 
collection and publication and were able to exit the questionnaire at any time. Due to the personal login code, only members of Balans were able to access the 
questionnaire and next to that participants were asked to indicate the nature of their relationship to Balans. If the participant was not a parent of a child with ADHD the questionnaire ended. The questionnaire could be completed only once per IP address. However, IP addresses were not traceable, and therefore participants’ anonymity was guaranteed. 
3.2.2 Study groups
In order to explore the association between QoL and response to treatment, 
descriptions for response to treatment had to be defined prior to conducting the study since these were not readily available. These descriptions were formulated 
by five ADHD experts. At the start of the study, the experts considered two assumptions to be necessary to serve as the foundation for the descriptions. First, 
based on an earlier study, response to medication had to be defined by recovery 
both at home and at school in order to reflect a proper description of the child’s daily functioning (functioning - F) 24. Second, as compliance to medication is known to play an important role in the child’s functioning, it was considered necessary to include a statement on the child’s compliance as well (compliance - C) 25. 
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Theoretically, this led to the following combinations: 
(C+; F+): Compliance to prescribed daily dose of medication, no problems in functioning.(C-; F-): Non-compliance to prescribed daily dose of medication, problems in functioning.(C+; F-): Compliance to prescribed daily dose of medication, problems in functioning.(C-; F+): Non-compliance to prescribed daily dose of medication, no problems in functioning. 
The experts decided to exclude combinations (C+; F-) and (C-; F+). The experts considered (C-; F+) to describe children not requiring medication, as no prob-lems arise when medication is not taken according to prescription. (C+; F-) 
was considered to reflect several situations in which proper compliance is not translated in proper functioning: inappropriate dosing, inappropriate medica-tion, incorrect primary diagnosis (not ADHD), or presence of an undiagnosed but relevant comorbid condition. The design of the study precluded to analyze these possibilities. The two remaining combinations, (C+; F+) and (C-; F-), were 
the basis for study group definitions. As it was deemed necessary to provide 
parents with a hands-on description of these groups, the experts operational-ized the combinations to the following descriptions: 
* Operationalization C+; F+ to ‘responder to treatment’: Your child uses the prescribed 
daily dose of medication. Using this treatment, your child’s functioningis fine and there are no noteworthy problems at home, at school, with peers or during leisure time.* Operationalization C−; F− to ‘non-responder to treatment’: The daily dose of medication used by your child differs from the dose prescribed. Using this treatment, your child’s functioning is hampered by problems at home, at school, with peers or during leisure time for short periods of time.
3.2.3 Quality of life measures
3.2.3.1 EQ-5D
EQ-5D is a validated generic QoL instrument that measures QoL based on five 
dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression 26. Each dimension is assessed by one question with a 3-point response scale of which higher scores indicate greater impairment (no (1), moderate (2) 
or severe problems (3)). The combination of the five scores together represents a 
specific health state, for example 12131. Based on the five questions and a 3-point 
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response scale, 243 possible health states emerge. These possible health states 
have been valued by the general public in order to reflect a preference according to a societal viewpoint 27.  These society-derived preferences are called ‘utilities’ and range from 0 (a health state valued as equal to death) to 1 (indicating perfect health). The valuation study to derive societal preferences was originally performed in the United Kingdom (UK), which led to the most widely used algorithm to calculate utilities, known as the ‘UK-tariff ’ 27. A similar study was performed in the Netherlands in order to establish a Dutch tariff 28. In the current study, both the UK-tariff and Dutch tariff were used to value QoL. Results based on the UK-tariff were included in this study to enable comparison to most other utility studies available in literature 28.  Despite a general preference for EQ-5D for calculation of utilities, its use in children comes with challenges, as it was originally not designed for use in children 17. As long as a validated child-specific version and associated tariff of the EQ-5D is not available, the recommended alternative that has been demonstrated to be 
valid and feasible for QoL assessment in children is the parent-proxy version of EQ-5D 20. Using a proxy version, the parent is asked to answer the questions in 
such a way that it reflects the rating of the child. 
3.2.3.2 KIDSCREEN-10KS-10 is a validated, generic instrument for measuring QoL in children aged 8-18 years 23,29. The instrument was added to the original KIDSCREEN-52 and KIDSCREEN-27 to offer a short QoL questionnaire useful for public health and clinical studies which would help to reduce response burden and administration costs 23. Furthermore, the ability to summarize scores into one single value was deemed useful for detecting overall changes in QoL which is a prerequisite for health economic studies. KIDSCREEN-27 and 52 do not provide this summarized value. KS-10 measures ten dimensions of well-being using 5-point response scales: physical well-being, psychological well-being, mood and emotions, self-perception, autonomy, parent relation and home life, peers and social support, 
school and environment, bullying and financial resources. The responses are 
combined in a 0-100 index score of which lower scores indicate a lower QoL and thus greater impairment. A validation study of KS-10 indicated that this version of the KIDSCREEN may be more focused on aspects of QoL related to mental health 23. 
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The KIDSCREEN Group Europe mentioned that KIDSCREEN self-report is not 
always possible in young children. As with EQ-5D, parent-proxy reporting was 
considered the best alternative and therefore a specific proxy version was developed 30. 
3.2.4 SubgroupsSubgroup analyses on child’s age were performed considering the following age categories: 8-12 and 13-18 years. These categories were determined according to the average age (13 years) at which children in the Netherlands transit from primary to secondary school. This transition is assumed to impact their daily routine as attending secondary school generally requires more self-responsibility. Marital status of parents was analyzed according to either living together or living alone (i.e. the sum of single, divorced and widow(er)). Other variables used in the analyses were: having a sibling with ADHD, gender, and presence of comorbidities 
(specified to asthma, bronchitis, epilepsy, anxiety disorder, mood disorder, learning 
disability, Gilles de la Tourette or tic disorder, oppositional defiant disorder (ODD)/conduct disorder (CD), mental retardation, autism spectrum disorder). Household income was categorized based on average annual income of €33,000 in the Netherlands 31: group 1: below average, group 2: average to 2x average and 
group 3: 3x average and above. Group 4 was represented by the group cannot or will not tell. 
3.2.5 Data Analytic Procedures Analyses were performed using SPSS, version 18.0. Student’s independent-samples 
t-test was used for group comparisons of continuous variables and Pearson’s chi-
square for comparisons of categorical variables. A two-tailed significance level of p<0.05 was chosen. Correlation between QoL (based on EQ-5D and KS-10) and 
categorical variables was measured by Spearman’s correlation coefficient and 
continuous variables were analyzed with Pearson’s correlation coefficient. EQ-5D 
and KS-10 analyses were performed according to their manuals and predefined 
analyses syntaxes. Single and multiple linear regression analyses by ANOVA were performed to study the association between QoL and treatment response and 
demographic characteristics or subgroup identifiers that might have an impact on this relationship. 
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3.3 RESULTS
3.3.1 Demographic characteristicsAnalyses were performed on 618 questionnaires for QoL of children and 590 questionnaires for QoL of parents (a small percentage of 4.5% did not complete all questions). Table 1 reports on the demographic characteristics of children with ADHD. Children were reported to be a responder to treatment in 428 cases (69.3%) and non-responder in 190 cases (30.7%). The majority of children were aged between 8 and 12 (mean age 11.8) and about 82% were boys. Most common comorbid disorders were learning disorders (39.1%) and autism spectrum disorder 
(25.3%). Approximately 32% of the children had two or more comorbidities, and 23.3% of children were attending schools for special education. A psychiatrist or a pediatrician diagnosed ADHD mainly (67.8% and 17.8% respectively). 
 There were almost no significant differences between children’s character-istics in the responder vs. non-responder group. Only the non-responder children 
experienced comorbidity more often: anxiety disorder (17.7% vs. 11.4%, p=0.038), mood disorder (15.5% vs. 9.0%, p=0.021), and Gilles de la Tourette or tic disorder (6.6% vs. 3.1%, p=0.046). 
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Table 1. Children’s characteristics
ENTIRE SAMPLE   RESPONDER NON-RESPONDER P-VALUEN 618 (100.0%) 428 (69.3%) 190 (30.7%)
Mean age 11.80 (8-18) 11.81 (8-18) 11.77 (8-18) 0.856
Age group8-12 years 392 (63.4%) 267 (62.4%) 125 (65.8%) 0.41713-18 years 226 (36.6%) 161 (37.6%) 65 (34.2%)
Gender   Male 509 (82.4%) 359 (83.9%) 150 (78.9%) 0.138Female 109 (17.6%) 69 (16.1%) 40 (21.1%)
Diagnosis byPediatrician 110 (17.8%) 75 (17.5%) 35 (18.4%) -(Child) psychiatrist 419 (67.8%) 291 (68.0%) 128 (67.4%)General practitioner 3 (0.5%) 1 (0.2%) 2 (1.1%)Other 86 (13.9%) 61 (14.3%) 25 (13.2%)
Comorbid disordersAsthma, bronchitis, CARA 78 (13.0%) 50 (11.9%) 28 (15.5%) 0.233Epilepsy 9 (1.5%) 7 (1.7%) 2 (1.1%) -
Anxiety disorder 80 (13.3%) 48 (11.4%) 32 (17.7%) 0.038Mood disorder 66 (11.0%) 38 (9.0%) 28 (15.5%) 0.021Learning disability 235 (39.1%) 159 (37.9%) 76 (42.0%) 0.341Gilles de la Tourette / tic disorder 25 (4.2%) 13 (3.1%) 12 (6.6%) 0.046ODD or CD 63 (10.0%) 42 (10.0%) 21 (11.6%) 0.556Mental retardation 4 (0.7%) 2 (0.5%) 2 (1.1%) -Autism Spectrum Disorder 152 (25.3%) 105 (25.0%) 47 (26.0%) 0.802
Number of comorbid 
disorders0 166 (27.6%) 126 (30.0%) 40 (22.1%) 0.0511 242 (40.3%) 170 (40.5%) 72 (39.8%)2 132 (22.0%) 89 (21.2%) 43 (23.8%)3 or more 61 (10.1%) 35 (8.3%) 26 (14.4%)
Type of education Primary 241 (40.2%) 165 (39.3%) 76 (42.2%) 0.119Special primary 86 (14.3%) 57 (13.6%) 29 (16.1%)Secondary 219 (36.5%) 165 (39.3%) 54 (30.0%)Special secondary 54 (9.0%) 33 (7.9%) 21 (11.7%)
- Pearson’s chi-square not possible due to low expected numbers.Table 2 on parents’ characteristics reveals that 95.3% of the questionnaires were completed by the mother. Mean age of the parents was 43.2 years. About 80% of 
the parents had paid work. Approximately 23% of the parents had more than one 
child with ADHD. There were no significant differences in the parent characteristics between study groups. 
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Table 2. Parents’ characteristics
CHARACTERISTIC ENTIRE SAMPLE    RESPONDER NON-RESPONDER  P-VALUEN 590* (100%) 415 (70.3%) 175 (29.7%)
Age (mean, range) 43.22 (30-63) 43.20 (30-63) 43.25 (30-59) 0.931
GenderMale 28 (4.7%) 22 (5.3%) 6 (3.4%) 0.328Female 562 (95.3%) 393 (94.7%) 169 (96.6%)
Marital statusTogether 534 (90.5%) 381 (91.8%) 153 (87.4%) 0.097Alone 56 (9.5%) 34 (8.2%) 22 (12.6%)
EducationLower 83 (14.1%) 59 (14.2%) 24 (13.7%) -Medium 265 (44.9%) 182 (43.9%) 83 (47.4%)Higher 232 (39.3%) 166 (40.0%) 66 (37.7%)Other 10 (1.7%) 8 (1.9%) 2 (1.1%)
Paid job  Yes 471 (79.7%) 328 (79.0%) 143 (81.3%) 0.541No 120 (20.3%) 87 (21.0%) 33 (18.8%)
Family incomeBelow average 90 (15.3%) 62 (14.9%) 28 (16.6%) 0.816
Average to 2x average 246 (41.7%) 172 (41.4%) 74 (42.3%)
3x average and above 136 (23.1%) 100 (24.1%) 36 (20.6%)Cannot / will not tell 118 (20.0%) 81 (19.5%) 37 (21.1%)
More than 1 child 
with ADHDYes 133 (22.5%) 85 (20.5%) 48 (27.4%) 0.065No 457 (77.5%) 330 (79.5%) 127 (72.6%)
-  Pearson’s chi-square not possible due to low expected numbers.
* 18 parents did not complete these questions compared to 618 completed questionnaires for QoL of 
children. 
3.3.2. Quality of life of childrenTable 3 and Table 4 present the QoL of children based on EQ-5D and KS-10 re-spectively. In the entire sample, the average EQ-5D utility score for the children 
was 0.80 (responder 0.83, non-responder 0.74, p<0.001) and KS-10 index was 41.67 (responder 42.24, non-responder 40.33, p<0.001). For EQ-5D, the differ-ence between responders and non-responders was maintained in almost all subgroups. For KS-10, the difference between responders and non-responders was only maintained in a part of the subgroups. In the non-responder group the 
QoL was significantly lower, which is true for both EQ-5D and KS-10 (p<0.001). 
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Simple linear regression analysis confirmed that QoL was significantly influenced by response to treatment (EQ-5D (p<0.001, R2=0.054; KS-10 p<0.001, R2=0.029), 
and showed that QoL was also significantly influenced by age category (EQ-5D p=0.034, R2=0.008, Β=0.087; KS-10 p=0.002, R2=0.015, Β=-0.124 ), having a sibling with ADHD (EQ-5D p=0.021, R2=0.009, Β=-0.095; KS-10 p=0.022, R2=0.009, Β=-0.094), and presence of comorbidity (EQ-5D p<0.001, R2=0.028, Β=-0.166; KS-10 p=0.008, R2=0.012, Β=-0.109). Table 3. Quality of life of children according to EQ-5D: UK-tariff (Dutch tariff)*
ENTIRE SAMPLE RESPONDER NON-RESPONDER P-VALUE!Entire group 0.80 (0.81) 0.83 (0.84) 0.74 (0.75) <0.001
GenderMale 0.81 (0.82) 0.83 (0.84) 0.75 (0.77) <0.001Female 0.77 (0.78) 0.82 (0.83) 0.69 (0.68) <0.001
Age8-12 years 0.79 (0.80) 0.82 (0.82) 0.73 (0.74) <0.00113-18 years 0.82 (0.83) 0.85 (0.86) 0.76 (0.77)   0.005
Sibling with ADHDYes 0.77 (0.78) 0.81 (0.82) 0.69 (0.70) <0.001No 0.81 (0.82) 0.83 (0.84) 0.75 (0.76) <0.001
ComorbidityYes 0.78 (0.79) 0.81 (0.82) 0.73 (0.74) <0.001No 0.85 (0.86) 0.88 (0.88) 0.77 (0.79)   0.006
Type of educationPrimary 0.80 (0.81) 0.83 (0.84) 0.72 (0.74) <0.001Special primary 0.74 (0.75) 0.76 (0.76) 0.71 (0.72)   0.384Secondary 0.83 (0.84) 0.85 (0.86) 0.77 (0.78)   0.002Special secondary 0.79 (0.80) 0.82 (0.83) 0.75 (0.76)   0.179
Parent’s marital statusTogether 0.80 (0.81) 0.82 (0.83) 0.73 (0.74) <0.001Alone 0.84 (0.84) 0.87 (0.87) 0.78 (0.80)   0.048
Parent has a paid jobYes 0.81 (0.82) 0.84 (0.85) 0.74 (0.75) <0.001No 0.78 (0.78) 0.80 (0.80) 0.73 (0.74)   0.120
Parent’s educationLower 0.80 (0.81) 0.83 (0.84) 0.72 (0.73)   0.034Medium 0.79 (0.81) 0.82 (0.83) 0.74 (0.75)   0.001Higher 0.81 (0.81) 0.84 (0.84) 0.73 (0.74) <0.001Other 0.83 (0.82) 0.85 (0.84) 0.76 (0.73)   0.246
Family incomeBelow average 0.82 (0.83) 0.84 (0.85) 0.76 (0.78)   0.058
Average to 2x average 0.80 (0.81) 0.83 (0.83) 0.74 (0.75)     0.00
3x average and above 0.81 (0.82) 0.83 (0.84) 0.73 (0.74)   0.001Cannot / will not tell 0.78 (0.78) 0.81 (0.82) 0.70 (0.71)   0.005
 
* The mean outcome is reported. Differences relate to responders vs. non-responders and were tested 
using the UK-tariff as dependent variable. 
! p value reflects within-group differences.
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Table 4. Quality of life of children according to KS-10* 
ENTIRE SAMPLE RESPONDER NON-RESPONDER P-VALUE!Entire group 41.67 42.24 40.33 <0.001
GenderMale  41.77 42.33 40.36 <0.001Female 41.24 41.79 40.21   0.126
Age8-12 years 42.15 42.79 40.79 <0.00113-18 years 40.84 41.37 39.38   0.032
Sibling with ADHDYes 40.78 41.43 39.64   0.078No 41.94 42.45 40.61 <0.001
ComorbidityYes 41.32 41.95 40.03 <0.001No 42.58 42.93 41.43   0.099
Type of educationPrimary 42.42 43.25 40.64 <0.001Special primary 41.49 41.69 41.11   0.563Secondary 41.20 41.67 39.70   0.023Special secondary 40.54 41.07 39.70   0.475
Parent’s marital statusTogether 41.61 42.12 40.35 <0.001Alone 42.33 43.64 40.31   0.023
Parent has a paid jobYes 41.57 42.25 40.00 <0.001No 42.12 42.21 41.88   0.727
Parent’s educationLower 42.54 43.09 41.17   0.224Medium 41.87 42.17 41.21   0.118Higher 41.20 42.06 39.06 <0.001Other 40.44 41.37 36.74   0.193
Family incomeBelow average 42.60 42.76 42.23   0.632
Average to 2x average 41.55 41.79 40.56   0.021
3x average and above 41.56 42.33 39.44   0.005 Cannot / will not tell  41.38  42.31  39.36    0.012
* The mean outcome is reported. Differences relate to responders vs. non- responders and were tested 
using the UK-tariff as dependent variable.
! p value reflects within-group differences.Multiple regression analysis showed that a regression model with response to 
treatment (p<0.001, Β=-0.234), comorbidity (p<0.001, Β=-0.152) and marital 
status of the parent (p<0.024, Β=-0.090) combined showed the highest predictive value of R2=0.087 (p<0.001). There was no significant interaction between these 
explanatory variables.
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For KS-10, multiple regression analyses confirmed that a model with response to treatment (p<0.001), age category of the child (p=0.002), presence of comorbidity (p=0.013), and parent’s education (p=0.025) had the highest predictive value (p<0.001, R2=0.064). 
3.3.3 Quality of life of parents based on their child’s response to treatmentQoL of the parents (EQ-5D) did not show an association with their child’s treatment response. Table 5 shows that this is also true for most of the subgroups studied. In multiple regression analyses, the parents’ occupational status was the only 
variable with a significant association with the parents’ QoL (R2=0.029, p<0.001). 
3.3.4 Relationship between quality of life of children and parents
We found a significant correlation between children’s QoL measured by EQ-5D and parents’ QoL (R2=0.207, p<0.001). The correlation between children’s QoL 
measured by KS-10 and parents’ QoL was less strong though still significant (R2=0.104, p=0.014). Simple linear regression analyses confirmed this finding for EQ-5D (R2=0.043, p<0.001) and for KS-10 (R2=0.011, p=0.014). Multiple linear regression analyses showed that parents’ occupational status (p<0.001) was the 
only significant addition to this model (R2=0.067, p<0.001), with EQ-5D of children 
remaining at p<0.001. A similar finding was true for a regression model (R2=0.042, p<0.001) with KS-10 (p=0.007) and parents’ occupational status (p<0.001). 
3.4 DISCUSSION
This study provided QoL data of a large sample of ADHD families that are member of the ADHD parents’ association and found that QoL of children aged 8-18 years 
as measured by EQ-5D and KS-10 is significantly higher in children who are a 
responder to their treatment. Next to response to treatment, comorbidity and 
parents’ marital status had an independent significant positive association with the child’s QoL. QoL of parents did not show an association with their child’s response 
status, but it did differ significantly according to their child’s comorbidity status 
with a significantly lower QoL for parents of children with comorbidity. QoL of 
parents was mostly influenced by their own occupational status with higher QoL when having a paid job. This study allows for the conclusion on an association between QoL and treatment response, though it cannot be concluded that ADHD 
Chapter 3 Quality of life and treatment response
82
Table 5. Quality of life of parents according to EQ-5D: UK-tariff (Dutch tariff)*
ENTIRE SAMPLE RESPONDER NON-RESPONDER   P-VALUE!Entire group 0.83 (0.84) 0.83 (0.85) 0.81 (0.83) 0.256
GenderMale 0.85 (0.85) 0.83 (0.83) 0.92 (0.92) 0.363Female 0.83 (0.84) 0.83 (0.85) 0.81 (0.83) 0.183
Gender (child)Male 0.83 (0.85) 0.84 (0.85) 0.82 (0.84) 0.420Female 0.81 (0.83) 0.83 (0.84) 0.78 (0.80) 0.401
Age8-12 years 0.83 (0.85) 0.85 (0.86) 0.80 (0.83) 0.07113-18 years 0.82 (0.84) 0.82 (0.84) 0.83 (0.85) 0.674
More than 1 child 
with ADHDYes 0.81 (0.83) 0.83 (0.84) 0.78 (0.81) 0.312No 0.83 (0.85) 0.84 (0.85) 0.82 (0.84) 0.509
Comorbidity of childYes 0.82 (0.84) 0.82 (0.84) 0.80 (0.83) <0.001No 0.86 (0.86) 0.86 (0.86) 0.84 (0.86) 0.099
Child’s type of 
education Primary 0.84 (0.86) 0.85 (0.86) 0.82 (0.85) <0.001Special primary 0.79 (0.81) 0.81 (0.82) 0.74 (0.77) 0.563Secondary 0.82 (0.84) 0.82 (0.84) 0.84 (0.85) 0.023Special secondary 0.85 (0.86) 0.87 (0.89) 0.81 (0.82) 0.475
Parent’s marital 
statusTogether 0.83 (0.84) 0.84 (0.85) 0.80 (0.82) <0.001Alone 0.84 (0.85) 0.80 (0.82) 0.89 (0.90) 0.023
Parent has a paid jobYes 0.85 (0.86) 0.85 (0.86) 0.83 (0.85) <0.001No 0.76 (0.79) 0.77 (0.80) 0.72 (0.76) 0.727
Parent’s educationLower 0.83 (0.85) 0.84 (0.86) 0.79 (0.82) 0.224Medium 0.81 (0.83) 0.82 (0.84) 0.80 (0.82) 0.118Higher 0.84 (0.86) 0.85 (0.86) 0.84 (0.86) <0.001Other 0.88 (0.89) 0.87 (0.88) 1.00 (1.00) 0.193
Family incomeBelow average 0.82 (0.83) 0.81 (0.82) 0.84 (0.85) 0.632
Average to 2x average 0.81 (0.83) 0.81 (0.83) 0.81 (0.83) 0.021
3x average and above 0.86 (0.87) 0.86 (0.87) 0.87 (0.88) 0.005 Cannot / will not tell 0.83 (0.85) 0.87 (0.88) 0.73 (0.78) 0.012
*   The mean outcome is reported. Differences relate to responders vs. non- responders and were tested 
using the UK-tariff as dependent variable.
! p value reflects within-group differences.
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and response to treatment have a causal impact on QoL of children, due to the lack of a control group and the cross-sectional design of our study. Most children in our study were boys, which is consistent with other studies in ADHD 2,32. It also has been recognized before that there is a substantial influence of comorbid disorders on ADHD outcome 33. We compared our results to two other available studies on EQ-5D measurements in ADHD, a study in the UK (n=83) and a study performed in the UK and the United States (n=126) 20,21. In these studies, 
QoL was also rated by parent-proxy, however, QoL of parents was not reported. EQ-5D scores reported in the two other ADHD studies using EQ-5D resulted in utilities of 0.74 and 0.78 respectively which are closer to the average scores reported in our non-responder study group (QoL based on EQ-5D 0.74) than our responder study group (QoL based on EQ-5D 0.83). The outcome of KS-10 cannot 
be compared with other studies in ADHD, since to our knowledge this is the first published study on ADHD using this questionnaire. In the absence of a control group, Dutch population norm scores could have been presented as a reference to the ADHD sample in this study. However, 
population norm scores are not available for EQ-5D proxy specifically. Population norm scores were reported for the standard EQ-5D in the Netherlands 34. The average score in 1,218 responders of the general public was 0.86, which is higher than the score of 0.81 (Dutch tariff) we found in this sample of ADHD children. In our study, children in the ‘responder to treatment’ group were closer to the population average compared to the non-responder group (responder 0.84 and non-responder 0.75). Minimally important differences (MID) for EQ-5D were reported to be 0.082 (standard deviation: 0.032) for the EQ-5D (UK-tariff) 35. Therefore, based on indirect comparison, ADHD children non-responding to medication represent a clinical important difference in QoL compared to EQ-5D norm scores (0.75 vs 0.86).  For parents of whom 95.3% were female with an average age of 43, the average EQ-5D utility value in our study was 0.84. A previous Dutch study that collected norm scores for the EQ-5D in the Netherlands reported on two online samples and one face-to-face sample with a breakdown to age group and gender. Outcome for females aged 40-44: (EQ-5D online sample 1: 0.85), (EQ-5D online sample 2: 0.88), and (face-to-face: 0.90) 34. The authors stated that scores obtained in face-to-face interviews are generally higher than those obtained in online 
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samples 34. Comparing a utility of 0.84 in our online sample to 0.85 (difference 0.01) and 0.88 (difference 0.03) combined with the reported MID of 0.082 leads 
to the conclusion that our findings for parents of ADHD children represent a small difference to the general population which is limited in clinical importance.  The KIDSCREEN Group Europe reported Dutch population norm scores for 
the KS-10 proxy index for different age groups (age 8-18, 8-11, and 12-18) and gender 36. The KS-10 index ranges from 0-100 where 100 represents perfect health. For children of whom 82.4% were boys with an average age of 11.8, the average 
KS-10 index in the current study was 41.67 (responder 42.24 and non-responder 
40.33). A median KS-10 index of 79.95 for boys aged 12-18 was reported in the KS-10 handbook (n=546) 36. Concluding, the ADHD children in our study had remarkably lower QoL scores compared to norm data for KS-10 with the lowest scores for children in the non-responder group. 
 For EQ-5D, the significant difference in QoL of children between responders and non-responders was maintained in almost all subgroups. However, for KS-10, the difference was only maintained in part of the subgroups. EQ-5D and KS-10 have recently been compared based on their psychometric properties and it was found that generally, correlations between the EQ-5D dimensions and KS-10 items were low 22. Concluding, the two instruments measure different constructs of QoL 
in children with ADHD which might explain the different outcomes in subgroups 22. The larger difference between (KS-10 vs. norm scores) and (EQ-5D vs. norm 
scores) might be explained by the fact that KS-10 is more focused on aspects of QoL related to mental health and may therefore have better detected QoL problems due to ADHD 23. 
 We found a significant association between QoL in children and parents. 
However, despite significance, the association was rather weak, albeit a bit stronger for EQ-5D than for KS-10. However, any correlation between children’s QoL (EQ-
5D) and parents’ QoL (EQ-5D) in this study could potentially be explained by the fact that parents used the same measurement instrument twice: once to rate their 
own QoL and once to evaluate their children’s QoL by proxy rating. This could also 
explain the weaker correlation between the children’s KS-10 and parent’s EQ-5D, 
as this instrument was only used once (as a proxy rating for the children’s QoL). Although it is recommended to measure QoL of children and adolescents 
by self-rating, this study used parent-proxy ratings. This was done because 
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administering the questions to the children was considered to potentially distressing and negatively affecting the response rate. It must be addressed that 
respondent choice can possibly influence results. However, it is difficult to draw a conclusion on a positive or negative bias 30. When comparing our data to other 
studies, the proxy rating in our study should be kept in mind. One could argue that alternative measurement instruments like the 5-level 
EQ-5D or the Child Health Utility Index (CHU 9D) could have been used. However, none of the available methods is universally superior over the other 30. There is some concern using EQ-5D in mental health, but it has been acknowledged that it is important to further test generic measures such as the EQ–5D in mental health 37. A recent study reported on the validity and responsiveness of EQ-5D in children with ADHD and concluded that EQ-5D is a valid instrument for measuring QoL in children 22. EQ-5D was chosen in this study because we intended to provide utility values for health economic purposes, and CHU 9D was not available yet. We 
explicitly choose 3-level EQ-5D rather than 5-level EQ-5D, because this enabled referring to earlier studies and has a wide availability of population norm scores. Furthermore, at the time the study was conducted no utilities or scoring algorithm for 5-level EQ-5D were available. Our study has several limitations. Because of respondents’ membership of an association, it was assumed valid to rely on the parents’ knowledge about the ADHD diagnosis of their child. This assumption was also made in an earlier study on children with ADHD based on considerations of practicability, convenience and reliability 38. Relying on membership of an association could have led to bias presumably towards better outcomes, due to a more consciousness of the parents towards the illness, more compliance, and perhaps closer follow up of illness than the general population of ADHD children. Due to anonymity, it was impossible to verify whether the diagnosis was valid, and we had no information on whether or not the parent was diagnosed with ADHD. Since children in this study were using medication, it was not possible to collect information on symptom severity 
that was not confounded by use of medication. Further, this study used a proxy method for QoL measurement. There are limitations regarding measuring utilities 
using a proxy version, like the unknown extent to which it is possible to report utility accurately for another person without incorporation of own preferences 39. 
However, a study specific on ADHD and the use of EQ-5D proxy showed that the 
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proxy version was able to detect impairment in children diagnosed with ADHD 20. 
The use of closed-ended questions without options for adding extra information did not allow participants to state any reactions to the questions.  To avoid abovementioned limitations, designs were considered a priori to include ADHD families already participating in an observational or treatment study related to ADHD. However, in order to limit burden for participants and similar problems related to bias in such a sample it was decided not to use this option. QoL data collected alongside a clinical trial or selection and recruitment by 
treating physicians would possibly be influenced by a self-selection bias 40. Clinical 
trials have strict inclusion and exclusion criteria, so generalization might be more limited that way than with this survey. On the other hand, data collection alongside 
a clinical trial would allow to draw conclusions on the effect of specific medications (and side effects) on QoL which is an area that requires further investigation 6. 
Selecting patients in a doctor’s office, another option that was discussed, would have had similar limitations. After discussing with several opinion leaders and careful analysis of another ADHD study in the Netherlands (n = 70) and a study in Belgium (n = 537), it was concluded that the recruitment policy used in our study was the most feasible option given the aim of the study 38,41. On the basis of our study, we would recommend future studies to use a random sample with 
possibilities to confirm diagnosis and severity of disease, including validated checks 
on compliance, existence of a control group using a longitudinal methodology with both patient and parent self-report.  Despite the limitations, the large sample, the combined utility measurement for children and parents and use of two QoL questionnaires which was not been reported before, could be considered as strengths of this study. The results of this study could serve as input in health economic modeling studies, obviously using 
appropriate confidence intervals in order to give account for the limitations in this study.
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3.5 CONCLUSION
Our study is the first large-scale study describing QoL of children with ADHD according to EQ-5D and KS-10 with a distinction to response and non-response to treatment. Also, we described QoL of parents simultaneously, which has not 
been reported before. QoL of responders to medication was significantly higher compared to non-responders. However, utilities of the parents were quite similar between study groups and were not associated with their child’s treatment response. These results are useful information in health policy making, guideline development, clinical decision making and economic evaluations of (new) treatment alternatives in ADHD. The results show that response to treatment is associated with higher QoL, and that QoL was more compromised in the presence of comorbid disorders. This stresses the relevance of achieving treatment response in children with ADHD. 
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PART II
SOCIETAL COSTS
“The first wealth is health”R.W. Emerson

Association between 
societal costs and 
treatment response 
in children with ADHD 
and their parents
4
Van der Kolk A, Bouwmans CAM, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart van Roijen L. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. Springerplus 2015;4:224.
Chapter 4 Societal costs and treatment response
96
ABSTRACT 
Background: Attention Deficit Hyperactivity Disorder (ADHD) is associated with considerable burden of illness at a patient, family and societal level. Although pharmacological treatment is recommended by authoritative guidelines, evidence 
on its influence on the broader burden of illness is limited. As treatment induces costs, proper healthcare decision making requires evidence on the associated 
societal costs or benefits and particularly the difference that response to treatment can make. 
Method: Data on ADHD related resource use of patients 8-18 years and parents were collected by means of a cross-sectional, online survey amongst members 
of the Dutch parent association. Children were stratified to responders and non-
responders to treatment according to pre-defined expert definitions. 
Results: Analyses were performed on 618 questionnaires (428 responders; 190 non-responders to treatment). Children were 11.8 years on average and mainly boys (82%). Total monthly costs for children were €578 and €839 for responders and non-responders, respectively (p=0.021), with a breakdown to direct medical costs (€322 vs. €512; p=0.068), direct non-medical costs (€222 vs. €296; p=0.090), and indirect non-medical costs (€34 vs. €57; p<0.001). For parents, total costs were €246 vs. €399 for the responding and non-responding children, respectively (p=0.006), with a breakdown to direct medical costs (€130 vs. €211; p=0.010) and indirect non-medical costs (€116 vs. €181; p=0.092). Total monthly costs of children and their parents together were €824 and €1,228 for responders and non-responders to treatment, respectively (p=0.002). 
Conclusion: These results stress the importance of a focus on response to treatment, 
not only beneficial for patients and their family, but also resulting in considerable 
societal benefits. 
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4.1 INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is a heterogeneous psychiatric disorder characterized by a chronic pattern of age-inappropriate inattention, hyperactivity and impulsivity with a worldwide-pooled prevalence of 5.3% 1-3. Adverse consequences of ADHD may be far-reaching and symptoms often persist into adulthood 4-7.  ADHD is associated with a considerable burden of illness at both the patient, family, and societal level 8-11. Several studies concluded that ADHD has a negative 
impact on family, school and environmental level reflected in a lower quality of life (QoL), increased use of healthcare resources and risk for injuries, substance abuse, delinquency, and driving violations 12-18. The influence of ADHD on others than the patient is previously shown by productivity losses of parents and an increased use of healthcare resources by family members 8,19. Treatment by medication has been shown to decrease ADHD symptoms and to consequently improve the level of functioning. Medication is recommended by authoritative treatment guidelines 
worldwide as a first-line treatment option in case of ADHD 20-24. A recent systematic review of long-term outcomes of ADHD treatment and non-treatment supports 
the premise that without treatment, people with ADHD experience poorer long-term outcomes 25. Also, non-adherence to treatment could jeopardize treatment outcome 26. However, evidence is limited regarding the influence of treatment by medication on health care resource use of ADHD patients and their families, and the associated economic burden. This is a hindrance for the evaluation of the cost-effectiveness of current and future pharmacological interventions for ADHD 10. Studies on health care resource use and costs are preferably conducted from the societal point of view 27. A profound societal analysis includes medical (inside the health care sector) and non-medical costs (outside the health care sector), both direct (e.g. a visit to a doctor) and indirect costs (e.g. absence from work due to illness) 27. This broad societal perspective is especially indicated in evaluating the economic burden of chronic diseases like Alzheimer’s disease, Multiple Sclerosis, 
Rheumatoid Arthritis and ADHD. These are all examples of disease areas where new innovations could lead to reductions in costs for society due to reductions in productivity gains and reductions in costs for community and informal care 27. However, only few studies have monetized the impact of ADHD systematically by 
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providing an impression of the overall impact of ADHD from a societal perspective with a comprehensive measurement of indirect costs 10,11. A recent review concluded that data is lacking to draw conclusions regarding the relative cost-effectiveness of different pharmacological agents in ADHD 10. In recent years, the issue of non-compliance with (pharmacological) treatment is studied further to evaluate the clinical and economic effects of the management of compliance in patients 28. In ADHD treatment, persistence to treatment is frequently suboptimal indicating impaired compliance 26. Poor compliance, or in broader terms poor response to 
treatment, reduces the potential benefits from therapy. To our knowledge, costs in children with ADHD have not been studied in association to response to treatment.  This paper therefore presents a cost study on ADHD from the societal perspective including costs related to resource use and productivity losses. As 
medication is recommended by guidelines as a first-line treatment option and 
response to treatment is associated with potential treatment benefit, proper healthcare decision making requires evidence on the associated societal costs or 
benefits and particularly the difference response to treatment can make. 
4.2 METHODOLOGY 
The present study was part of a larger study on the burden of ADHD from a societal perspective including QoL 18. The current study analyses all direct and non-medical indirect costs related to ADHD (Table 1). Data on healthcare consumption of children and their parents and productivity losses of parents were collected by means of a cross-sectional, online survey that was completed by parents. 
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Table 1.  Types of resource use included for children (Ch*) and parents (P**) or both groups (Ch-P***)
DIRECT INDIRECT
Medical
Medical consultations (Ch-P)***Skills training (Ch)Parent training (P)Day-care treatment (Ch)Hospitalization (Ch)Medication (Ch-P) ****
Non-medical Weekend care (Ch)Remedial teaching at school (Ch)Care after school (Ch)Diet (Ch)
Agency for child welfare (Ch)Police (Ch)Special education (Ch) Productivity lossesAbsenteeism (P)Presenteeism (P)
*Ch: Item included in the cost calculation of the children only; **P: Item included in the costs for parents 
referred to their own health consumption because of their child’s ADHD; ***Ch&P: Item included in 
both the cost calculation for the children as well as in the cost calculation for the parents, but costs for 
children are not included in the costs for parents; ****Indirect medical costs are excluded according to 
the Dutch guidelines for pharma-economic research 55. 
4.2.1  Study sampleThe study sample was derived out of the members of the Dutch association Balans for parents of children with ADHD. Parents of children with ADHD were asked via the magazine of the association to join the study online by means of a personal login code. Inclusion criterion: being a parent of a child aged 8-18 years diagnosed with ADHD. Because of this membership, it was assumed valid to rely on the parents’ knowledge about the ADHD diagnosis of their child. Due to anonymity it was not possible to verify whether the diagnosis was indeed valid.  The questionnaire was available from 01-09-2010 until 03-10-2010. The parent taking care of the child most of the day was asked to complete the questionnaire. Parents were not reimbursed for their participation in any way. In case the parent had more than one child with ADHD, parents were asked to answer the questions for their youngest child. Since the study did not interfere with clinical practice, according to Dutch regulation no approval of an ethics 
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committee was needed. Also, with the methodology of this study focusing on parents instead of patients, it was not obligatory to use informed consent forms. Nevertheless, the protocol took into account all privacy aspects and all necessary efforts were taken in this study to protect privacy. Participants were informed 
on the purpose of data collection (scientific publication), respondents were fully 
free to decide to join and were able to exit the questionnaire at any time. Due to the login code that was distributed by Balans magazine, only members of Balans were able to access the questionnaire. The questionnaire could be completed only once per IP address, but these IP addresses were not saved and/or traceable so participants’ anonymity was guaranteed. Also, adequate security measures were employed in order to prevent unauthorized access, manipulation to or disclosure 
of the personal data although these were already unidentifiable when stored.
4.2.2 Responder groupsIn order to investigate the association between costs and response to treatment, 
descriptions for response to treatment had to be defined since these were not 
readily available. These descriptions were created by five Dutch ADHD experts. This 
number of five experts was considered appropriate for the study, in accordance with minimum requirements of a Delphi panel 29. The panel of experts was selected 
based on their experience in the field of ADHD treatment, and a scientific focus. 
The experts included were child- and youth psychiatrists (n=5), both male (n=4) 
and female (n=1) and aged 43 to 55 (mean 49.8). The experts had 10 to 22 years 
of experience with ADHD medication and treated 30-90 ADHD patients per month. 
The experts were consulted independently and were not aware of the identity of 
the other experts joining the panel. An expert not joining the Delphi panel verified 
the questions proposed to the experts in advance. The questions for the panel 
were sent and returned by email. After all experts had returned the questionnaires, 
their answers were combined. The proposals for the final answers, as well as the 
anonymous individual answers of the participants were reported to the experts after 
round 1. In the second round, experts were asked whether they liked to change their 
previous answers, based on the proposal for the final answer. Before distributing 
the questions to the experts, it was decided that consensus was supposed to be 
reached after two rounds of answers when (a) feedback of the experts was clear 
and (b) when experts did not all change their answers based on the mean of the 
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feedback of the first round. The experts indicated that two assumptions were crucial 
for the foundation of the definitions for response to treatment and non-response to 
treatment. First, based on an earlier study, response to medication had to be defined 
by recovery both at home and at school in order to reflect a proper description of the child’s daily functioning (functioning - F) 30,31. Second, as compliance to medication is known to play an important role in the child’s functioning, it was considered necessary to include a statement on the child’s compliance as well (compliance - C) 32. Theoretically, this led to the following combinations: 
(C+; F+): Compliance to prescribed daily dose of medication, no problems in functioning.(C-; F-): Non-compliance to prescribed daily dose of medication, problems in functioning.(C-; F+): Non-compliance to prescribed daily dose of medication, no problems in functioning.(C+; F-): Compliance to prescribed daily dose of medication, problems in functioning.
The experts decided to exclude combinations (C-; F+) and (C+; F-). Experts considered (C-; F+) to describe children not requiring medication, as no problems arise when medication is not taken according to prescription. (C+; F-) was considered to 
reflect several situations in which proper compliance is not translated into proper functioning. The design of the study precluded to analyze these situations. The two remaining combinations, (C+; F+) and (C-; F-), were the basis for responder 
group definition. As it was deemed necessary to provide parents with a hands-on 
description of these groups, the experts operationalized the combinations to the following descriptions based on treatment compliance and functioning in family, school and the environmental level:
* Operationalization C+; F+ to ‘responder to treatment’: Your child uses the prescribed 
daily dose of medication. Using this treatment, your child’s functioning is fine and there are no noteworthy problems at home, at school, with peers or during leisure time.* Operationalization C−; F− to ‘non-responder to treatment’: The daily dose of medication used by your child differs from the dose prescribed. Using this treatment, your child’s functioning is hampered by problems at home, at school, with peers or during leisure time for short periods of time. 
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4.2.3 The questionnaireThe questionnaire on healthcare consumption and productivity losses for patients with psychiatric disorders (TiC-P) was used, which is designed for self-report and is focused on psychiatric disorders like ADHD 33. Two versions are available, one for adults and one for adults to describe their children 34,35. The selection of this questionnaire was based on feasibility, reliability and validity combined with comprehensiveness of cost items and ability of online use 36. The questionnaire had been used on an ADHD sample in another study before 14. In the present study, both TiC-P versions were used. The questionnaire was adjusted using information from a previously performed study focused on societal cost related to ADHD as is allowed by the TiC-P manual 14,37. The recall period was one month for both medical consumption and productivity losses. TiC-P starts with general demographic questions on gender, age, (type of) education, marital status, and job. 
TiC-P questionnaires are generic, meaning that items are not related to a specific disorder. In this study, resource use was supposed to be related to the ‘target 
disorder’ ADHD. Parents were provided with examples of costs that were either related (visiting a doctor for ADHD problems) or non-related to ADHD (visiting an ear, nose and throat specialist for ear tubes) to aid them in making a correct distinction. This could also mean costs for parents getting coaching and/or parenting tips; this is only necessary because of their child with ADHD and therefore these costs are considered related to ADHD. Costs for parents referred to their own health consumption only plus costs due to productivity losses. Table 1 presents the cost items that were included, Table 2 presents the unit costs per cost item. For children, additional questions to Table 2 were focused on costs for diet, the use of ADHD medication, use of special education and absence from school or sports. Costs of productivity losses were focused on productivity losses of paid work including absenteeism (absence from work) and presenteeism (reduced productivity while at work). Non-paid work was not included in this 
study, since parents of children aged 8-18 were expected to have limited voluntary activities. 
4.2.4 Cost calculationBottom-up methodology was used to calculate total direct medical costs; that is, the total number of medical contacts was multiplied by the reference prices based on 
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the Dutch manual for cost studies (prices were updated to 2012 prices) 38. A visit to ‘RIAGG’ (Dutch mental health facility: a combination of 1st and 2nd line care) was assumed to have similar costs as 1st line mental health care in case of ADHD. Unit costs for a visit to a school doctor and a company doctor were assumed to be similar to a general practitioner visit as costs for a school doctor and a company doctor 
were not defined in the costing manual. These assumptions were confirmed by a specialist in costing studies (LH). Costs for individual and group trainings were 
not specified in the costing manual. For individual sessions, costs for ambulatory 2nd line care were assigned based on communication by the Dutch mental health association ‘GGZ Nederland’. For group trainings, the association estimated time 
used by the expert divided by the number of clients per session. For day-care, a weighted average of day-care treatment (8 hours a day) and half-time treatment (4 hours a day) was used (day-treatment €183.70 + half-time treatment €163.53). For parents, the average number of days of medication use in the entire group of parents per month was multiplied by mean public Dutch costs of medication use in adults (€0.66 per day) 39. Direct non-medical costs related to weekend care and 
care after school were based on several sources as these were not defined in the costing manual. Weekend care was estimated based on productivity costs 38. For remedial teaching, average price per hour for remedial teaching were used for cost calculation 40. Care after school was rated based on average costs for baby-sitting 41. For diets, parents were asked to define costs below €25, between €25 and €50 or above €50 in one month if a special diet was indicated. For indirect non-medical costs, the agency for child welfare and police were assumed to have the same cost 
price since costs for police was not defined in the costing manual 38. Prices for special education were based on prices of the Dutch Ministry of Education with a yearly additional cost of €4,700 42. 
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Table 2.  Unit costs used for children (Ch) and parents (P) or both groups (Ch-P) in Euro 2012
CH-P UNIT COSTS 381Consultation per session - -General Practitioner Ch-P 29.73Psychologist2 Ch-P 84.95Social worker Ch-P 69.02
Psychotherapist, first line3 Ch-P 81.76RIAGG4 Ch-P 81.76Phychiatrist outpatients’ department P 109.37Medical specialist Ch 109.37Emergency Room Ch 160.34Physiotherapist Ch 38.23Occupational therapist Ch 23.36Speech therapist Ch 35.04Alternative therapist Ch-P   50.00 56Paramedical (physiotherapist, occupational and alternative therapist) P 37.12School doctor Ch 29.73Company doctor P 29.73Trainings per session - -Social skills training / creative therapy / self regulation5 - individual Ch 181.58Social skills training / creative therapy / self regulation5 - group Ch 100.00Psychological education6 / parent training / family coach – individual P 181.58Psychological education6 / parent training / family coach – group P 100.00Day-care treatment Ch 173.62Hospitalization Ch 246.35Agency for child welfare Ch 69.02Weekend care (hours) Ch 13.27Police (contacts) Ch 69.02Remedial teaching at school (hours)7 Ch 55.00 40Care after-school (hours) Ch 5.93 41
1 Dutch cost manual unless specified otherwise and prices were indexed to 2012 prices; 
2 Second line care aimed at more severe complaints needing a longer treatment duration; 
3 Short duration (up to 8 sessions) aimed at mild to moderate complaints; 
4 Regional institution for ambulant psychiatric health care 
5 To control or direct oneself according to rule;
6 Provide information to parents regarding coping with the ADHD of their child;
7 Special teaching for backward and slow learners.
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This led to extra monthly costs for special primary and special secondary education of €392 compared to regular education. For the questions on child’s health-related school absence and failure to participate in sports due to ADHD no costs were assigned. Cost of absence from work of the parent related to their child with 
ADHD was calculated by multiplying the number of days off work with predefined 
productivity costs per hour of absence with a specification to age group and gender 38. Costs of presenteeism was determined by the Osterhaus method 43. Parents were asked about the number of days of hindrance due to ADHD of their child 
and their estimated efficiency on these days in comparison to usual efficiency. 
Linear extrapolation (LE) was applied as it was in a former ADHD study as well 14. 
Applying LE, all costs were extrapolated to one year by multiplying the monthly 
costs by twelve assuming the monthly costs to reflect usual costs. There is no 
specific reason to assume that the cost distribution is non-linear, although there might be small variations during the year.
4.2.5 Statistical AnalysisCompleteness of the data is reported based on numbers completing the questionnaire. Furthermore, the data was reviewed for fraudulent responses, errors (intentional or not), missing data and possible strange patterns indicating programming errors. Study variables are described using absolute numbers 
(mean and median), percentages and 95% confidence intervals. Missing data was replaced by means of multiple imputation as is the recommended method to 
reflect estimates across the range of circumstances considered 44. Variables were considered candidates for the imputation process based on simple regression 
followed by a regression model based on significance and their independent 
influence on total costs. To check if distribution was normal, data were tested for skewness. Descriptive statistics, independent samples t-test and Chi-square test were used accordingly for analyzing differences between groups (p<0.05; 2-tailed). As healthcare cost data tend to be skewed, tests were repeated using Mann-Whitney tests to check if conclusions remained similar using a test for non-parametric data. Multiple regression analysis was used to check for independent 
influence of other factors than treatment response on the mean total costs. A 
p-value of <0.05 was considered significant. It was not possible to examine test-retest reliability in this study, since the questionnaire was administered only once. Analyses were performed in IBM SPSS Statistics version 21. 
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4.3 RESULTS 
4.3.1. Demographic characteristicsAnalyses were performed on 618 questionnaires of children and 590 questionnaires of parents (28 respondents – 4.5% – did not complete all questions). Table 3 reports on the demographic characteristics for children and parents. ADHD had mainly been diagnosed by a psychiatrists or a pediatrician (67.8% and 17.8%, respectively). Children were reported to be a responder to treatment in 428 cases (69.3%) and non-responder to treatment in 190 cases (30.7%). Mean age of children was 11.8 years. The number of comorbidities was similar between responder groups, 
although there was a near-significant difference of more children with three or more comorbidities in the non-responder group compared to the responder group (p=0.051). Comorbidities in the entire sample were Asthma or chronic Bronchitis 
(n=78; 13%), Epilepsy (n=7; 1%), Anxiety disorder (n=80; 13%), mood disorder (n=66; 11%), learning disorder (n=235; 38%), Gilles de la Tourette / tic disorder (n=25; 4%), ODD/CD (n=63; 10%), mental retardation (n=4; 0.6%) and, Autism 
Spectrum Disorder (ASD) (n=152; 25%). Anxiety disorder (responder n=48 - 11.2%, non-responder n=32 - 16.8%; p=0.049), and mood disorder (responder n=38 – 
8.9%, non-responder n=28 – 14.7%; p=0.023) differed significantly between the responder and non-responder group with more cases in the responder group.  
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Table 3. Children’s and parent’s characteristics
ENTIRE 
SAMPLE RESPONDER
NON-
RESPONDER P-VALUE*ChildrenN 618 (100.0%) 428 (69.3%) 190 (30.7%)
Mean age 11.8 (8-18) 11.8 (8-18) 11.7 (8-18) 0.856
GenderMale 509 (82.4%) 359 (83.9%) 150 (78.9%) 0.138Female 109 (17.6%) 69 (16.1%) 40 (21.1%)
Number of comorbid 
disorders0 166 (27.6%) 126 (30.0%) 40 (22.1%) 0.0511 242 (40.3%) 170 (40.5%) 72 (39.8%)2 132 (22.0%) 89 (21.2%) 43 (23.8%)3 or more 61 (10.1%) 35 (8.3%) 26 (14.4%)
Type of education Primary 241 (40.2%) 165 (39.3%) 76 (42.2%) 0.119Special primary 86 (14.3%) 57 (13.6%) 29 (16.1%)Secondary 219 (36.5%) 165 (39.3%) 54 (30.0%)Special secondary 54 (9.0%) 33 (7.9%) 21 (11.7%)ParentsN 590** (100.0%) 415 (70.3%) 175 (29.7%)Age (mean, range) 43.2 (30-63) 43.2 (30-63) 43.3 (30-59) 0.931
GenderMale 28 (4.7%) 22 (5.3%) 6 (3.4%) 0.328Female 562 (95.3%) 393 (94.7%) 169 (96.6%)
Marital statusTogether 534 (90.5%) 381 (91.8%) 153 (87.4%) 0.097Alone 56 (9.5%) 34 (8.2%) 22 (12.6%)
EducationLower 83 (14.1%) 59 (14.2%) 24 (13.7%) ***Medium 265 (44.9%) 182 (43.9%) 83 (47.4%)Higher 232 (39.3%) 166 (40.0%) 66 (37.7%)Other 10 (1.7%) 8 (1.9%) 2 (1.1%)
Paid jobYes 471 (79.7%) 328 (79.0%) 143 (81.3%) 0.541No 120 (20.3%) 87 (21.0%) 33 (18.8%)
More than 1 child 
with ADHDYes 133 (22.5%) 85 (20.5%) 48 (27.4%) 0.065No 457 (77.5%) 330 (79.5%) 127 (72.6%)
* p value reflects differences between responders and non-responders;
** 28 parents did not complete the questionnaire;
*** Pearson Chi-Square not possible due to low expected numbers.
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Data on resource use for children was missing for 19 respondents and data on resource use and production losses for parents for 27 respondents. This missing data was replaced by means of multiple imputation. Data were imputed based on the most optimal regression model. For children, this model was based on responder group (responder vs. non-responder), gender of the parent, >1 child with ADHD in the family and comorbidity. For parents, data was imputed based on a model with responder group, >1 child with ADHD, comorbidity and marital status. 
 Table 4 presents the mean and median monthly costs and their 95% confi-dence interval for direct medical and non-medical costs and indirect non-medical costs of children and parents. The group non-responding children incurred 
significantly higher total costs per month compared to responding children. 
This was reflected in total direct medical costs (€190 higher), direct non-medical costs (€74 higher) and indirect non-medical costs (€23 higher). Day-care, trainings and doctor’s consultation differed most remarkably between responder groups 
(€71, €65 and €57 higher for non-responders, respectively), with a significant difference for doctor’s consultations (1.3 visits responding children vs. 2 visits non-responding children; p=0.004). Remedial teaching at school accounted for 
€33 extra per month for the non-responder group (€132 for responders, €165 for non-responders; p=0.045). For the questions on child’s school absenteeism and failure to participate in sports no costs were assigned. Absence from sports due to ADHD was mentioned by the responder and the non-responder group (7.7% vs. 16.8% respectively, p=0.002). School absenteeism was reported for 72 days by the responder group and for 50 days by the non-responder group (16.8% vs. 26.3% respectively, p=0.003). Estimated annual costs for responders and non-responders to treatment were €3,864 vs. €6,144 for direct medical costs (p=0.068), 
direct non-medical costs €2,664 vs. €3,552 (p=0.090); indirect non-medical costs €408 vs. €684 (p<0.001); and total costs for children €6,936 vs. €10,068, p=0.021 (responder vs. non-responder). Monthly costs per responder group are reported in Table 4.
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Table 4.  Mean (median; 95%CI) costs of children with ADHD and parents per month (in Euro 2012) 
ENTIRE 
SAMPLE RESPONDER
NON-
RESPONDER P-VALUE*
CHILDREN
Direct medical costsDoctor’s consultations** 114 (30) 96 (0; 78 – 115) 153 (95; 123 – 193) 0.004Trainings 126 106 (0; 69 – 148) 171 (0; 117 – 240) 0.068Day-care treatment 73 51 (0; 11 – 84) 122 (0; 32 – 218) 0.144Hospitalization 41 41 (0; -10 – 93) 41 (0; -37 – 125) 0.999Medication 26 (12) 27 (12; 25 – 30) 24 (12; 20 – 29) 0.300Diet 5 4 (0; 2 – 5) 6 (0; 4 – 10) 0.145Total direct medical costs 386 (109) 326 (96; 222 – 422) 518 (145; 334 – 691) 0.068
Direct non-medical costsWeekend care 83 80 (0; 59 – 104) 91 (0; 60 – 122) 0.578Remedial teaching at school 142 (110) 132 (0; 114 – 151) 165 (110; 137 – 194) 0.045Care after-school 6 6 (0; 3 – 9) 7 (0; 2 – 12) 0.638Total direct non-medical costs 232 (110) 218 (110; 191 – 253) 290 (150; 224 – 315) 0.090
Indirect non-medical costsAgency for child welfare 10 6 (0; 3 – 9) 20 (0; 9 – 20) <0.001Police 0 0 (0; 0 – 0) 1 (0; 0 – 1) 0.154Special Education 30 (28) 28 (0; 23 – 33) 36 (0; 28 – 45) 0.090Total indirect non-medical costs 41 34 (0; 28 – 40) 57 (0; 46 – 68) <0.001Total costs children 658 (322) 578 (266; 465 – 691) 839 (511; 648 – 1029) 0.021
PARENTS
Direct medical costsDoctor’s consultations*** 60 47 (0; 39 – 57) 88 (33; 69 – 108) <0.001Trainings 93 81 (0; 54 – 109) 118 (0; 74 – 166) 0.145Medication 1.60 0.93 (0; 0.5 – 1.3) 3.1 (0; 2 – 4) <0.001Total direct medical costs 154 130 (0; 98 – 162) 211 (82; 153 – 269)   0.010
Indirect non-medical costsProductivity losses due to absenteeism and presenteeism 136 116 (0; 74 – 159) 181 (0; 113 – 259)   0.092Total costs parents 292 (65) 246 (21; 191 – 300) 399 (182; 298 – 482)   0.006
CHILDREN AND PARENTStogether   Total costs 948 (524) 824 (412; 690 – 957) 1228 (740; 1003 – 1453)   0.002
*p value reflects differences between responders and non-responders. 
** All consultations are summed up. Table 2 provides an overview specified per type of doctor.
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For parents, total monthly costs were significantly different between responder groups, incurring higher costs of €153 for a parent when having a child non-responding to treatment. Estimated annual costs were €2,952 for the parents of responding children and €4,788 for parents of non-responding children (p=0.006). Both total direct medical and indirect non-medical monthly costs were higher for parents of a non-responding child with €81 (p=0.010) and €65 (p=0.092) respectively. As for children, doctor’s consultations differed largely between 
responder groups and this difference was significant (responder 0.75 per month vs. non-responder 1.43 per month; p<0.001). Estimated annual costs were €1,560 vs. €2,532 for direct medical costs (p=0.010); indirect non-medical costs were €1,392 vs. €2,172 (p=0.092) and total costs were €2,952 vs. €4,788 (p=0.006) (responder vs. non-responder).
 Costs for children and parents combined led to a significant difference 
between responder groups in total costs with €404 extra per month when a child is a non-responder to treatment (monthly costs responder €824, non-responder €1,228; p=0.002). Estimated annual costs were €9,888 for the responder group and €14,736 for the non-responder group (difference €4,848; p=0.002). Multiple regression showed that the factors treatment response, gender of the parent, >1 
child with ADHD and comorbidity had an independent influence on total costs for children. For total costs of parents, the factors treatment response, >1 child with 
ADHD, comorbidity and marital status of the parent were independent influencers.
4.4 DISCUSSION 
The purpose of this study was to estimate ADHD related costs for children and their parents taking a societal perspective associated with treatment response. 
Non-response to treatment was shown to be associated with significant higher direct and indirect costs both inside and outside healthcare for children as well as their parents. Estimated annual costs differed between response groups, with 
extra costs of €4,848 for non-responders. Costs for special education were very 
low relative to the other cost items in this study. This could reflect little need 
for extra attention, but it can also be a reflection of the general national Dutch trend towards less use of special education 45. A study on the economic impact of ADHD in Europe concluded that the largest cost category was in fact in education representing 50% of national costs on average 10. The study did not include non-
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paid work based on the assumption that parents of children aged 8-18 would have limited voluntary activities. They could be coach of sports teams, be of help in their church or follow higher education. These costs were not included and could have impacted the absolute results. Most children were boys, which is consistent with other studies in ADHD. In the entire sample, only 28% had no comorbidity and 10% even had more than three comorbidities. This is consistent with the 
estimation that in general around 60–100% of patients with ADHD exhibit one or more comorbid disorders 46,47. The percentage of 10% of children with comorbid ODD/CD and 25% of ASD in our study group seems to be low compared to other studies 46. Anxiety disorder and mood disorder differed significantly between the responder and non-responder group with more cases in the responder group. This 
outcome was not expected, since comorbidity is expected to negatively influence ADHD outcomes 46.  Recently, a systematic review was performed on European studies of ADHD-related costs published between 1990 and 2013 10. Only seven studies were found. The studies were conducted in Belgium, the Netherlands, Germany (n=3), Sweden and the United Kingdom. All studies included direct medical costs for children, but only one study included direct medical costs for family members whereas only two included costs of productivity loss of family members (indirect non-medical costs) 14,48. Considering the methodology and the country of origin, only one study in the review can be compared well to the study at hand 14. In that study, three 
groups were studied based on proxy reporting by the mother: 70 children treated by a pediatrician for ADHD, a non-matched group of 35 children with behavior problems and 60 children without behavior problems. The study showed the yearly 
direct medical costs of ADHD patients to be €2,040. Moreover, ADHD children incurred yearly direct medical costs of €5,908 which is in the range we found in our study (€3,864 for responders to €6,144 for non-responders). Indirect costs for the mothers of children with ADHD were €2,243 for mothers compared to €1,560 in our responder group and €2,172 in our non-responder group.  It has been described before that studying ADHD is a challenge and concessions must be made considering time, money and information needed 49. Limitations of our study are the following. First of all, a practical choice had to be made regarding selection of participants. As an alternative, the possibility to include parents of children already participating in a trial related to ADHD was discussed. 
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It was decided not to do so, because of burden for participants and potential bias. We chose for parents who are a member of an ADHD parent association. Because of this membership, it was assumed valid to rely on the parents’ knowledge about the ADHD diagnosis of their child. Due to anonymity it was not possible to verify whether the diagnosis was valid or to collect data on disease severity. Similar considerations were stated in an earlier study, which used the same method of parent selection based on considerations of practicability, convenience and reliability 13. With respect to generalizability of this data, future studies should 
take the specific study group in this study into account. Second, other than the descriptions provided by parents, no insight in actual medication use by means of 
for example a saliva test was available. This has been shown to provide different results compared to parent report 50. Third, the definition of non-responder in this study differs from clinical trials. These trials mainly aim at short-term effects and therefore at symptomatic improvement. This study aimed to focus on functional 
improvement as well. We explicitly broadened our definition of response and non-response, given our attempt to add to data generation on burden of illness in ADHD. Furthermore, it is questioned if current clinical trial designs in ADHD 
and response definitions are useful for measurement of individual treatment response anyway 31. The definition we used provided a hands-on description of the study groups which provided easy reference to the respondents. Since we also wanted to ask questions on quality of life and costs for both the children and the parents we decided not to increase the questionnaire any further with a more in-depth description of functioning consisting of multiple questions. The 
statement of responders has been carefully assessed by the experts, but not by 
parents. We assumed the definition to be clear to parents, although the potential for alternative interpretations cannot be fully ruled out. Fourth, since we relied on a membership pool of an ADHD parent association, it could be the case that more severe ADHD cases were included in this study with a potential upward bias 
in the estimation of costs. Although, this is in conflict with the low percentage of comorbid ODD and ASD. Fifth, due to the cross-sectional methodology we cannot speculate about the causal relationship between these results and/or potential 
long-term benefits or disadvantages. A sixth point of interest in this study is that 
the definition of ‘response to treatment’ and ‘non-response to treatment’ includes some statement on impaired functioning of the non-responding child. One might 
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postulate that impaired functioning a priori leads to higher costs. On the other hand, 
the response definitions did not include any statement on health care resource use which is the main focus of this study. Considering the remarkable difference in costs between both groups, the main conclusion of our study implying that non-response to treatment leads to higher costs seems to hold. We therefore assume 
the influence of this response definition to be modest only. Seventh, in case parents reported to have more than one child with ADHD, they were asked to report on 
their youngest child in order to reach consistency. The influence of this guidance 
is unknown. It could have resulted in underestimation of costs due to experience of the parent with the older child with ADHD, but also in overestimation since the youngest child was diagnosed most recently which could be associated with higher costs or younger children requiring more attention in general. Finally, 
next to pharmacological treatment, other types of treatment could have had an 
influence on the results since multimodal interventions are recommended for ADHD treatment 24,51. Pharmacological treatment together with interventions using behavioral techniques form the foundation for ADHD treatment 24. A meta-analysis of randomized controlled trials concluded that behavioral interventions have positive effects on a range of outcomes when used with patients with ADHD 51. Due to the method of our study it cannot be distinguished what the specific 
influence of either pharmacological treatment or behavioral interventions has been.  On the basis of our study, we would recommend future studies to use a 
random sample from multiple countries with possibilities to confirm diagnosis including validated checks on compliance, including validated questionnaires reporting on symptomatology (e.g. ADHD-RS-IV ADHD Rating Scale version 4 52) and functioning (e.g. CGI-I Clinical Global Impression scale) 53, and existence of a control group using a longitudinal methodology with patient self-report,  and parent and teacher report.
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4.5 CONCLUSIONS
The results of this study provide relevant information for health care provision and use, since the results stress the importance of focusing on achieving response to treatment in children receiving (pharmacological) treatment for ADHD. Direct 
medical costs for children – specifically day-care treatment and trainings – were 
identified to be the most disparate with higher costs in the non-responder group. Direct non-medical costs were also unequal between groups with the highest difference in coaching at school. For parents of children with ADHD, doctor’s consultations were higher in the responder group. Treatment pathways should 
incorporate a focus on achieving response to treatment reflected in recovery both at home and at school and proper compliance to prescription. Also family involvement should be a standard part of the pathway.  The results of this study contribute to the large evidence gap in societal cost calculation related to ADHD and emphasize the need for a broad perspective when analyzing problems related to ADHD since non-medical costs have a large contribution to total ADHD-related costs. With the trend of cost-effectiveness studies being used increasingly in guideline development and clinical decision-making, there is a clear need for comprehensive cost studies like the study at hand 54. As was described by others, programs to facilitate collaboration among payers, patients, employers, and educational institutions may provide opportunities to create strategies to consider the societal impact of ADHD and strategies to mitigate its impact 11. This study may aid in indicating which parts of healthcare consumption and non-direct and indirect costs such strategy should primarily be focused on.
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ABSTRACT
Background: Attention Deficit Hyperactivity Disorder (ADHD) has been shown to impair major life activities including educational functioning. However, there 
is no consensus on the specific cause for the impact on this worse educational outcome. This systematic review aims to identify factors that have been associated with educational and academic underperformance of children and adolescents with ADHD. 
Method: A literature search was conducted using PubMed and the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The study focused on articles presenting results of data-based analyses related to ADHD and keywords related to education. 
Results: The search resulted in 376 records that were screened by title. Of these, 185 articles were screened by abstract and 35 met the eligibility criteria for inclusion in the review. These 35 articles were related to seven domains: educational training, educational environment, pharmacological treatment, ADHD symptoms, associations of ADHD with academic outcomes, self-concept, and 
specific skills. The main source of educational challenges seems to be related to the inattentive symptoms (or subtype) of ADHD. This outcome is different than 
expected, since hyperactive symptoms are pronounced more prominently and often refer children to clinical practice. Inattentive symptoms amongst others 
refer to difficulties in organization skills and can lead to decreased self-efficacy 
and development of depressive symptoms. This decreased self-efficacy and the 
depressive symptoms were also found to be related to influence the relation between ADHD and academic performance. Educational outcomes were shown to be improved using small group work, learning via a computer-based service and as a result of coaching and pharmacological treatment. 
Conclusion: To help children and adults achieve educational goals that now are out of reach, more attention should be spent to the inattentive symptoms of ADHD 
and possibilities to overcome experienced problems. 
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5.1 INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is the most common neuro-psychiatric disorder in children and adolescents 1. The prevalence rate is similar across countries in Europe and throughout the world and is estimated at 5.3% 1. Core symptoms of ADHD comprise inappropriate levels of inattention, hyperactivity and impulsivity 2. Multiple follow-up studies have been published that show ADHD persists into adolescence and adulthood in around two-thirds of the population 3,4. Adult ADHD is estimated to have a worldwide-pooled prevalence of 4.4% 1. It has been shown that ADHD impairs major areas of life, including quality of life (QoL), social relations, family functioning, and education and occupational functioning 5-8.  DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) state that a diagnosis of ADHD is only confirmed if the child exhibits a number of inattentive, impulsive and hyperactive behaviors over a period of 
six months, which started before the age of seven, which should be present in 
school and at home, and which significantly impair daily functioning 9. In practice, indeed problems in school often bring the child with ADHD to clinical attention 10. Numerous studies have reported on the association of ADHD and poorer grades, poorer reading and math standardized test scores, and increased grade retention 10-14. Also, children with ADHD are more likely to use special educational services than children without ADHD 15. As several studies report on lower IQ (intelligence quotient) in children with ADHD compared to youth of the same age and gender without the disorder, it could be the case that IQ is related to the 
educational problems rather than specific ADHD symptoms 16. However, even 
when taking IQ into account, children with ADHD showed significant educational 
under-attainment relative to what would have been expected on their intellectual potential 14. Therefore, it could be the case that several factors together account for the lower average education achievements in children and adolescents with ADHD. It seems fair to conclude that there is a general consensus on a certain 
but not precisely defined negative impact of ADHD on school outcome. However, 
there is no consensus on the specific cause for this impact: is it the ADHD itself that causes the impact or are underlying factors at stake? 
Chapter 5 Educational performance
122
Given these considerations, this systematic review focuses on the following question: “Is it possible to identify factors that have been demonstrated to be associated with educational and academic performance in ADHD based on the current available evidence, and if so: which factors are those?’ This research will contribute to understanding the impact of ADHD on educational and academic performance and will offer insights for studies of interventions to decrease the negative impact. To our knowledge, no other systematic review has been performed 
on this specific topic so far.
5.2 METHODS
A literature search on English-language articles was conducted using the PubMed® (Public Medline) database (biomedical literature from MEDLINE® - Medical Literature Analysis and Retrieval System Online, life science journals, and online books) to gain insight in the association of ADHD and educational and academic performance. The search was focused on articles published in PubMed from 
January 2000 till the final search that was conducted on October 13th 2014. 
5.2.1 Guidelines systematic reviewAssessment of the tracked records followed the PRISMA guidelines for methodology (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 17. PRISMA 
is the most often used methodology for reporting systematic reviews, expressing the aim of standardized reporting and enhancing the clarity of systematic reviews with a generic approach 18. 
5.2.2 Identification and screeningFor this search, the Medical Subject Headings (MeSH®) for indexing PubMed 
citations were used, but no extra subheadings were selected.  The key words were combined with the term “ADHD” using the PubMed Search Builder. The single MeSH term ADHD was used with selection of ‘Restrict to MeSH Major Topic’. 
The following broad terms were used and a filter was used during the search on publication date (2000 onwards), and language (English): MeSH term “education” with selection of ‘Restrict to MeSH Major Topic’.
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Specific PubMed search:
“Attention Deficit Disorder with Hyperactivity”[Majr] AND (“Education”[Majr]) AND (“2000/01/01”[PDAT]: “2014/10/13”[PDAT]) AND (“english”[Filter]).
All search results were combined into a single master Reference Manager (RM) 
database. References within the master RM database were transferred to Excel and then screened independently by both AvdK and MvA based on title for the following keywords to identify articles of possible relevance: “ADHD”; 
“Attention Deficit Hyperactivity Disorder”; “Attention-Deficit Hyperactivity 
Disorder”; “Attention Deficit-Hyperactivity Disorder”; “Attention Deficit/
Hyperactivity Disorder”; “Attention Deficit/Hyperactivity-Disorder”; 
“Attention-Deficit/Hyperactivity Disorder”; accompanied with either one of the keywords: “(Special) education(al)”; “school(ing)”; “homework”; “IQ”; “(primary/high) school”; “student(s)”;  “academy’, “academic(al)”; “college”; “graduation”; “university”; “training”; “class(room)”. Articles were then screened by abstract by two authors, again independently 
(AvdK and MvA). The following in- and exclusion criteria were applied: Inclusion: ADHD needed to be the major area of interest of the study, but comorbidity 
was not necessarily an exclusion criterion. Studies were only included if they 
provided data analyses. The review aimed to include explanatory articles for the relationship between ADHD and poorer educational performance. Therefore, also articles presenting outcomes of a certain class-room intervention were included, 
since we assumed this could provide information on beneficial factors related to ADHD and educational outcome which in turn provide information on impacting 
features. Articles with a focus on for example working memory and ADHD were 
also included, as this could provide specific information on explanatory factors for the negative impact of ADHD on school outcome. If no abstract was available, 
this study was included for full-text selection to be sure not to miss relevant 
information. Articles were excluded if the study was descriptive or an essay not containing the generation of data. Studies with the clear aim of analyzing if ADHD in fact accounts for a lower grade point average, increased school drop-out or 
other factual representations of worse educational outcome were excluded, since 
the focus of our review was on explanatory variables and not on the relationship itself. Articles describing interventions for teachers and/or parents to overcome 
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problems related to ADHD were excluded, since we wanted to provide an answer to possible associations related to the ADHD schoolchild/student rather than the teacher or parent. Studies on abuse of medication by non-ADHD adolescents or 
drug-abuse by ADHD students were excluded. Articles with a focus on diagnosing 
ADHD in a specific setting were excluded. In this review, the snowball procedure 
was not applied, since the research question was not as specific as can be in a search for clinical trials, so we decided to keep the focus on the PubMed results to increase replication possibilities. Disagreement regarding eligibility was resolved 
through discussion and mostly by inclusion of the article for full-text review. Table 1 provides an overview of the literature search.
5.2.3 Eligibility 
Articles selected for full-text screening based on screening on title and abstract were then synthesized in a qualitative way by the two researchers (AvdK and MvA). There was no disagreement on articles selected for qualitative analysis. Since the validity of a systematic review has more direct practical implications, possibility 
for synthesis and assessment of results was based on a flowchart presented by the Finnish Institute of Occupational Health 19. Based on the flowchart, results were analyzed by means of narrative synthesis, that is, describing the results as well as possible 19. This method was chosen, since the various study elements (especially outcome) were not similar enough in structure between the different articles to combine results. This narrative process also provides ideas for implications for future research. The narrative approach was preferred over the levels of evidence method described by the Cochrane Back Review Group and the vote counting method, since these methods are mainly based on p-values. 
 There was no specific focus in this review on the way the diagnosis of ADHD was stated. This was decided, since no uniformly agreed upon diagnostic tool 
for ADHD exists. Therefore, no clear cut-off rule could be established regarding which diagnostic tool would be deemed valid and which would be not. In general, it is assumed that a clinical interview should be part of diagnosis to be able to incorporate ADHD symptoms and their impact, but also academic and social functioning should be assessed 20,21. However, five guidelines published by governmental organizations in Europe do not show consensus on the proper 
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Table 1. Literature search      
LITERATURE SEARCH SELECTION FOR INCLUSION BASED ON TITLEPubMed ─ Search criteria ─ January 1st 2000 till October 13th 2014 ─ English language ─ MeSH terms: ADHD and Education
ADHD major area of interest + keyword ─ (Special) education ─ School(ing) ─ Class(room) ─ Homework ─ IQ ─ Student ─ Study ─ Academy ─ Academic ─ Training ─ Primary/High school ─ College ─ University ─ Graduation
SELECTION FOR INCLUSION BASED ON ABSTRACT AND ELIGIBILITY PHASE
Exclusion: ─ ADHD was not the major area of interest ─ Describing etiology of ADHD. ─ Focus on diagnosing of ADHD (in a specific setting). ─ Descriptive studies or essays not containing data generation.  ─ Only factual representations of worse educational outcome. ─ General needs of students with ADHD ─ Interventions for teachers to handle ADHD ─ Studies on abuse of medication by non-ADHD adolescents. ─ Articles describing interventions for teachers and/or parents. ─ Studies on drug-abuse by ADHD students. ─ Study size below n=15 in case of one study group, n=30 in case of two study groups, and n=45 in case of three study groups. 
Inclusion: ─ ADHD as major area of interest of the study, but comorbidity was not 
necessarily an exclusion criterion.  ─ Explanatory articles for the relationship between ADHD and poorer educational performance.  ─ Outcomes of a certain class-room intervention were included.  ─ Focus on for example working memory and ADHD. ─ If no abstract was available.
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diagnostic process 22-26.  Therefore, we relied on the validity of the diagnosis of ADHD as stated by the authors of the included articles. 
 The first data extraction included country of origin, sample size, and 
research question. A second table was constructed based on main findings, and conclusions for the articles included.
5.3 RESULTS
The master database included 376 records, no duplicates were found. These 376 records were screened by title for relevant articles. Of these, 185 articles were 
screened by abstract and 35 articles were identified for inclusion in the review. Figure 2 presents the screening process in more detail. For each of the studies included in the qualitative synthesis, Table 2 displays the country of origin, the number of participants and the research question. Table 3 presents the main outcomes per included study. The articles were grouped together based on their subject, these groups were not determined beforehand in order to be as inclusive as possible, but evolved based on the content of the articles eligible for inclusion. Meta-analysis was not feasible owing to the heterogeneity in outcomes reported across all study types included in the review; however, results per study type were combined and used for concluding statements. 
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The 35 articles selected were based on studies executed in several countries or regions, however, the United States of America (USA) was the main source of evidence: USA n=24, Canada and Israel n=2, Netherlands, Australia, Taiwan, Spain, Italy, Belgium, Germany n=1, total of Europe n=11. Most articles reported on an ADHD group and a group of controls (n=25).  Results are reported based on their content and their assigned domain. Topics were articles related to training, coaching, instruction, educational consultation; educational environment; pharmacological treatment; symptoms, symptom severity and persistence of symptoms; predictive factors or associations of ADHD with academic outcomes; 
self-concept; or working memory or a specific skill. 
Table 2. Country of origin, sample size and research questions of selected articles 
COUNTRY SAMPLE SIZE RESEARCH QUESTION REFERENCEArticles relating to training, coaching, instruction, educational consultation 
USA 175 ADHD  ─ What is the differential effect of two models of educational consultation (typical and behavioral) on the academic functioning of sample ADHD students? 29
USA 26 ADHD  ─ What is the classroom outcome for children with ADHD following an intervention called Family Skills Training (behavioral parent training and child focused self-regulation training) for ADHD-Related Symptoms? 
30
USA 19 ADHD
 ─ What is the effect of ADHD coaching on students’ perceptions of the process they ─ used to achieve or maintain academic goals such as grade point average?  ─ What benefits do students associate with coaching services?
31
Israel 27 ADHD24 controls
 ─ What is the functioning in daily tasks of children with ADHD compared with those without ADHD? ─ What is the efficacy of occupational therapy intervention?
27
Israel 20 ADHD16 controls  ─ Can attention deficits of children with ADHD be ameliorated by an individualized training program (exercising the attentional networks)? 28
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COUNTRY SAMPLE SIZE RESEARCH QUESTION REFERENCEArticles relating to educational environment or tool
Italy 27 ADHD28 ADHD + LD29 controls
 ─ Are three types of knowledge better acquired and retained when provided by a hypermedia tool as opposed to traditional instruction? ─ Do hypermedia tools yield the same better learning outcomes (if any) both in the acquisition and in the retention phase? ─ Do groups differ in knowledge assimilation according to the instructional setting to which they are assigned?
32
USA 19 ADHD16 controls  ─ Are children with ADHD more affected by distractions in the virtual classroom than those without ADHD? 33
Belgium 31 ADHD31 controls
 ─ Are attention-related problems in the 
classroom exacerbated in children with ADHD 
by specific class conditions? ─ Does the teacher’s supervision level influence 
the relation between class-context and on-task behavior?
34
Germany 55 ADHD55 controls
 ─ How much on-task behavior and what kind of on-task behaviors do children with ADHD display?  ─ How would the lesson context affect the behavior of students with ADHD?  ─ Are there differential effects of context on the behavior of students with ADHD compared with matched control students?
35
Articles relating to pharmacological treatment
USA 92 ADHD143 controls  ─ What is the relationship between ADHD medications, study habits, and academic achievement of ADHD diagnosed undergraduates? 39
USA 24 ADHD26 controls  ─ What is the effect of lisdexamfetamine (three doses) on ADHD symptoms and executive functioning vs. placebo? 37
USA 45 ADHD  ─ What is the effect of methylphenidate on academic achievement and behavior vs. placebo? 38
Spain 34 ADHD16 controls  ─ What is the therapeutic effect of a pharmacological intervention compared to a psycho-pedagogical treatment? 36
[ continuation on next page ]
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COUNTRY SAMPLE SIZE RESEARCH QUESTION REFERENCEArticles relating to symptomatology, symptom severity and persistence of symptoms
USA 2844 ADHD  ─ What is the importance of acknowledging subtype symptoms in outcomes for children with ADHD as associated with interventions across time? 40
USA 326 ADHD213 controls
 ─ What is the relationship between attendance and academic Grade Point Average?  ─ Does symptom severity predict poorer outcomes within the ADHD group above and beyond the contribution of IQ and parental education?
41
USA 147 USA273 China
 ─ What is the relationship between ADHD symptomatology and academic and social 
adjustment to college, self-confidence, and study skills? ─ What is the separate influence of inattentive and hyperactive symptoms, while controlling for depression, which may affect the ability to pay attention?
42
USA 68 ADHD19 former ADHD200 controls  ─ Do ADHD symptoms predict college adjustment after the association between personality traits and adjustment is corrected for? 12
Taiwan 333 persistent ADHD166 non-persistent ADHD266 controls
 ─ Is childhood ADHD negatively associated with school performance? ─ Does the current persistence of ADHD predict adverse outcomes? 43
Articles relating to predictive factors or associations of ADHD with academic outcomes
USA 15 ADHD  ─ What are the factors that help college students with ADHD? ─ What are the factors that hinder college students with ADHD? 44
USA 153 current ADHD73 past ADHD3.153 controls
 ─ How do students with ADHD function in academic, social, and emotional domains relative to students without ADHD? ─ What is the predictive association between ADHD and students’ adjustment?
45
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COUNTRY SAMPLE SIZE RESEARCH QUESTION REFERENCEArticles related to self-concept 
USA 21 ADHD20 controls
 ─ What are the reported levels of college adjustment, self-esteem, and social skills of ADHD students vs. non-ADHD peers? ─ Do social skills and self-esteem act as mediators in the relationship between ADHD and college adjustment?
47
Australia 87 ADHD87 and 3.374 controls
 ─ Are there differences in academic buoyancy (students’ capacity to successfully overcome setback) between students with and without ADHD? 48
USA 130 ADHD94 controls
 ─ Do college students with ADHD differ from students without ADHD in their endorsement of 
specific behavioral information?  ─ Do college students with ADHD differ from college students without ADHD in their endorsement of global ratings of behavior?  ─ Are college students with ADHD more likely than students without ADHD to give ratings indicating a positive illusory bias?
49
USA 17 previous ADHD19 controls
 ─ What is the performance of college students diagnosed with ADHD relative to peers without the diagnosis on a number of independent measures, including academic performance, self-concept and psychological well-being?
46
USA 102 ADHD499 controls
 ─ What is the level of self-esteem among the study population? ─ Do these ratings vary by disorder characteristics and medication use? ─ Can we identify predictors of low self-esteem while adjusting for socio-demographic factors?
50
Articles related to working memory or a specific skill
USA 68 ADHD  ─ What is the performance and use of instructional accommodations of students with ADHD in foreign language courses? 52
Canada 16 ADHD30 controls  ─ How does working memory work in university students with ADHD? ─ Is working memory related to academic functioning at the university level?
53
[ continuation on next page ]
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COUNTRY SAMPLE SIZE RESEARCH QUESTION REFERENCE
[ continuation ] Articles related to working memory or a specific skill
Canada 26 ADHD6 ADHD + LD30 LD
 ─ Will working memory training lead to improvements in working memory performance on cognitive tasks?  ─ Will the effects of working memory training generalize to daily-life activities involving working memory, such as academic performance and self-regulation? ─ Are gains in functioning persistent (i.e., for at least two months)?
51
USA 44 ADHD42 controls  ─ Auditory and visual-spatial working memory: what effect does distraction have? 54
USA 24 ADHD24 controls  ─ What is the ability of ADHD adults to perform a visual cancellation task compared with health controls? 55USA 20 ADHD20 controls  ─ What are time estimation abilities of college students with and without ADHD? 56
NL 62 ADHD  ─ Does computerized working memory training with game elements enhance motivation and 
training efficacy in children with ADHD vs. standard working memory training? 57USA 31 ADHD27 controls  ─ What is the effect of ADHD on written expression compared to a control group? 58
USA 14 ADHD42 ADHD + LD16 LD
 ─ Is explanatory style predictive of success as measured by Grade Point Average for college students with learning disorder and attention disorders? 59
USA: United States of America; NL: the Netherlands.
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Table 3. Outcomes and reported associations of selected articles 
MAIN OUTCOME REFERENCEArticles relating to training, coaching, instruction, educational consultation 
 ─ The findings support academic consultation to enhance academic functioning in children with ADHD.  ─ Large effect sizes (>.80): math calculation, math fluency, reading fluency and passage comprehension.
29
 ─ Results indicated significant classroom improvements for externalizing behaviors and attention problems with medium and large main effects. ─ Significant results were observed for changes in ADHD symptoms of inattention due to family training (p<0.01). 30 ─ Students were harmonious in their belief of coaching improving how they worked on academic goals.  ─ Coaching helped to be more self-regulated: to set more realistic and specific goals, use effective time management, be able to avoid distraction in class). 31 ─ Children with ADHD improved after a social skills training aiming to improve occupational performance and no longer differed from the children without ADHD (p<0.008). ─ Difficulties were related to: energy, time, and adaptation, following 
instructions and terminating the task, difficulties in organizing actions, talking too frequently.
27
 ─ The participants showed improvement in non-trained measures of reading comprehension, and passage copying as well as a reduction of reports of inattentiveness (p<0.05).  ─ Children with ADHD received a computerized attentional training program 
composed to activate sustained, executive and selective attention, and orienting of attention.
28
Articles relating to educational environment or tool ─ Hypermedia instruction (computer-based devices designed to promote learning in educational settings) produced better learning outcomes than traditional instruction. 32 ─ Children with ADHD were more affected by distractions in the virtual reality classroom while performing a continuous performance task than those 
without ADHD (non-significant).
33
 ─ Children with ADHD were significantly less on-task than controls during individual work and whole class group teaching, but not during small group work.  ─ Children with ADHD had significantly shorter on-task span during academic tasks (mathematics, language, and sciences), but not during music and arts.
34
 ─ ADHD students displayed more problems of actively disruptive behavior 
across classroom contexts (p<001).  ─ More disruptive behavior was observed during individual silent work compared with normal classroom teaching. 35
[ continuation on next page ]
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MAIN OUTCOME REFERENCEArticles relating to pharmacological treatment
 ─ ADHD students using stimulant medication said the drugs helped them concentrate and organize better. 39 ─ Lisdexamfetamine was associated with large reductions in ADHD symptoms 
and improvement in executive functioning.  ─ Linear lisdexamfetamine effects were found for specific aspects of executive functioning related to task management, planning, organization, study skills, and working memory.
38
 ─ Data showed significant improvement of methylphenidate on academic measures.  ─ Note-taking quality, written language usage and productivity, on-task and disruptive behavior and homework completion.  37 ─ Both medication and pedagogical interventions were effective for reducing the main symptoms of ADHD (inattention and hyperactivity). 36Articles relating to symptomatology, symptom severity and persistence of symptoms ─ There are significant differences in academic achievement according to long-term stimulant treatment status within each subtype symptom class (over a period of 4 years).  ─ Associations between receiving stimulant treatment and academic achievement were inattentive: 0.21; hyperactive-impulsive: 0.11; and combined class: 0.38.
40
 ─ Adolescents with ADHD completed and turned in a significantly lower 
percentage of assignments were significantly less likely to be working up to their potential. ─ Baseline symptom severity of ADHD, oppositional defiant disorder and 
conduct disorder for adolescents with ADHD were not significant predictors of for grade point average, attendance, drop-out, or class placement.  ─ IQ was significantly lower in the ADHD group (102 vs. 111; p<0.001), they were more absent (p<0.01), and were more tardy (p<0.01). ─ For academic for grade point average, R2 values were as follows: group only  =0.80, IQ only =0.78, parent education only =0.78, and full model =0.88.
41
 ─ Higher levels of inattentive symptoms were related to decreased academic 
and social adjustment, career decision-making, self-efficacy, and poorer study.  ─ Depression itself clearly plays a role in college students’ adjustment, but this appears to be independent of the role of ADHD symptomatology.  ─ Higher levels of ADHD were associated with higher levels of depression  
(p<.001), depression significantly predicted social adjustment (p<.001).  ─ Higher levels of ADHD were related to lower levels of academic adjustment (p<.01), poorer study skills (p<.001), and lower levels of social adjustment to college (p=.31).
42
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MAIN OUTCOME REFERENCE
[ continuation ] Articles relating to symptomatology, symptom severity and persistence of symptoms ─ Students with ADHD reported more academic concerns and depressive 
symptoms. This was explained by higher rates of inattention among students with ADHD and was unrelated to hyperactivity.  ─ Students currently diagnosed with ADHD reported more concerns about their academic performance and higher rates of depressive symptoms (effect size 0.48 and 037). ─ Inattentive symptoms remained a significant predictor of depressive symptoms after personality factors were controlled for p<.001.
12
 ─ The most consistent correlates for all domains of impaired school functioning were youth- and mother reported inattention symptoms and increased age.  ─ Both ADHD groups (persistent and non-persistent ADHD) had lower full-scale IQ (p<0.001). 43Articles relating to predictive factors or associations of ADHD with academic outcomes ─ Identification of three global themes: gaining insight about ADHD, managing life and utilizing sources of support. Each global theme contains factors that hinder, as well as factors that help the college student with ADHD.  ─ Persistent symptoms created challenges to academic success because of poor 
time management and organization skills, difficulty staying focused, failure to complete work on time, poor motivation, poor reading and study skills and 
difficulty sleeping and getting up in the  morning.
44
 ─ Relative to other students, those with self-reported ADHD reported more academic concerns, depressive symptoms, social concerns, and emotional instability.  ─ For groups with current and past symptoms, inattention was present to a 
larger extend compared to hyperactivity (1.23/0.88 vs. 1.00/0.73).
45
Articles related to self-concept ─ The results suggest that the relation between ADHD and college adjustment is partially mediated by self-reported levels of self-esteem (p<.001).  ─ There were significant main effects for group (p<.001) and gender  (p<.03). Female participants in general reported better social skills than  male participants do.
47
 ─ There is a significant association between academic buoyancy (students’ capacity to successfully overcome setback and challenge) and outcomes for students with ADHD.  ─ For the ADHD and non-ADHD groups, academic buoyancy is positively correlated with achievement (0.19 and 0.13) and engagement (0.38 and 0.35).
48
 ─ ADHD participants were significantly more likely to engage in the positive illusory bias (effect of people thinking they are “better than average”) for work skills ratings (p=.005). 49
[ continuation on next page ]
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MAIN OUTCOME REFERENCE
[ continuation ] Articles related to self-concept ─ Students with ADHD reported significantly higher paternal support than 
controls (p<.04) who reported significantly greater support from friends  (p<.02).  ─ There was a significant effect for gender for grade point average, (females scoring higher than males; p<.022).  ─ For students with ADHD, environmental mastery (competence in managing their environment, making effective use of available opportunities) 
significantly predicted total self-concept (p<.009).
46
 ─ Children with ADHD criteria had significantly lower self-esteem (p<0.05).  ─ Total self-esteem scores varied significantly by type of associated disorders and were lowest for children with comorbid internalizing symptoms (p<.001). ADHD alone: n=52; Piers-Harris Self-Concept Scale (PHSCS) 65.4 
- ADHD + externalizing: n=40; PHSCS 61.9 - ADHD + internalizing: n=18; 
PHSCS 46.8 - ADHD + externalizing + internalizing: n=18; PHSCS 47.7.
50
Articles related to working memory or a specific academic skill ─ Two thirds of the students with ADHD passed all of their foreign language 
courses without the use of instructional accommodations (for example for 
example extended time).
52
 ─ The ADHD group displayed significant weaknesses on auditory–verbal working memory tasks.  ─ Within the entire sample, there was a significant relationship between for grade point average and auditory–verbal working memory (r=.405, p<.01). 53 ─ Participants receiving computerized working memory training showed 
significantly greater improvements and self-reported fewer ADHD symptoms and cognitive failures. 51 ─ Students with ADHD demonstrated worse auditory working memory. 54 ─ The ADD/ADHD group made significantly more left-sided omission errors. 55 ─ Controlling for cognitive ability, ADHD participants were significantly different on all dependent measures related to time estimation abilities (p<0.05). Controlling for IQ did not change the main outcomes. 56 ─ Children using the game working memory training showed greater motivation, better training performance, and better working memory (i.e., higher scores on a working memory task) versus the regular working memory training. 57 ─ No statistically significant differences are found between groups on measures 
of executive function and written expression. 
58
 ─ Significant positive correlations are found between the Attribution Style Questionnaire to measure causal thinking scores and for grade point average for the subgroup with co-occurring ADHD and learning disabilities and for the three subgroups combined. 59
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5.3.1 Training, coaching, instruction, educational consultation
A total of five studies were related to this domain, three from USA and two from Israel 27-31. The studies focused on the possible beneficial effect of certain types of training for school-children with ADHD (n=4; age 6-13) and college students (year: freshman to senior) 31. All five studies reported on beneficial effects of training, consultation or coaching on academic functioning. Effects were reported 
for specific tasks (math or reading), but also for the basic characteristics of ADHD 
related to externalizing behavior and attention problems with the largest influence on attention problems. Amongst others, coaching helped to be more self-regulated 
(ability to control one’s emotions, behavior, and desires in the face of external demands), which was reported by students (college sample), teachers (children with ADHD showed better motivation and study skills) and parents (reduction in symptoms of inattentiveness). So, training could improve attention in school and account for more self-regulated behavior. 
5.3.2 Educational environment or toolFour studies reported on educational environment or a tool used to deliver knowledge to either an ADHD or a control group (Origin Italy, USA, Belgium and Germany; respondent’s age 6-14 years) 32-35. Topics related to acquiring and attaining knowledge, distraction, and behavior in general in relation to class conditions (class structures and academic content types). Children with ADHD were more distracted compared to controls and had a shorter on-task span during academic tasks (mathematics, language, and sciences). However, this shorter on-task span was not present during music and arts. Also, learning via a computer-based service yielded better results compared to traditional instruction and could 
specifically improve outcomes related to attention deficits. Another environmental outcome was better functioning while working in a small group compared to individual tasks or whole class work. Individual task work accounted for more problems than whole class work. 
5.3.3 Pharmacological treatmentFour studies were related to ADHD and pharmacological treatment, three were originated in USA, one in Spain 36-39. Studies were focused on the effect of different types of pharmacotherapy (stimulants and non-stimulants) on study habits, 
Chapter 5 Educational performance
138
academic achievement in general, ADHD symptoms and executive functioning. One of the studies was a double-blind, placebo-controlled study reporting a positive effect on symptom relieve (inattention and hyperactivity), but this study 
was not specifically designed to report on academic achievements 38. The other 
studies reported beneficial effects of pharmacological treatment on concentration, 
planning, organization, executive functioning and working memory. More 
specifically to studying, effects on note-taking quality and homework completion were reported.
5.3.4 Symptoms, symptom severity and persistence of symptomsThe DSM-IV divides the symptoms of ADHD into two groups: symptoms of in-attention and symptoms of hyperactivity–impulsivity 9. Five studies reported on subtype symptoms, symptom severity, and persistence of symptoms 12,40-43. Four 
studies were USA based; one was executed in Taiwan 43. One study was both 
related to pharmacological treatment (specifically with a stimulant) and subtype symptom class 40. The result was that especially inattentiveness was related to 
worse academic outcomes with effects on self-efficacy and depressive symptoms. Depressive symptoms independently turned out to be related to college and social 
adjustment. Baseline symptom severity turned out not to be significant predictors of for grade point average, class attendance, or drop-out, although the ADHD 
group was significantly more absent and tardy compared to controls. Two studies 
reported on IQ and concluded on a significantly lower IQ for ADHD students 41,43. 
5.3.5 Predictive factors or associations of ADHD with academic outcomesTwo USA studies related to factors associated with ADHD and problems in college 
specifically 44,45. One study also searched for factors that can help students with ADHD, although only 15 respondents were included in this qualitative study 44. 
Inattention turned out to be present to a larger extent compared to hyperactivity. 
Students with ADHD reported challenges to academic success due to difficulties in focus, completing work in time and poorer time management and organization skills. Coping with the ADHD and managing challenges in everyday life were 
also mentioned by the ADHD group related to difficulties with academic success. 
Depressive symptoms and emotional instability were present to a larger extent in the ADHD population. 
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5.3.6 Self-concept One’s self-concept (also called self-construction, self-identity, self-perspective or self-structure) is a collection of beliefs about oneself that includes elements such 
as academic performance gender roles, sexuality and racial identity and accounts for the regard for oneself as a person 46. Four studies from USA and one from Australia were focused on studies related to (predictors of low) self-esteem, ratings of own behavior, and psychological well-being 46-50. All four studies were based on an ADHD group compared to controls. It is suggested that reported levels of 
self-esteem mediates the relation between ADHD and college adjustment. Next to 
that, children with ADHD reported significantly lower self-esteem and scores were lowest for children with ADHD and comorbid internalizing problems, especially in 
the areas of anxiety and popularity, although females tend to report better social skills. Medication use was not a predictor of lower self-esteem scores. Students’ capacity to successfully overcome setback and challenge (academic buoyancy) 
was significantly associated with outcomes for students with ADHD and also academic buoyancy was positively correlated with academic achievement and engagement. On the other hand, one study reported that students with ADHD were more engaged in the bias of thinking they are “better than average” (positive illusory bias), which is in contrast with lower self-esteem. 
5.3.7 Working memory or a specific skill Working memory refers to the ability to temporarily maintain and manipulate information necessary for achieving a certain goal 51. The largest group of studies 
(n=9) reported on working memory or specific studies related to time estimation, 
explanatory style, or written expression 51-59. ADHD students display significant weaknesses in the auditory–verbal working memory tasks compared to controls 
and were significantly worse in time estimation abilities. When using computer-based working memory training with game elements, ADHD children showed better training performance, and better working memory outcomes compared to regular computer-based training, although students with ADHD trained with computerized 
working memory training showed significantly greater improvements and self-
reported fewer ADHD symptoms and cognitive failures. Executive function, written 
expression and passing of foreign language courses did not relate to significant differences between ADHD and control students. 
Chapter 5 Educational performance
140
5.4 DISCUSSION
This systematic review focused on the question: Is it possible to identify factors that have been demonstrated to be associated with educational and academic performance in ADHD based on the current available evidence, and if so: which factors are those? This question was raised, since based on available literature it can be concluded that there is a certain negative impact of ADHD on school 
outcome, but without consensus on the specific cause for this impact. The study focused on articles presenting results of data-based analysis related to the main 
topic ADHD and specific keywords related to education. A total of 35 studies met the eligibility criteria for this analysis. They were analyzed by means of narrative synthesis since outcomes were too heterogeneous to combine results. The articles related to seven different domains; educational training, educational environment; pharmacological treatment; symptomatology, associations of ADHD with academic 
outcomes, self-concept, and specific skills. 
 One main finding stands out when trying to answer the question: is it the ADHD itself that causes the impact on educational achievements or are underlying factors at stake. When reviewing all included studies, the main source of problems seems to be associated with the inattentive symptoms of ADHD and not so much in 
the hyperactive or impulsive symptoms. This outcome is different than expected, since hyperactive symptoms, which are more prominently pronounced, are usually the main cause of referral to clinical evaluation, probably since teachers and 
other students experience burden of particularly those symptoms 1,60. It also has been reported that the prevalence of the hyperactive-impulsive subtype decreases when children get older, whereas the inattentive subtype increases 61. This is a very important finding in the light of the results of this systematic review. The ongoing impact of ADHD, which frequently maintains into adulthood, seems to be associated with inattentiveness and according to our review, it is the inattentiveness that seems to be associated with educational performance. This yields important information as to which areas to target when it comes to opting for clinical or non-clinical interventions in order to mitigate the impact of the ADHD.  Studies relating to educational environment and content showed that ADHD children in general had a shorter on-task span, but were better able to perform 
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in small group work, in music and art classes and in learning via a computer-based service, especially when including game-elements. ADHD students showed weaknesses in the auditory–verbal working memory. Studies reporting on 
training and coaching concluded on beneficial effects of different training types, with especially positive effects on inattentive symptoms and related behavior. 
Pharmacological treatment showed beneficial effects on concentration, planning, 
organization, executive functioning and working memory. Problems in school can also be related to occupational achievements, since individuals that are diagnosed with ADHD often continue to have problems during adulthood and into their working life 62. The negative impact of ADHD on work performance of adults has 
been demonstrated in extensive surveys 63,64. ADHD is associated with 22-35 annual days of lost role performance compared to respondents without ADHD related to decrements in work performance or absence 63,64. These problems in working life might be mitigated when proper help is offered when in school. A factor that might play a role in the large impact of inattentive symptoms 
on educational and academic outcomes is the existence of comorbidities. In ADHD, symptom overlap or comorbidity with other conditions is the rule rather than 
the exception 65,66. In our review, ADHD was required to be the major area of 
interest of the study, but comorbidity was not necessarily an exclusion criterion. 
The review concluded that the inattentiveness also affected self-efficacy and 
depressive symptoms which in turn influence the relation between ADHD and educational and academic outcome. Also, children with ADHD are at high risk of adolescent depression 67. Next to the influence of inattentiveness on school 
outcome, our review found that depressive symptoms also influence the effect of ADHD and academic outcome. Another phenomenon frequently mentioned in this respect that could be involved in comorbidity and academic outcome is stigmatization 68. Stigma can have a harmful effect on social functioning and can increase depressive symptoms 47. Stigmatization can be obvious and direct, for 
example when a classmate makes a negative remark about the ADHD 68. Our review showed that social functioning of ADHD children improved after a social skills training and therefore potentially could reduce the harmful effect of stigmatization. 
Next, our review found that female participants in general reported better social skills than male participants do. Taking this into account, stigmatization might affect boys more than girls, due to more obvious symptoms (hyperactivity) and 
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having less social skills to begin with.  As with all research, the value of a systematic review depends on what was done, what was found, what was reported and what was concluded 17. A limitation of this review is related to its sources: selection of patients is not always clear. In our 
review, there was no specific focus on the method of diagnosing ADHD. This was decided upon, since no clear cut-of could be established of which ADHD diagnostic 
would be included. We choose not to focus on this specific aspect of the studies, since no evidence would have been left for inclusion in this review due to the lack of a uniform method of diagnosis. We therefore had to rely on the investigators’ discretion in guaranteeing the validity of the diagnosis of ADHD in their subjects. 
However, future studies might choose to specifically focus on method of diagnosing 
ADHD and the influence on educational outcomes. As described, comorbidity is often present in children and adolescents with ADHD. In the articles included 
in our review, we did not specifically focus on the existence of comorbidity or the moderating effect that comorbidity could have. Finally, treatment status of respondents was not always reported (adequately), so the establishment of a clear relationship between impact of ADHD and the mitigation by certain treatment types cannot properly be made. This review highlights areas of interest for future studies. As school systems and referring systems differ between countries, it is recommendable to perform studies on the effect of ADHD in several countries at the same time. Finally, more longitudinal studies might contribute a lot to the knowledge on the effect of ADHD on education and academic performance and occupational performance later in life. 
5.5 CONCLUSION
The main association of educational and academic problems seems to be the inattentive symptoms (or subtype) of ADHD. This outcome is different than 
expected, since hyperactive symptoms are more prominently pronounced. The answer to the question if the ADHD itself causes the impact on negative educational outcomes or that underlying factors at stake is that both seem to be true. The inattentive symptoms of ADHD tend to be associated with most of the problems 
experienced, but also other factors like educational environment, depression and 
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self-concept seem to play a role. Since ADHD is considered a treatable disorder the negative impact on educational and academic outcome has the potential to be mitigated if patients are diagnosed and treated adequately 69-71. More important 
for the patients at stake, next to a relief of clinical symptoms, proper help when diagnosed with ADHD might also help children and adults to achieve educational goals that now are sometimes out of reach. Especially, overcoming negative 
outcomes of inattentiveness should be a major focus, next to improvement of social skills to deal with everyday life in schools (especially in males). Simple interventions could be found in environmental changes, since children with ADHD showed better functioning while working in a small group. Lower education outcome in its turn will also have an economic impact in the end 14. More attention and support should be given to ADHD students to improve their chances in society 
and the economic influence of ADHD based on lower academic levels should be an important foundation when it comes to allocating resources to support ADHD patients.
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“The aim of health care is not to save money but to save people 
from preventable suffering and death” 
Bonneux et al., BMJ, 1998
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ABSTRACT
Background: The current evidence on the societal burden of ADHD is scattered, isolated to single elements and often based on a narrow focus of the patient only. 
 
Aim: This study quantified the societal ADHD burden by comparing societal costs and QoL of an ADHD sample (children and parents) (n=618) to population controls (n=704). 
Method: Societal cost calculation was based on a questionnaire on healthcare consumption and productivity losses (TiC-P), and QoL was measured by the preference based EuroQol 5-dimension (EQ-5D) and the KIDSCREEN-10 (KS-10). 
Results: Total monthly societal costs were higher in the ADHD sample (€948 vs. €140 controls; p<0.001). QoL was lower for both children with ADHD (KS-10 ADHD 41.67 vs. controls 55.46; p<0.001 - EQ-5D ADHD 0.80 vs. controls 0.96; p<0.001) and their parents (EQ-5D ADHD 0.83 vs. controls 0.88; p<0.001), also when corrected for comorbidity. The dimensions ‘felt sad’ and ‘felt lonely’ (KS-10) 
and ‘usual activities’ and ‘anxiety/depression’ (EQ-5D) accounted for the largest difference in QoL. 
Conclusion: The findings show that children with ADHD feel less happy, fit 
and satisfied than population controls. Children with comorbidity need special attention since their QoL is impacted further. Although this study has methodological limitations, the magnitude of the differences seems to justify the conclusion that ADHD causes a high societal burden. Although the ‘danger’ of overdiagnosing should always be kept in mind, it still counts to carefully assess every individual child with a potential ADHD diagnosis and associated problems 
that might be experienced. QoL instruments might be a useful tool to indicate which areas are impacted for a certain child. Special attention is to be paid to 
internalizing rather than externalizing symptoms which usually are central in debates on ADHD.
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6.1 INTRODUCTION 
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by age-inappropriate hyperactivity, impulsivity and/or inattentiveness and is diagnosed by integrating information from multiple sources (child, parent, teacher) about symptoms in multiple settings (e.g. at school or at home) 1. The DSM classification system distinguishes three ADHD presentations: mainly inattentive, mainly hyperactive–impulsive and combined 2. ADHD is frequently comorbid with other disorders; in particular with oppositional 
defiant disorder (ODD), learning disability (LD, e.g. dyslexia and dyscalculia) and autism spectrum disorder (ASD) 3,4. The worldwide-pooled prevalence of ADHD in children is 5.3% and remained stable over the years 5-7. Current discussions focus on a rise in diagnosis and treatment of ADHD 
specifically 8-18. Effects of overdiagnosing and overtreatment are described as unnecessary labelling (stigma), harms of unneeded tests and therapies, and cost of wasted resources. 12,19 The apparent increase in ADHD prevalence however could also be an increase in the administrative prevalence due to increased awareness 7. 
 It is however rather difficult to put these discussions into perspective, due to the scatteredness of the evidence on the burden of ADHD. The evidence is often isolated to single elements as healthcare costs  and is mostly based on a narrow focus on the patient. There is a need for a broader perspective on the societal burden of ADHD. This should take into account quality of life (QoL) and societal costs as being essential to assess the overall burden of a disease and forming the basis of economic evaluations aiding health care policy making. The societal perspective includes QoL from the patient and parent as well as direct and indirect 
costs, for example, productivity losses (e.g. absence of work) 20. QoL has shown to be seriously compromised in children with ADHD, but there is a lack of data that allow for comparisons with other disease areas as well as a lack of data on QoL of parents 21. Health care costs of children with ADHD compared to non-ADHD children have been reported to be higher 9,21-25. Further, ADHD imposes a burden in a broader sense than health care alone, such as 
educational difficulties and impacts parents’ productivity 26. Also, more European-based cost studies are needed 26.
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This study therefore focused on the question how the burden of a Dutch ADHD sample relates to a sample of population controls with respect to QoL and costs from a societal point of view. This societal view means data is included for both a wide range of cost items and QoL measured with a preference based instrument 
for children and their parents. The hypothesis is that QoL is significantly lower 
and that significant higher societal costs are incurred for both ADHD patients and their parents compared to population controls.
6.2 METHODOLOGY 
6.2.1 Study participantsFor this retrospective, cross-sectional study two study samples were compared. The ADHD sample enrolled parents of children diagnosed with ADHD based on self-
report of a clinical diagnosis, and the type of doctor that confirmed the diagnosis. Children were using pharmacological treatment for ADHD and were aged 8-18 years. The ADHD sample was recruited through the Dutch parent organization ‘Balans’. Parents joined online for completion of a one-time questionnaire and answered questions on health care visits, work loss and QoL about their children and themselves 27,28.  A control sample representing the general population (population controls) was recruited separately. This group was selected via an independent consumer 
research agency on the basis of pre-defined characteristics in order to match the ADHD sample. Selection criteria of the control sample were: absence of any chronic disease including ADHD, no use of special education (as this could have been an indicator for health problems), and no use of ADHD medication. Quotas were used for gender in order to match the ADHD sample: parent 100% female and child 80% male. Time consumed to complete the questionnaire was around 
fifteen minutes. Contrary to the ADHD sample, respondents in the control sample were reimbursed for participating, since this is common practice in this kind of population research. 
6.2.2 EthicsAccording to Dutch regulation no approval of an ethics committee was needed for both study samples, since the study did not interfere with clinical practice 
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and no additional procedures were imposed on patients. Consequently, since the methodology of this study focused on parents rather than on patients themselves, it was not obligatory to use informed consent forms. Nevertheless, the study protocol took into account all privacy aspects. Participants were informed on the purpose 
of data collection (scientific publication), respondents were fully free to decide 
to join and were able to exit the questionnaire at any time. Adequate security measures were employed in order to prevent unauthorized access, manipulation 
to or disclosure of the personal data although these were already unidentifiable when stored 27,28.
6.2.3 The questionnaire
6.2.3.1 Cost measurement The questionnaire for the control sample mirrored the questionnaire used for the ADHD sample which is described in earlier publications 27,28. Following a societal perspective, the questionnaire on healthcare consumption and productivity losses (TiC-P) was used 29. The TiC-P was adapted to the control sample by excluding five items that were not scored in the ADHD sample: day-care treatment, medication other than ADHD medication, special education, police and agency for child welfare. Total costs for the ADHD sample were calculated with and without these cost items (referred to as standard and additional items). More information on cost item selection and cost prices applied can be found in an earlier publication 28.
6.2.3.2 Quality of life measurementQoL of children was measured by two generic instruments, the EuroQol 5-dimension (EQ-5D) and the KIDSCREEN-10 (KS-10); parents’ QoL was measured by EQ-5D 30. Generic instruments aim to be applicable to a wide range of health conditions and interventions and are amongst others used in economic evaluations 31,32.
 EQ-5D measures QoL based on five dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression). EQ-5D is a preference-based instrument and provides a comprehensive individualized measure of how a person values the current health state. An additional advantage of a preference-based instrument is that the outcomes can be incorporated into decision analyses and cost-effectiveness analyses 30,32. EQ-5D outcome is presented as a utility in a range from 0 (equal to death) to 1 (perfect health). EQ-5D was originally not designed 
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for use in children and therefore the recommended alternative of the parent-proxy version was used 33,34. Using a proxy version, the parent is asked to answer the 
questions in such a way that it reflects the rating of the child. 
 The KS-10 is an abbreviated version of the 52-item KIDSCREEN, and was 
specifically designed to reduce response burden and assess the QoL of children in one single value. 35 KS-10 includes ten dimensions and provides a parent-proxy version as well. The ten dimensions are physical well-being, psychological well-being, mood and emotions, self-perception, autonomy, parent relation and home 
life, peers and social support, school and environment, bullying, and financial resources. KS-10 is not preference-based, but presents a T-value with scale means around 50 and standard deviations around ten with higher values indicating higher QoL. More in-depth information on QoL assessment can be found in an earlier publication 27.
6.2.3.3 Statistical analysesAnalyses were performed using IBM SPSS 21.0. Descriptive statistics, independent samples t-test and Chi-square for p-values were used for analysis on significance in differences between samples and groups (p<0.05; 2-tailed). EQ-5D and KS-10 
were analyzed based on their respective manuals and predefined syntaxes. Any 
imbalance in samples and influence on overall outcomes was tested by regression 
analysis. Multiple regression analysis was used to check for independent influence of other factors than study sample (ADHD or control sample) on the mean societal costs and QoL values. As healthcare cost data tend to be skewed, tests were repeated using the non-parametric Mann-Whitney test. 
6.3 RESULTS
6.3.1 Demographic characteristicsIn the ADHD sample, data were available on 618 children and 590 parents where the control sample included 704 respondents for both children and parents (Table 
1). Samples were well balanced, except for age and type of education. Regression 
analyses confirmed that this imbalance did not exert influence on the overall results. In the ADHD sample, comorbidities were present in more than 70% of the children with LD and ASD being the most prevalent. 
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Table 1. Characteristics ADHD and control samples - n (%)
ADHD SAMPLE CONTROL SAMPLE P-VALUE*
CHILDRENN 618 (100) 704 (100)
Mean age 11.8 (8-18) 12.6 (8-18) <0.001
Age group8-12 years 392 (63.4) 339 (48.2) <0.00113-18 years 226 (36.6) 365 (51.8)
Gender**Male 509 (82.4) 570 (81) 0.513Female 109 (17.6) 134 (19)
Diagnosed byPediatrician 110 (17.8) 0 (0) NA(Child)psychiatrist 419 (67.8) 0 (0)General practitioner 3 (0.5) 0 (0)Other 86 (13.9) 0 (0)
Type of educationPrimary 327 (54.5) 282 (40.1) <0.001Secondary 273 (45.5) 422 (59.9)
Comorbid disordersAsthma, Bronchitis, CARA 78 (13) 0 (0) **Epilepsy 9 (1.5) 0 (0)
Anxiety Disorder 80 (13.3) 0 (0)Mood Disorder 66 (11) 0 (0)Learning Disability 235 (39.1) 0 (0)Gilles de la Tourette, Tic Disorder 25 (4.2) 0 (0)ODD or CD 63 (10) 0 (0)Autism Spectrum Disorder 152 (25.3) 0 (0)
Number of comorbid disorders0 166 (27.6) 0 (0) **1 242 (40.3) 0 (0)2 132 (22) 0 (0)3 or more 61 (10.1) 0 (0)
[ continuation on next page ]
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ADHD SAMPLE CONTROL SAMPLE P-VALUE*
PARENTSN 590 (100) *** 704 (100)
Age (mean, range) 43.22 (30-63) 44.96 (29-58) <0.001
GenderMale 28 (4.7) 0 (0) **Female 562 (95.3) 704 (100)
Marital statusTogether 534 (90.5) 609 (86.5) 0.030Alone 56 (9.5) 95 (13.5)
Paid jobYes 471 (79.7) 574 (81.5) 0.404No 120 (20.3) 130 (18.5)
More than 1 child with ADHDYes 133 (22.5) 0 (0) **No 457 (77.5) 704 (100)
*Comparison ADHD sample vs. control sample; 
** Control sample selected based on these quotas and/or exclusion criteria; 
*** 28 parents dropped-out after providing data on their child; 
NA: not applicable due to absence of a diagnosis in the control sample. 
6.3.2 Societal cost outcomes
Total monthly societal costs were significantly different between the ADHD and control samples, with higher costs for both children with ADHD and their parents (Table 2). Largest differences were found for children’s doctor’s consultations (ADHD €114 vs. controls €34; p<0.001), behavioral/psychological interventions (social skills training, creative therapy and self-regulation) (ADHD €126 vs. controls €10; p<0.001), coaching at school (ADHD €142 vs. controls €20; p<0.001) and productivity losses of parents (ADHD €136 vs. controls €11; p<0.001). For 
children in the ADHD sample specifically, the highest significant independent 
influence (p<0.001) on total standard costs was shown in a regression model with three predictive variables combined; >1 child with ADHD, comorbidity (yes) and (higher) total standard costs in parents. For parents of children with ADHD, a 
significant independent influence (p<0.001) on total standard costs was shown by two predictive values combined; >1 child with ADHD and (higher) total standard costs of the child.
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Table 2.  Mean (median; 95%CI) monthly costs of children with ADHD and parents (in Euro)*ADHD sample Control sample p-value**
CHILDRENTotal direct medical costs 1 381 (109; 292-469) 49 (0; 37-61) <0.001Total direct non-medical costs 2 237 (110; 211-262) 42 (13; 35-49) <0.001Total indirect non-medical costs 41   (0; 36-46) *** <0.001Total costs children standard items 1,2,# 518 (251; 448-588) 91 (13; 77-105) <0.001Total costs children additional items ADHD sample 2,& 658 (322; 560-756) 91 (13; 77-105) <0.001
PARENTSTotal direct medical costs 3 154 (10; 126-181) 38 (0; 29-48) <0.001Total direct non-medical costs **** ****Total indirect non-medical costs4 136 (0; 101-171) 11 (0; 6-16) <0.001Total costs parents standard items 3,4,# 289 (82; 241-336) 49 (0; 39-60) <0.001Total costs parents additional items ADHD sample 4,& 290 (82; 242-337) 49 (0; 39-60) <0.001
CHILDREN AND PARENTS 
COMBINEDTotal costs similar items 1,2,3,4,# 806 (447; 715-897) 140 (42; 120-160) <0.001Total costs additional items ADHD sample 2,3,4,& 948 (524; 832-1064) 140 (42; 120-160) <0.001
 
* Indirect medical costs are excluded according to the Dutch guidelines for pharma-economic research 
applicable at the time of study execution 36; 
**p value reflects differences between total ADHD and control sample;
*** Indirect non-medical costs were not included in the control sample questionnaire, since these were 
hardly scored in the ADHD sample;
**** Not included in the questionnaire for parents;
1 Medical consultations, skills training, creative therapy, self-regulation, hospitalization;
2 Weekend care, remedial teaching at school, care after school, diet;
3 Medical consultations, parent training (medication was excluded);
4 Absenteeism (absence from work), presenteeism (reduced productivity while at work);
# Excluding items day-care treatment, medication other than ADHD medication (direct medical costs 
child and parent), special education, police, and agency for child welfare (indirect non-medical costs); 
& Including items day-care treatment, medication other than ADHD medication (direct medical costs 
child and parent), special education, police and agency for child welfare (indirect non-medical costs).
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6.3.3 Quality of life outcomes
QoL between children with ADHD and the control sample differed significantly, both for KS-10 (ADHD 41.67 vs. controls 55.46; p<0.001) and EQ-5D (ADHD 0.80 
vs. controls 0.96; p<0.001). EQ-5D values of parents differed significantly as well (ADHD 0.83 vs. controls 0.88; p<0.001). Figure 1 shows the KS-10 results for children per study sample. The largest difference between samples was found for the dimensions ‘felt sad’ and ‘felt lonely’ (p<0.001). Figure 2 shows EQ-5D results of children per study sample. Analysis per EQ-5D dimension showed that the 
ADHD sample experienced ‘some’ and ‘extreme problems’ more often compared to the control sample, especially for the dimensions ‘usual activities’ (p<0.001) 
and ‘anxiety/depression’ (p<0.001). For the ADHD sample specifically, comorbidity and QoL of the parent were found to be predictive for QoL based on KS-10, with a higher QoL in the group without comorbidity and a high QoL in parents (p<0.001). Analysis in the ADHD sample for EQ-5D results showed that age category and 
comorbidity combined were significant influencers with a higher QoL in the age group 13-18 and without comorbidity (p<0.001). When this analysis in the 
ADHD sample was specified to type of comorbidity, four comorbidities combined 
(anxiety disorder, mood disorder, Gilles de la Tourette / Tic disorder and ASD) 
had a significant decreasing influence on QoL (p<0.001). There was no significant interaction between the variables in the regression models.  
6.4 DISCUSSION
This study examined the question how the burden of an ADHD sample relates to a sample of population controls with respect to QoL and costs from a societal 
point of view. Significantly higher monthly societal costs (including medical and non-medical costs) were reported for children with ADHD and their parents vs. population controls (€948 vs. €140). The higher costs in the ADHD sample were primarily constituted by children’s doctor consultations, children’s trainings, 
children’s coaching at school and parent’s productivity losses. Next, a significantly lower QoL for both children with ADHD and their parents compared to population controls were shown (ADHD and controls KS-10 41.67 vs. 55.46 and EQ-5D 0.80 vs. 0.96 – parents ADHD and controls EQ-5D 0.83 vs. 0.88). Qol and costs of the children and parents seem to be inversely associated. These results indicate a high
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burden of disease for children with ADHD and their parents on all items studied. 
When corrected for comorbidity, QoL remained significantly lower in the ADHD sample compared to the control sample. In the KS-10 questionnaire, lower scores 
indicate that children with ADHD feel less happy, fit and satisfied with regards to family life, peers and school life 37. The lower QoL was mainly associated with higher rates of internalizing problems; children with ADHD seemed to feel more 
sad and lonely (KS-10) and to experience more problems with usual activities and 
anxiety/depression (EQ-5D).  EQ-5D provides the ability to compare QoL across disease areas. A review of health utilities across conditions common in paediatric populations reported on EQ-5D data in children for asthma, diabetes mellitus and skin diseases 38. For asthma, children reported a utility of 0.92 prior to an intervention and 0.98 at the end of the study 39. For diabetes mellitus with severe hypoglycaemia, the utility was 0.85 and without severe hypoglycaemia 1.0 40. Children with acne reported a utility of 0.84 prior to treatment and 0.93 after treatment 41. Indirect comparison of a utility of 0.80 of the ADHD sample in our study shows that the impact of ADHD on QoL is higher compared to asthma, diabetes mellitus and acne.
 These findings add to the public debate about ADHD, where the ADHD 
burden is quite often called into question and usually the externalizing symptoms as hyperactivity and impulsivity are mentioned prominently, rather than the internalizing ones 42. Bearing in mind that all children with ADHD were on 
medication, and many used behavioral/psychological interventions, the findings call for further studies on the optimal use of these interventions and possible improvements 43. Further, development of more effective pharmacological and non-pharmacological treatments for ADHD is highly welcomed. The discussion on overdiagnosis focuses on adverse effects of diagnosis and treatment, however, it does not seem unrealistic to think that the outcomes for the ADHD sample would have been worse without treatment at all. Further, since all aspects studied were impacted for the ADHD sample it would suggest there is a need for more appropriate care integrating several sectors (inside and outside healthcare). Public debates on ADHD should therefore start to focus on helpful solutions focused on the patient instead of convincing others of being in the right. 
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6.4.1 Strengths and limitations of the studyThis study used the societal perspective, is large in terms of sample sizes, includes preference based QoL data and included data on parents 20. The results should 
be considered within the context of its limitations. The limitations discussed in this paragraph focus on selection of the control sample rather than on the methodology of the ADHD sample selection that has been reported elsewhere 27,28. Firstly, the sample of children with ADHD and the control sample were selected in different years (end 2010 and beginning 2014) and therefore the study obviously was not a direct comparative study. Secondly, respondents in the control sample were member of a public panel, whereas respondents in the ADHD sample were members of a patient organization. This difference might have caused a different selection of person characteristics; however, it is not sure which 
type of bias this might have caused on QoL and cost outcomes. Third, next to the anonymous data collection based on self-report no database analysis could be performed to check on possible differences between reported and actual health care use. Regarding both samples, data of fathers is lacking; the ADHD sample included 80% mothers and the control sample was matched accordingly. Despite these disadvantages, the magnitude of differences in absolute results seem to 
justify the general conclusion that ADHD accounts for significantly higher costs and lower QoL for patients, parents and society compared to population controls. 
6.4.2 Meaning and implications of the study Clinical implications of our study are that the lower QoL found in children with ADHD is an indicator of ADHD as an impactful disorder with a sincere clinical need, and with also co-occuring internalizing problems meriting clinical attention 21. In the anamnesis, QoL could be viewed as one of the indicators of the overall health 
of the child. A more thorough examination of QoL can provide further angels for treatment for children and their parents. Children with comorbidity and one or more siblings with ADHD need special attention since their QoL is even more 
impacted, especially in case of anxiety disorder, mood disorder, Gilles de la Tourette / Tic disorder and ASD. Given the lower QoL of parents, proper support should be offered to the parents of children with ADHD as well. Taking the burden for the parent into account and therefore increasing the parent’s QoL might have an 
accelerating effect on the child’s treatment outcomes, based on the finding that QoL of the parent and the child is associated.
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6.4.3 Unanswered questionsOn the basis of our study, we would recommend future studies to (1) evaluate societal costs and QoL based on a random ADHD sample, with particular attention, (2) immediate inclusion of a control group without ADHD and control groups with other psychiatric disorders or with chronic physical disorders, and (3) use a prospective longitudinal design with patient and parent self-report accompanied with comparisons of parent and child ratings with objective register data. To 
expand the societal focus, future studies should focus on including both parents, data on the monetary impact of absence at school and sports, school performance and inclusion of criminal justice costs. 
6.5 CONCLUSION
The burden of an ADHD sample compared to a sample of population controls 
verifies the hypothesis that ADHD accounts for significantly lower QoL and higher societal costs. This study showed a high burden of disease for children with ADHD and their parents on all items studied. Mainly internalizing problems as sadness 
and anxiety were found to be associated with a lower QoL in children with ADHD. These results provide directions for an even more patient-centered, but also family-centered focus based on the association of outcomes of children and parents. Although the ‘danger’ of overdiagnosing should always be kept in mind, it still counts to assess every individual child with a potential ADHD diagnosis and 
associated problems that might be experienced. In this assessment, using QoL instruments might be a useful tool to indicate which areas are impacted for a certain child, with special attention to be paid to internalizing symptoms rather 
than the externalizing symptoms which are usually brought to the attention in debates on ADHD.
Chapter 6 Burden compared to population controls
166
References1. Goodman DM, Livingston EH. JAMA patient page. Attention-deficit/hyperactivity disorder. JAMA 2013; 309(17):1843.2. Swanson JM, Wigal T, Lakes K. DSM-V and the future diagnosis of attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2009; 11(5):399-406.3. Rommelse NN, Altink ME, Fliers EA, Martin NC, Buschgens CJ, Hartman CA et al. Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. J Abnorm Child Psychol 2009; 37(6):793-804.4. Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rastam M et al. Co-existing disorders in ADHD -- implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I80-I92.5. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007; 20(4):386-392.6. Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 2007; 166(2):117-123.7. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 2014; 43(2):434-442.8. Ellison P. ADHD Myths. Science over Cynisism.  1-6-2003. 14-7-2015. 9. Barkley RA. International consensus statement on ADHD. January 2002. Clin Child Fam Psychol Rev 2002; 5(2):89-111.10. Batstra L. Hoe voorkom je ADHD? Door de diagnose niet te stellen. (How to overcome ADHD? By not diagnosing). 2014.11. Horton-Salway M. Repertoires of ADHD in UK newspaper media. Health (London) 2011; 15(5):533-549.12. Thomas R, Mitchell GK, Batstra L. Attention-deficit/hyperactivity disorder: are we helping or harming? BMJ 2013; 347:f6172.13. Cortese S. Are concerns about DSM-5 ADHD criteria supported by empirical evidence? BMJ 2013; 347:f7072.14. Tudor HJ. ADHD is a social problem. BMJ 2013; 347:f7028.15. McClure I. ADHD is a behavioural construct, not a psychiatric condition. BMJ 2013; 347:f7071.16. Chen Q, Sjolander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for 
attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348:g3769.17. McClure I. Prescribing methylphenidate for moderate ADHD. BMJ 2013; 347:f6216.18. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9(3):490-499.19. Batstra L, Thomas R, Mitchell G. Authors’ reply to Cortese. BMJ 2013; 347:f7080.20. Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 2009; 10(4):357-359.21. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C et al. The 
quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2009.22. National Institute for Health and Clinical Excellence (NICE). Methylphenidate, atomoxetine 
and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. http://www.nice.org.uk/TA098. London.  2006. 7-12-2013. 23. Ray GT, Levine P, Croen LA, Bokhari FA, Hu TW, Habel LA. Attention-deficit/hyperactivity 
disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr Adolesc Med 2006; 160(10):1063-1069.24. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. The guideline on diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72.  2013. 
Burden compared to population controls
167
25. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines, Third Edition, Toronto ON; CADDRA.  2011. 26. Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry 2013; 23(7):578-98.27. van der Kolk A, Bouwmans CAM, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van Roijen L. Association between Quality of Life and Treatment Response in Children with 
Attention Deficit Hyperactivity Disorder and their Parents. J Ment Health Policy Econ 2014;(17):111-121.28. van der Kolk A, Bouwmans CAM, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van 
Roijen L. Association between costs and treatment response in children with Attention Deficit Hyperactivity Disorder and their parents. SpringerPlus 2015; 4(1):1-12.29. van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996; 12(3):405-415.30. EuroQol. A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16(3):199-208.31. Ravens-Sieberer U, Erhart M, Wille N, Wetzel R, Nickel J, Bullinger M. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations. Pharmacoeconomics 2006; 24(12):1199-1220.32. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33(5):337-343.33. Lloyd A, Hodgkins P, Sasane R, Akehurst R, Sonuga-Barke EJ, Fitzgerald P et al. Estimation of 
utilities in attention-deficit hyperactivity disorder for economic evaluations. Patient 2011; 4(4):247-257.34. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D et al. The link between 
health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25(3):166-174.35. Ravens-Sieberer U, Erhart M, Rajmil L, Herdman M, Auquier P, Bruil J et al. Reliability, construct and criterion validity of the KIDSCREEN-10 score: a short measure for children and adolescents’ well-being and health-related quality of life. Qual Life Res 2010; 19(10):1487-1500.36. College voor zorgverzekeringen afdeling pakket. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie.  2006. 29-7-2014. 37. THE KIDSCREEN GROUP EUROPE. The KIDSCREEN questionnaires. Quality of life questionnaires for children and adolescents. Handbook. 2006.38. Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K et al. A review of health utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes 2010; 8:12.39. Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of a nurse-led 
telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff Resour Alloc 2007; 5:10.40. Nordfeldt S, Jonsson D. Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatr 2001; 90(2):137-142.41. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist 
care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000; 43(2 Pt 1):229-233.42. Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M et al. Impact of 
attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2008; 2(1):31.43. Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep 2013; 15(7):371.

7
Methodological 
limitations and their 
implications for the 
interpretation of the 
current results and 
future research
Chapter 7 Methodological interpretation
170
INTRODUCTION
The purpose of the studies reported in this thesis was to provide information on the 
burden of illness of ADHD. Next to a systematic review on the educational implications 
of ADHD, a survey among a sample of children with ADHD using pharmacological 
treatment for their ADHD was analyzed with respect to the outcomes of quality of life 
(QoL) and societal costs based on parent report. This sample of children with ADHD 
was also compared with a sample of population controls. This chapter elaborates on 
the methodological choices that were made during the course of this research, and 
their consequences for interpretation of the results.
7.1 STUDY TYPES
The overall problem statement of this study was: ‘What is the individual, 
interpersonal and societal impact of Attention Deficit Hyperactivity Disorder (ADHD) in terms of quality of life and societal costs and how is this impact related to response to treatment?’. Many studies have been performed to provide insight in isolated components of the burden of ADHD. This study contributed to a better understanding of the ADHD burden from a broad societal perspective, based on an observational study design. 
7.1.1 Study aim of this thesisAs was elaborated on in the introduction of  this thesis, the ADHD treatment is in principle based on a combined approach of non-pharmacological and pharmacological interventions as recommended in international guidelines 1. 
The current study was set up to examine the association between pharmacological treatment of ADHD and QoL and societal costs among children diagnosed with ADHD and their parents in a real-world setting (in care as usual). More precisely, we were interested in the effect on QoL and societal costs of either using the medication as prescribed by their physician or not using the medication as prescribed (either 
methylphenidate or atomoxetine). The aim of this study was not to study efficacy 
of pharmacological ADHD treatment, as the efficacy of pharmacological treatment 
has already been extensively studied by others. Moreover, the study design was not suited to answer this question. The question on the association of QoL and 
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societal costs in children responding and non-responding to medication was considered a relevant question to society which could not be answered based on the available evidence. Especially in case of health policy making and health care provision it is essential to understand the overall burden of ADHD based on a societal perspective to provide appropriate interventions.
7.1.2 Cross-sectional study designIt was considered appropriate to use an observational design to accomplish the study aim which would result in a screenshot of a certain situation (also referred 
to as non-interventional or non-experimental design). Figure 1 provides an overview of the traditional hierarchy of study types in the evidence continuum. However, as postulated by the chairman of the National Institute for Health and 
Clinical Excellence (NICE) in 2008: “Hierarchies of evidence should be replaced 
by accepting – indeed embracing – a diversity of approaches” which is reflected in Figure 1 as well ². The method of the randomized controlled trials (RCTs) is high in the traditional hierarchy of evidence. However, RCTs mainly focus on accurately presenting the causal relationship between an intervention and a certain outcome. But, an RCT could not capture the real-world compliance to treatment as the 
RCT follows pre-defined protocols which are not necessarily reflective of daily life’s way of treatment administration. Other study designs like observational studies, also referred to as real-world evidence, seem to be essential to generate a comprehensive body of evidence in today’s health care setting 3. 
Figure 1. From a traditional hierarchy of evidence assessment towards a diversity of approaches 4
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As the aim was not to conduct an experiment, a clinical trial (either an RCT or other form) was not considered to be the most appropriate study method. A cohort study was not obvious as we did not want to study (the effect of) an intervention or health state over time. Case-control studies would have been interesting when the aim was to study children at risk for a certain disorder. The cross-sectional design was chosen over a retrospective or prospective observational design. A retrospective 
cohort study would have focused on existing clinical or administrative data. 
However, we were not aware of any databases including QoL data and the specific cost data we were interested in and this approach would have had privacy issues. As our study aim was to have a broad insight in QoL data both for parents and children and societal cost data that was not readily available in a certain database the choice was made for a one-time cross-sectional survey. The choice was made not to follow a prospective design or to repeat the survey at another time-point 
as this could influence results based on the Hawthorne effect (individuals modify 
their behavior in response to the awareness of being observed) ⁵. Figure 2 provides an overview of the cross-sectional study design in this thesis. 
Figure 2. Overview of the cross-sectional study design in this thesis ADHD sample in chapters 2, 3, 4 and 6, reference sample in chapter 6.
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7.2 DISCUSSION ON STUDY DESIGN
The prior paragraph highlighted the choice for the study design of this thesis. 
This paragraph will further discuss three specific elements of the design: sample 
selection via a patient association, parent report, and the classification in responder to treatment groups.
7.2.1 Sample selection via a patient associationA survey was performed via an online questionnaire to collect QoL and societal cost data on children with an ADHD diagnosis using pharmacological treatment and their parents based on parent report (the parent was asked to answer the 
questions in such a way that it reflected the rating of the child). The sample was comprised of members of the Dutch ADHD parent association ‘Balans’. Parents of children aged 8-18 years diagnosed with ADHD were enrolled. Completing the questionnaire was voluntary and anonymous.  It was assumed plausible by the researchers to assume that parents who are a member of an association are motivated and easy to access which would lead to many participants at low costs in little time. The use of a patient association to 
complete a survey is used in several other studies, for example in a study among 
spina bifida patients and prostate cancer patients 6;7. However, sample selection via a patient association might have resulted in a selection bias of participants which 
could have influenced the results of our study.  Table 1 provides an overview of the potential bias of this approach based on a brainstorm among the researchers of 
this study. Concluding, the use of a patient association could potentially influence 
results in both ways: an ADHD sample from a patient association could exist out of more severe ill patients, however, parents of a child with severe ADHD might not have the energy to participate in a survey and thus may be underrepresented.
Therefore, from the arguments in the table it is evident that it is difficult to draw a conclusion on whether sample selection via a patient association would create an overall bias in either a positive or a negative direction, e.g. potential under- or overestimation of QoL and/or societal costs. 
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Table 1. Data collection and influence on study results
7.2.2 Parent reportThis study was based on parent reported outcomes on all measures of QoL and 
societal costs. Next to that, the ADHD diagnosis and existing comorbidities were also based on parent report. This paragraph will discuss the different types of 
information in this study retrieved by parent proxy report and the implications this could have on the study results.
7.2.2.1 Parent report on ADHD diagnosisBecause of participants’ membership of an association, it was assumed to be valid to rely on the parents’ knowledge about the clinical ADHD diagnosis of their child without verifying the diagnostic reliability. Due to anonymity, it was impossible to verify whether the diagnosis was valid. However, the aim of this study was not to verify the diagnosis, but to study the real-world QoL and societal costs of a group of children with an established ADHD diagnosis and thus who were treated “as having ADHD”. Whether the diagnosis was correct or not is on itself an interesting question, but was not the topic of the present study. The questionnaire did include questions on the type of doctor and the date of diagnosis as to focus participating 
parents on the actual existence of the diagnosis. An alternative to the parent report on diagnosis would have been to include diagnostic questionnaires on 
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symptomatology and functioning. These questionnaires were not included since the assumption was made that inclusion of any more questions would have led to less participants and high drop-out rates due to a time-consuming survey. Further, 
results from the DSM-5 field trials indicate a very good reliability of diagnosing 
ADHD (intraclass kappa 0.61, 95% confidence interval 0.51–0.71) 8.
 The specific question is whether the results would have been very much 
different if the survey would have included confirmation of diagnosis and therefore 
possibly excluding certain participants. When our sample would have included a (substantial) number of children with an incorrect ADHD diagnosis (thus without ADHD), this might have had an impact on the results. If all non-ADHD children would be present in one of the responder groups (responder or non-responder), this would probably have provided an overestimation of QoL and an underestimation of societal cost in this group and therefore an overestimation of the absolute difference between groups. However, as these children could be present in both the responder and non-responder group it is not possible to 
conclude what the impact of an incorrect or no longer existing ADHD diagnosis would be. Concluding, the absolute difference between the two responder groups in terms of QoL and societal costs are large. Our assumption is that a bias in responder group selection will not change the relative outcomes of this study as such that it would lead to another conclusion. 
7.2.2.2 Parent report on comorbidities
Existence of a certain comorbid disorder was also based on parent report. In the entire sample, only 28% had no comorbidity and 10% even had more than three comorbidities. This is consistent with the estimation that in general around 60–100% of patients with ADHD have one or more comorbid disorders 9. When the presence of comorbid disorders as reported by parents would have been over- or 
underestimated and thus would have been incorrect, it is very difficult to predict how this might have biased our results.
7.2.2.3 Parent report on QoL - overlap with classification of responder groups?As discussed in the introduction of this thesis, evaluation of QoL has become increasingly important in health care, because it describes the health of patients and is an important supplement to traditional or biological measured health 
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status. QoL in this thesis refers to all aspects of life and as such it includes both 
health-related QoL, but also QoL in a broader sense. At first sight, there seems to be a certain overlap between parent reported functioning and QoL, However, these are different concepts. QoL is a multidimensional construct as was also discussed in the thesis introduction. Our operationalization of study groups (responder or non-responder) was based on an indication of functioning at home, at school, with peers and during leisure time. However, it is possible to have little concrete 
problems, but this does not define you as a person with a good QoL. QoL has a broader focus including psychological health, mood state, and emotion regulation whereas functioning is more focused on the ability to perform certain tasks (at school or at home as a family member) and has less focus on how the child actually feels 10-12 . It is expected that both concepts would be linked where improved functioning would results in a higher QoL and vice versa. Therefore it is relevant to study whether a child with ADHD that has little problems with functioning indeed has a higher score on QoL compared to a child who is hampered in functioning 13. 
7.2.3 Classification in responder to treatment groupsMost clinical studies in ADHD have focused on symptom reduction as a measure 
of efficacy of a specific treatment, but the question to what extent the symptom reduction translates into functional improvement is at least as relevant 14-16. This functional improvement provides the patient amongst others with the ability to enjoy daily life, achieve good grades and be a pleasant family member. Since inclusion of both short-term and long-term effects was found to be necessary to 
capture all relevant aspects of the burden of suboptimal treatment use, a definition should therefor include a reference to functioning 17. Five Dutch ADHD experts 
operationalized a definition based on the concepts compliance and functioning: 
‘response to treatment’. The description on characteristics of experts and 
further explanation on the process is provided in chapters 3 and 4 of this thesis. Theoretically, this led to the following combinations:
(C+; F+): Compliance to prescribed daily dose of medication, no problems in functioning.
(C−; F−): Non-compliance to prescribed daily dose of medication, problems in functioning.
(C−; F+): Non-compliance to prescribed daily dose of medication, no problems in functioning.
(C+; F−): Compliance to prescribed daily dose of medication, problems in functioning.
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7.2.3.1 Exclusion of combinations (C−; F+) and (C+; F−)With this study we wanted to study the effect of using the medication as prescribed by the physician and being without problems in functioning (responders) vs. not 
using the medication as prescribed and experiencing problems in functioning (non-
responders). The following paragraphs will explain the rational for the decision 
to exclude combinations (C−; F+) and (C+; F−) and the possible implications of this approach for the interpretation of study results.
(C−; F+): Non-compliance to prescribed daily dose of medication, no problems in 
functioning.
The (C−; F+) group was not included in this study, as for these children no problems in functioning arise when their ADHD medication is not taken according to 
prescription by their physician. Inclusion of a definition based on (C−; F+) would have caused an interpretational problem of the data since the question would have risen whether the medication prescription had been valid. The children could have been diagnosed with ADHD, but their symptoms and functional problems 
might have declined over time and did no longer exist. Hence, there may not be longer any need for medication treatment. Although this reduction in symptoms could be the case for the children in all four groups based on compliance and functioning it was considered the most prominent in this group. Based on the interpretational issues it was decided at the beginning of the study not to collect data on this group in this study. 
(C+; F−): Compliance to prescribed daily dose of medication, problems in functioning.
The (C+; F−) group was not included in this study, as it was considered to reflect several situations in which optimal compliance is not translated into optimal 
functioning. This could be due to several not mutually excluding factors, such as partial response instead of full response to medication, suboptimal dosage, wrong medication, complicating comorbidity, complicating life events, etc. The design of the study precluded to analyze these situations.  In clinical practice, a doctor will consider a change in the treatment regimen for such a patient, which made it less relevant to include this group, as the study aim was not to draw conclusions on 
the efficacy of medication. It could be needed to increase the dosing or a switch to another mode of action. Children in this group require action and inclusion on 
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this patient group in our survey would have led to interpretational issues similarly 
as the (C−; F+) group. 
 The two remaining combinations, (C+; F+) and (C−; F−), were the basis 
for responder group definition. As it was deemed necessary to provide parents 
with a hands-on description of these groups, the experts operationalized the combinations to the following descriptions based on treatment compliance and functioning in family, school and the environmental level. 
* Operationalization C+; F+ to ‘responder to treatment’: Your child uses the prescribed 
daily dose of medication. Using this treatment, your child’s functioning is fine and there are no noteworthy problems at home, at school, with peers or during leisure time.* Operationalization C−; F− to ‘non-responder to treatment’: The daily dose of medication used by your child differs from the dose prescribed. Using this treatment, your child’s functioning is hampered by problems at home, at school, with peers or during leisure time for short periods of time.
The definition of a responder or a non-responder in this study clearly differs from clinical trials. Analysis of an individual response to medication which is also linked to a dose-response relationship is usually established in a prospective manner: baseline scores, administration of medication and follow-up on results. The cross-sectional study design did not allow a prospective analysis. 
7.2.3.3 Interpretation of study results based on responder groups: bandwidth in a 
continuum.Our study focused on real-world compliance and functioning based on real-
world data in order to evaluate the potential loss of benefit of non-compliance 
to pharmacological treatment in ADHD. These insights were expected to inform several stakeholders on the possible room for improvement in the treatment of children with ADHD so action can be taken to assure the best possible care. 
As discussed, the responder to treatment groups defined in this study provides 
insight in the extreme black-white differences between optimal and sub-optimal 
response to pharmacological ADHD treatment. One may assume there exists a range (or bandwidth) as to where children can be placed in a continuum of 
potential pharmacological benefit combined with their compliance and functioning, which is visualized in Figure 3. As Figure 3 shows, the presentation of results is a straight line where 
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a decrease in compliance results in a decrease of functioning. Linearity is not 
necessarily the case, as described in the introduction of this thesis as well. Next, an increase in compliance does not necessarily result in a linear increase in functioning in individual cases. Also, this assumes that optimal functioning (100% in Figure 3) is a similar state for all children which is not essentially the case.  That 
means that omitting the two other groups (C-; F+) and (C+; F−), for which we had valid reasons (see above) may have led to overestimation of the contrast between optimal and sub-optimal response to medication, and to overestimation of the impact of medication treatment of QoL and societal costs. Since we did omit these two other groups from the beginning, we lack information on the size of these 
two groups in relation to two groups (C+; F+) and (C-; F−) that were included in the data-analysis. As a consequence, we can only speculate as to the size of our overestimation.
Figure 3. Hypothesized model for the association between compliance and functioning in ADHD 
* This study included definitions of C+;F+ and C-;F- which are both at the end of the continuum therefore 
representing the maximum bandwidth of the effect of response and non-response to ADHD treatment 
and accompanied functioning on QoL and societal costs.
Chapter 7 Methodological interpretation
180
Concluding, the real-world impact of responding or non-responding to pharmacological ADHD treatment in absolute terms could be smaller than 
presented in our results. However, the overall suggestion of the findings in our study based on a subset of patients in a real-world setting remains: non-responders to prescribed pharmacological ADHD treatment (sub-optimal compliance) is associated with a decrease in QoL and an increase in societal costs incurred by children and their parents. Given this high psychological as well as social and economic burden, the prevention of reduced compliance and accompanied 
reduced functioning is shown to be very important. The extent as to how large 
the influence on their decreased QoL and what the possible effect of comorbid disorders is can be discussed; however, any decreased QoL should be reason for a willingness to search for innovative strategies to improve compliance to (pharmacological) ADHD treatment. It should be mentioned that our focus on the improvement of compliance to pharmacological treatment does not rule out the possible relevance of accompanied non-pharmacological interventions such as diet, parent management training or mindfulness. 
7.3 RESEARCH ON THE EFFECT OF PHARMACEUTICAL TREATMENT ON QOL 
AND SOCIETAL COSTS
The methodology of our study offers first insights in the burden of ADHD related to pharmacological treatment. Future studies could study the effects on QoL and societal costs of different pharmacological treatment options for ADHD in a randomized setting to be able to study causality. As described in the introduction, pharmacological treatment options include stimulants (methylphenidate, 
dexmethylphenidate, mixed amfetamine salts, dextroamphetamine and 
lisdexamfetamine dimesylate) and non-stimulants (atomoxetine, guanfacine, and clonidine) 18. As first-line pharmacotherapy the recommendations are unanimous 
for stimulants, confirmed in meta-analysis showing the greatest significant effect size on ADHD outcomes 1;19. Several guidelines recommend atomoxetine as a 
first-line treatment as well, although most often when specific comorbidities are present 14. 
 Based on this prescription pattern, a first study method could be to include 
methylphenidate short-acting, methylphenidate long-acting and atomoxetine in a 
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randomized controlled trial (RCT). This trial should include five arms, including a control sample of children with ADHD without pharmacological treatment (but who are eligible for it) and a control sample of children without ADHD. This requires a large sample and ideally would include participants out of several countries. Our study found an association between outcomes for the child and the parent. Future studies on ADHD treatment should involve parents and the effects on them as well.
 A first step would be to re-diagnose ADHD in all participants (except off course the control sample of children without ADHD) based on a combined 
assessment of the child, parent and teacher report. Next, the treatment response to the assigned drug should be analyzed in a prospective manner. When treatment response is established the effects of medication on QoL and societal costs can be analyzed in a prospective study taking into account the effects of non-pharmacological ADHD treatment. Ideally, the parent ratings on societal costs should be validated with objective register data. This clinical trial setting could 
include validated checks on compliance, although this could influence results based on the Hawthorne effect (compliance might increase due to supervision) 5. Further, QoL measurement of the children could be based on self-report by the 
children in order to avoid any proxy-bias. This should take into account the age 
of the child, for example, EQ-5D-Y (youth) can only be administered from age 8 onwards.
7.4 CONCLUDING
  This survey-based burden of illness study for ADHD adds to current literature on real-life cost and QoL in ADHD patients and their parents. Further, the study 
suggests that the potential clinical benefits of pharmacological ADHD treatment are reduced or lost due to non-compliance (operationalized as a combination of compliance and functioning in this thesis).  Several methodological choices were made which were carefully discussed in this chapter. The focus on the real-world setting reduces the ability to study 
causality, but offers the possibility to analyze many parameters at once. Next, it was discussed that it is not possible to draw a conclusion on a potential under- or overestimation of QoL and societal costs based on this studies sample selection. 
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The method of parent proxy report for ADHD diagnosis, comorbidities and QoL was 
assumed not to have influenced results in a specific direction. The classification in responder to treatment groups focused on the effect of using medication as prescribed vs. not using the medication as prescribed. The choices made lead to 
an overview of the potential loss of benefit of pharmacological treatment in ADHD. The absolute results might differ in the overall real-world ADHD group, but the direction of results remains the same.  The data presented in this thesis offer value for several stakeholders which 
will be discussed in the general discussion of this thesis (chapter 8). 
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INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is often highlighted both in lay 
media as well as in the scientific literature with a wide range of interpretations and 
normative elements 1-7. The public debate on medicalization and overdiagnosis seems 
to distract attention from the actual public health problem and societal implications 
of ADHD. This thesis on the burden of ADHD has adopted a broad societal perspective 
on ADHD by providing real-life  data on quality of life (QoL) of children with ADHD, 
QoL of their parents, costs that patients and their parents incur inside and outside 
health care and a comparison to a reference sample. This type of information is 
to assist decisionmakers in their decision-making process about appropriate and 
cost-effective interventions. Next, this information could aid the public domain to 
portrait ADHD in an accurate and appropriate manner. 
8.1 OUTLINE
Following the research question, this thesis contributed to answering the question what the impact of ADHD is on the individual, interpersonal relationships and society in terms of QoL and societal costs. The emphasis has been placed on the role of response to ADHD treatment as it was deemed relevant to know what the effect of optimal treatment can be for patients and society. To optimize cost-
effectiveness analyses, actual and well-defined data on utilities, medical and non-medical costs are needed. The thesis was devided into three parts, each part of the thesis highlighting the burden of ADHD, either focusing on the measurement of QoL (Chapter 2), presenting QoL and cost data (Chapters 3, 4, 6), providing literature-based evidence (Chapter 5), or comparing ADHD data to population controls (Chapter 
6) . Key findings of the different chapters are presented in Table 1. The main conclusion of this thesis based on the different chapters is conclusive in one direction: the individual, interpersonal and societal impact of ADHD is high, both in terms of societal costs and QoL (Chapter 3, 4, and 6). It was found that QoL can be accurately measured using the widely used preference based instrument EuroQol 5-Dimension (EQ-5D) and the KIDSCREEN-10 (KS-10) in a child and adolescent population with ADHD (hereafter referred to as 
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child/children) (Chapter 2). A significant positive correlation between the QoL of children with ADHD and their parent was demonstrated (Chapter 3). Concerning response to treatment, the burden is higher for children without a response to 
treatment, as defined by the combined concepts of compliance and functioning to take account of both short-term and long-term effects of treatment (Chapter 3 and 4). From a societal perspective, total monthly costs for children with ADHD were much higher for non-responders to treatment compared to responders and the same trend applied to their parents (Chapter 4). With these results, the 
study suggests that the potential benefits of pharmacological ADHD treatment are reduced or lost due to non-compliance (operationalized as a combination of 
compliance and functioning). The systematic literature review specifically focused 
on educational outcomes and identified several factors to be associated with ADHD and educational underperformance (Chapter 5). The literature review further highlighted that the main source of educational challenges seems to be related to the inattentive symptoms (or subtype / presentation) of ADHD. The studied literature showed that using small group work, learning via a computer-based 
service, coaching and pharmacological treatment were identified as factors that might improve educational performance. When the ADHD sample was compared to population controls, the health problem of ADHD based on QoL and societal costs became even more apparent (Chapter 6). The comparison between the ADHD sample and the population controls showed that QoL in children with 
ADHD and their parents is significantly comprised. The lower QoL in children with ADHD is mainly associated with internalizing problems such as sadness and 
anxiety and is associated with the QoL of their parents as well. The finding of a 
strong influence of the inattentive symptoms is consistent with the results of the systematic literature review on educational performance (Chapter 5). The results of this thesis add to current literature on real-life cost and QoL in ADHD patients, which is of fundamental importance amongst others for future cost-effectiveness analyses. 
 Considering that the findings of each separate study in this thesis have been discussed at the end of each chapter, this discussion will mainly focus on the overall 
discussion related to the consequences of the findings for different stakeholders. 
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 Table 1. Key findings of this thesis
OVERALL RESEARCH QUESTION OF THIS THESIS
What is the individual, interpersonal and societal impact of ADHD in terms of quality of life 
and societal costs related to response to treatment?PART 1 QUALITY OF LIFE
Chapter 2 The instruments EuroQol 5-dimension (EQ-5D) and KIDSCREEN-10 (KS-10) are responsive and discriminative in ADHD QoL studies; they measure different constructs of QoL and are both valid for measuring QoL in children.
Chapter 3 QoL according to EQ-5D and KS-10 was lower for children who are non-responders to ADHD treatment; their parents showed the same trend. 
Also, a significant positive correlation between the QoL of children with ADHD and their parent was demonstrated.PART 2 SOCIETAL COSTS
Chapter 4 Total monthly costs for children with ADHD who are non-responders to treatment are higher which accounts for their parents as well. These results stress the importance of a focus on response to treatment to limit patient and societal burden.
Chapter 5 Based on a systematic literature review, the educational and academic underperformance of children with ADHD seems to be mainly related to the inattentive symptoms of ADHD. PART 3 COMPARISON OF AN ADHD SAMPLE AND POPULATION CONTROLS 
Chapter 6
A comparison of the ADHD sample vs. population controls shows total 
monthly societal costs are significantly higher and QoL for children and 
parents is significantly lower. For QoL, feeling sad and feeling lonely 
(KS-10) and usual activities and anxiety/depression (EQ-5D) accounted for the largest QoL decrease for children with ADHD compared to the reference sample. 
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8.2 METHODOLOGICAL CONSIDERATIONS AND RECOMMENDATIONS 
This thesis used different data sources and methods. Two surveys were performed: 
one among an ADHD sample and the second among population controls. Next to this, a systematic literature review and a cost-effectiveness analysis were performed. 
8.2.1 ADHD sample (Chapters 3, 4, 6)The selection of respondents via the Dutch ADHD association may have caused abias, as was described in chapter 7. A suggestion would be to repeat this study in the Nordic countries, since contrary to most countries including the Netherlands; these countries have nationwide prescription databases covering all dispensed drugs, with potential for linkage to outcomes 9. This offers the possibility to combine datasets from various settings, therefore providing the ability to chain a documented diagnosis and actual health care use 9. A recent literature review concluded that the Nordic databases represent an outstanding resource for assessing the effects of drug use in large populations, under routine care conditions, and with the potential for long-term follow-up 9. In particular, a potentially useful 
way of using the available Nordic databases would be to use them for specific studies on the effectiveness of interventions aiming to optimize compliance. 
8.2.1.1 Quality of life measurement (also accounting for the reference sample)
Our study used parent-proxy measures for QoL determination. It is of note that 
the choice for the rater of QoL can influence results, but there are pros and cons 
to both self-rating by a child and parent-proxy rating. Self-rating can cause issues due to linguistic and cognitive abilities of young children in general. Further, a potential lack of concentration of children with ADHD 
might cause difficulties in completing a QoL instrument. Also, it was shown that children with ADHD do not perceive themselves to be impaired (positive illusory bias) and underestimate the impact of ADHD 12,13. On the other hand, the perception 
of the parent could be influenced by the presence of other children in the family and parents’ own mental health 12. Overall, most studies on QoL in children used 
the parent proxy method 13. A recent meta-analysis studied QoL in children with 
ADHD by both parent-proxy report and child self-report using the Pediatric QoL 
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inventory (PedsQL) 13. The parent-child discrepancy in the impact of ADHD on QoL was not found in this meta-analysis, although this should be interpreted cautiously, 
since there was a considerable variability in the findings observed 13. Given the described considerations, the recommendation for future studies is in line with that of other authors: to measure QoL of children by both perspectives (self-rating and parent-rating) offering the possibility to rate the parent-child agreement 13. It 
should be highlighted that this approach can influence the number of responders and/or missing data as it would require the child and parent to be present at the same time. With respect to the different QoL instruments studied, the most important selection criterion for selecting an instrument is the study aim. If a general 
impression or a utility score is needed, EQ-5D can be used; when more specific information is requested there can be a preference for (inclusion of) the KS-10. 
8.2.1.2 Cost-selection (also accounting for the reference sample)Costs included in this study followed the societal cost approach. As described in a recent meta-analysis, little data was available on the societal perspective 14. Our study collected a large number of measures simultaneously accounting for a thorough overview on the burden of ADHD. Future studies could add a few additional items as justice costs (i.e., incarceration costs, victim costs, etc.), costs of non-paid work and the monetary impact of school drop-out. The Nordic databases as described previously could be of use in this respect 9. 
8.2.2 Reference sample representing the general population (Chapter 6)An online reference group representing the general population was recruited via 
an independent market and consumer research agency on the basis of pre-defined characteristics in order to match the ADHD sample. 
8.2.2.1 Timing of sample selection (Chapter 6)The reference group was recruited almost four years after the ADHD sample was studied. In the beginning of this thesis the aim was to mainly study the impact of response to treatment, but while analyzing the data of the ADHD sample, the question came up how these data on ADHD would compare to the general 
population. A possible influence of this recruitment in different years is the 
General discussion
191
possible change in access to health care that provides a bias in the reason for 
more or less general care. We do not have specific reasons to believe that such 
a change was present in this case. It is difficult to specify a possible effect and this would need a thorough study of health care access for children. To avoid any possible effect of health care access future studies should recruit both samples at the same time. 
8.2.3 Systematic review (Chapter 5) Chapter 5 presented a systematic literature review where assessment of the tracked records followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 15. Applying the PRISMA guideline has been questioned 16. A recent review concluded that usage of systematic review reporting guidelines other than PRISMA may be under-utilized with negative implications both for the reporting and methodological quality of systematic reviews 16. A recommendation for future systematic reviews would be to complement PRISMA with another reporting guideline such as MOOSE (Meta-analysis Of Observational Studies in Epidemiology) 17. Amongst others, MOOSE provides additional guidance for hand-searching and approaches to deal with unpublished or non-English work 16,17.  Although using the PRISMA guideline did improve the reported quality and provided readers with the ability to assess strengths and weaknesses of the review plus the ability to repeat the study, the PRISMA guidance does not provide an assessment of the risk of bias in the included studies as described by the Cochrane handbook for systematic reviews of interventions 18. The Cochrane Database of Systematic Reviews (CDSR) is the leading resource for systematic reviews in health care. There are several Cochrane Review Groups that take responsibility 
for a specific area of health care or policy. In the case of ADHD and educational performance a future study by the Cochrane Developmental, Psychosocial and Learning Problems Group could focus on a systematic review including a meta-
analysis of specific topics that could improve educational performance in children with ADHD. Such an analysis could highlight the best intervention to implement in a broad sense (e.g. small group work, learning via a computer-based service, coaching or pharmacological treatment).
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8.3 IMPLICATIONS FOR DIFFERENT STAKEHOLDERS
In this section, the implications of this thesis on the burden of ADHD will be discussed for several stakeholders, at the level of the patient, the individual patient-physician relationship and at the higher policy level.
8.3.1 Implications for patients, parents and associations Patients and parents know what it is to live with ADHD and can indicate what they need. Therefore, they should be involved in decision making and in shaping new initiatives in ADHD care. Involvement of patients and parents is especially relevant 
in the field of ADHD since there is a constant and broad impact on all aspects of daily life for patients and parents. Especially since ADHD is a disorder in children 
with persistence into adult age it influences a person’s entire life. A policy letter written for the European Ministerial Conference on Health Systems of the World Health Organization (WHO) in 2008 highlights this need with the title ‘Where are the patients in decision-making about their own care?’ 19. This policy letter mainly highlights the item of informing patients (health literacy) and shared decision making (SDM), where patients are involved as active partners with their physician. Optimally, such an involvement would evolve beyond information sharing and SDM based on available therapies and should focus more on co-creation.  In the Netherlands, two associations for ADHD patients are present: Balans and Impuls&Woortblind 20,21. A positive trend on patient co-creation was found in a recent initiative for updating and improving ADHD guidelines for diagnosis, treatment and follow-up, since this guideline will be drafted in cooperation with amongst others these associations 22. The involvement of these experienced-
based experts needs to be prominent so these updates will provide more specific guidance for the individual patient situation including the parents. The results of this thesis could be used in the guideline discussions with special attention paid 
towards the importance of compliance for QoL and costs incurred, the finding of association of QoL in children and parents and the large contribution of inattentive symptoms. 
 A relevant task for patient associations can be to share scientific evidence 
on ADHD in the public domain. An increase in interactivity on scientific results could improve the public dialogue. Usually, the truth is far more nuanced than 
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reflected in news items or press releases and TV and radio often let a single sceptic 
analyze an influential body of research. Media need quick content that is easily 
understood and fitting into current ideas. Next to the need of the media exists the need for scientists to grab attention in order to attrackt funding. The line between ‘selling’ a story (and ‘hyping’ it) beyond this evidence to get noticed is not a easy task. Associations could play a role in ensuring that messages from research are translated into the public domain in an accurate and appropriate manner. A more 
pro-active attitude could be relevant next to responses to over-selling statements from both scientists and media. The results of this thesis could help patients and possibly mainly parents to place the societal discussion into perspective by the conclusion that when diagnosed with ADHD impact is present. There is a risk of a lower QoL which should be carefully monitored and medication might be a relevant treatment option which will be most effective when being compliant.  
8.3.2 Implications of results for physicians and guideline development
The findings on the association of a lower QoL without response to treatment (based on compliance and functioning) indicates that there is room for improvement in the treatment of children with ADHD. The diagnostic interview 
and history taking (anamnesis) is the very important first step in the treatment of 
all patients and ADHD in particular to get an overview of patient’s difficulties in different life domains (home, school, friends). In practice, the anamnesis is often based on a descriptive conversation and an interpretation by the physician. Based on our study, it could be considered to use the KS-10 for every child at baseline with follow-up once or twice a year. Especially since our study showed that the 
QoL dimensions ‘felt sad’, ‘felt lonely’, ‘usual activities’ and ‘anxiety/depression’ accounted for the largest difference in QoL, the more internalizing problems should be carefully captured in the anamnesis. 
 This thesis specifically showed the adverse consequences of non-compliance 
to treatment. When pharmacological treatment is prescribed or studied, a specific focus should be applied to the compliance to medication with the concepts of the I-change model in mind (thesis introduction) 23. The I-change model assumes that behavior is determined by a person’s motivation and this motivation is built 
from the factors attitude, social influences and self-efficacy. Again, these factors 
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are influenced by various awareness factors (e.g. knowledge about ADHD). When drafting a protocol for future studies or treatment improvement these elements 
should be involved in order to find angles for clinicians to improve their guidance 
for children with ADHD using (pharmacological) treatment. Next, the current evidence and future data on interventions improving compliance should be captured in clinical guidelines. The recommendation in this paragraph to improve compliance assumes 
the use of methylphenidate (MPH) to be beneficial in ADHD treatment which is in line with the consensus of national and international ADHD guidelines 8. However, a recent meta-analysis by the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG) on the use of MPH concluded that the magnitude of effect of MPH on ADHD would be uncertain 24. Meta-analysis can be a reliable source of information, but only under the condition that the meta-
analysis is performed in a transparent way taking into account existing guidelines 
for meta-analysis conduction. For example, the risk of bias of the included studies by the CDPLPG differed from the Cochrane Handbook 18.  This CDPLPG review used 
very strict criteria for assessment of the underlying evidence. Next, the guidance 
for defining types of studies included was not followed and consequently, the multimodal treatment study of children with ADHD (MTA) was mentioned to be placebo-controlled whereas it is not 25. All 185 included randomized controlled trials (RCTs) were assessed as having a ‘high risk for bias’. In this respect, a great deal of importance is assigned to the so-called ‘vested interest bias’: funding by any 
party that might be considered to have a conflict of interest (e.g. a manufacturer of MPH). The vested interest bias is not described as a bias domain in the Cochrane Handbook, whereas it was added by the authors of the CDPLPG. Furthermore, the authors considered trials with one or more unclear risks of bias domains as trials with a high risk of bias. Normally, when bias in a certain domain is unclear in a Cochrane review these studies are assigned to the ‘unclear risk of bias’ group as was presented in a recent meta-analysis on ADHD and use of amphetamines 26. Irrespective of these limitations in methodology, the results of the meta-analysis on MPH were embraced without criticism followed by the recommendation to use non-pharmacological interventions in ADHD treatment instead 27. However, a meta-analysis on non-pharmacological interventions for ADHD concluded that ‘evidence is not strong enough to form a basis for clinical practice guidelines’ 28. 
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The analysis of the MPH meta-analysis highlights that physicians should remain to be critical on studies performed and especially the methodology applied, since underlying methodological choices are critical for the implementation of the results in clinical practice. The call by the CDPLPG for more long-term studies on use of MPH in itself is of course welcome, as this is relevant for all disease areas and pharmacological therapies used. In this light, two Dutch studies already focus on the long-term use of MPH and the developing brain 29. 
8.3.3 Implications of results for health care organization and policy-makersThe thesis indicated several points of interest for treatment and policy for children with ADHD. ADHD is associated with loss of QoL, parents are affected, costs for society are high and educational challenges are present. Recent questions by Members of the Dutch Parliament on ‘the ADHD-epidemic’ highlight the need of policy-makers for information on ADHD. The questions raised are relevant, but framed and normative due to the use of the word ‘epidemic’ and focused solely on increased medication use referring to medicalization instead of assuring the best care for those that need it 7. The answers of the Dutch State Secretary of Health Welfare and Sports highlighted the focus on an action plan based on a previous Health Council report 3,22. This action plan calls for a joint approach for appropriate 
ADHD care including timely interventions by qualified physicians embedded in a sequence of interventions where health care and educational facilities are 
integrated. Next to this, further studies should be performed to provide an overview 
of the benefit and necessity of pharmacological interventions as part of treatment for ADHD 7,22. A specific part of the action plan refers to an action to further study 
the possible influence on the pressure to perform in society and a link to increase of ADHD or ADHD-like behavior 22. This relates to the aforementioned discussions on ADHD as a result of societal changes. Before these results are clear and the role of societal changes can be changed, children and parents should be offered care 
for their existing symptoms and needs.
8.3.3.1 A specific focus on interpretation of cost-effectiveness resultsThis burden of illness study that was focused on ADHD provided data to be used in future cost-effectiveness modeling. 
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The Netherlands health care system has a substantial national coverage and therefore is confronted with the question which treatments and pharmaceuticals 
should be included in the benefit basket 30. The basic care package is subject to annual change based on certain decision criteria to assess the package. The Healthcare Institute uses the following criteria to assess the content of the basic 
benefit package: 30 
1. Care should be essential: Does the illness, disability or the care needed justify a claim on 
solidarity within the existing cultural context? 2. Effectiveness: Does the intervention do what it is expected to do? In other words: it is prov-en to be effective and evidence based. 3. Cost-effectiveness: Is the ratio between the cost of the intervention and the outcome acceptable? 4. Feasibility: Is it feasible to include the intervention in the basic package, now and in the future?  As stated in the introduction of this thesis, the main purpose of Health Technology Assessment (HTA) is to inform policy decision making. HTA is a method to obtain a systematic and overall insight in a certain health issue and accompanied interventions in order to support decision-making and resource allocation. The cost-effectiveness analysis (CEA) is the most often performed part. But that is what it is: one part of HTA. Therefore: the outcome of a CEA can never be the sole basis of a policy or clinical decision and should always be integrated in a broader discussion on epidemiological implications, medical effectiveness, social characteristics, 
ethical implications, and financial/economic aspects. Our study shows a probability between 93 and 99% for the long-acting MPH being cost-effective for children responding suboptimally to treatment with short-acting MPH, but this does not necessarily mean that all children responding suboptimally to short-acting mph should be transferred to long-acting MPH. So, results of health economic studies should still be viewed in light of a broader discussion as described previously. This broad discussion counts when different pharmacological treatment options are reviewed, but is also relevant since non-pharmacological treatment options 
often lack cost-effectiveness data. For example, Mindfulness-Based Therapies and 
physical exercise for ADHD show promising results in reducing ADHD symptoms and improving functioning (both inattention and hyperactivity/impulsivity), but these interventions should also be subjected to cost-effectiveness analysis and need further analysis based on HTA before recommended as part of a treatment 
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regimen and/or the insurance package 31,32. In such a way, all possible treatment modalities would be evaluated according to the same scrutiny, which is different from today’s situation.  Irrespective of these considerations regarding cost-effectiveness studies, the Dutch Health Care Institute published a report ‘Kosteneffectiviteit in de praktijk’ (Cost-effectiveness in practice) with the focus of an increasing role of cost-effectiveness as criteria in the overall package assessment 33. The report states that societal limits need to be established to decide what interventions 
should be included in the Dutch basic benefit package for health care based on 
maximum costs per quality adjusted life year (QALY) that should vary per disease 
burden: Disease burden 0.10-0.40 = Maximum cost per QALY €20.000; 0.41-0.70 = €50.000 and 0.71-1.00 = €80.000 33. The Healthcare Institute is working on how 
the basic benefit package should be defined, using cost-effectiveness as well as the concept of disease burden. Especially in case of ADHD, this report should be 
critically reviewed by all parties in health care, including ethical experts, as the perception of disease burden of certain diseases with such an approach could 
have a large influence on the content of the basic benefit package.  Another focus of the Health Care Institute is the integration of cost-effectiveness data in clinical guidelines 33. It could be questioned if integration of cost-effectiveness in clinical guidelines is the way forward. The Dutch health care system is referred to as an egalitarian system: efforts should be directed 
to mitigating existing health inequalities 34. An integration of cost-effectiveness into clinical decision making would relate stronger to the utilitarian standpoint: 
maximizing output of health care 34. In essence, health economics is not contrary to medical ethics, even though it can be discussed whether physicians should become responsible for cost containment in health care. If physicians want to play a role 
in cost containment they should focus on the entire field of cost-effectiveness, not 
only referring to cost of medication. Perhaps physicians cannot be expected to 
fully understand the field of health economics and to apply the principles in daily practice. In that case, their core-business should remain a focus on the treatments 
they would want to use to maximize the health of each individual while taking 
into account benefits and adverse consequences of certain interventions. Next, costs should be a matter of policy makers; they should judge if funding optimal 
treatments is possible, for example based on HTA including cost-effectiveness studies. 
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8.3.4 Implications for media and public 
As described in paragraph 8.3.1, it is relevant to share scientific evidence in the public domain in an accurate and appropriate manner. This is of relevance for both 
media and scientists that try to sell their findings via press releases and media 
needing quick content that is easily understood and fitting into existing stereotypes. In general in the media, stories need to be attractive and therefore less nuanced than they in reality are. Then again, if the public mainly reads the attractive and controversial stories, media is not the only one to blame for increasing the focus on these messages. The general tendency of media coverage is out of scope for this 
thesis, but some reflection on the consequences on the aforementioned trend are presented in the light of the main question underlying this thesis. 
 In case of ADHD, media has an influence in strengthening misperceptions and stigmatizing beliefs about patients suffering 35. The often firm attitudes of oppo-nents are putting pressure on one single cause, answer or solution regarding ADHD. Further, the focus on ADHD in this respect is striking. The neurodevelopmental section of DSM-5, lists ADHD, learning disorder, tics and Autism Spectrum Disorder 
(ASD). When taking ASD as an example with similar diagnostic options, presence 
at a young age and deficit in social interactions, a totally different movement is 
present with for example the ‘Autism Speaks’ campaign which was broadly shared on social media 36,37. Similar to ADHD, the DSM-5 made changes to ASD criteria: all previous subcategories (e.g. Asperger syndrome) were compiled into one category: ASD. Also, the need for symptoms before a certain age was changed to ‘symptoms in the early developmental period 37. While little complaints were expressed for this change in age limit when it comes to ASD, major issues raised in case of ADHD 38-41. ADHD is not the same for everyone, so the individual story and accompany-ing needs should be leading in discussions on ADHD. It always relates to the 
severity and problems experienced. Media should behave responsibly when issuing certain claims, be aware of the consequences and should facilitate more often in communication with several scientists in order to provide balanced stories that lead to in-depth discussions where different standpoints are accepted.
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APPENDIX 1 
SUPPORT AND FINANCIAL DECLARATION 
Financial support by Janssen-Cilag BV, Breda, the Netherlands. A. van der Kolk is 
an external PhD student of Radboud University Nijmegen as well as an employee of 
Janssen. As external PhD student, there was no scholarship at Radboud University 
for execution of the thesis. The support of Janssen on this thesis is part of the general focus on development of employees. Janssen provided the possibilities, 
but was not involved in the scientific content of the thesis. Janssen funded the fees for use of the respective questionnaires, attendance of congresses for A. van der Kolk, fee for use of the website used for data collection, printing costs, and article-processing fees. No sabbatical was provided by Janssen to pursue this project. Janssen was involved in approval of the study protocols, but solely on the basis of general procedures regarding data collection where privacy aspects and possible safety reporting are checked. Content of the thesis should be attributed 
to the author, and do not necessarily reflect the company perspective. The start of this project was marked by the employment of A. van der Kolk at Janssen-Cilag BV. 
Her knowledge and experience on ADHD regarding the perception of the general public on ADHD raised the question for objective data on the impact of ADHD. It 
was concluded that an objective image on ADHD as a disorder would be of benefit for all parties involved in ADHD, especially for patients and their families. The project started low key with literature reviews, but eventually the conclusion was 
drawn that the only way to study this topic objectively would be a scientific study based on data collection and systematic literature review followed by publication of these results via peer-reviewed journals. Based on further discussions, it was concluded that the form of a PhD thesis would be ideal as this would allow for 
thorough research with dedicated support by experts. The hypotheses was that ADHD would have a major impact, however, at the time this had not been studied in an integrated manner. The results of the study verify the hypothesis. The results 
of this thesis do not necessarily fulfill a commercial benefit to Janssen. The focus 
of the thesis is not specifically on treating ADHD with medication, but on treating better – focused on achieving compliance to medication and other treatments for 
ADHD in general. Four of five papers were published and therefore peer-reviewed 
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by independent experts in the field and available in the public domain. The fifth manuscript is submitted for publication and will be publicly available as well.  The patients’ and parents’ association Balans was not reimbursed for participation. They consented to the data collection via their members by means of an invitation that was added to their quarterly magazine. Balans received the 
questionnaire, but did not influence the study in any way. The letter as provided 
to the members of Balans can be found in appendix 2. The website SurveyMonkey was used for the online data collection (www.surveymonkey.com). This website and domain name were based on an account of the Institute for Medical Technology Assessment (iMTA) of the Erasmus University Rotterdam, with which the study was performed. Data generated by 
the SurveyMonkey questionnaire was assembled in an Excel sheet provided to the iMTA and was shared with A. van der Kolk. Parents/caregivers received a code for entering the website where the questionnaire could be completed, so when a person was not a member of Balans, he or she would have no access to 
the questionnaire. The questionnaire could be filled in only once per IP address. However, the IP addresses were not traceable by Janssen nor by the iMTA. The choice was made to list iMTA as the sender of the questionniare to avoid any bias. This was declared towards both Balans and iMTA by means of a letter.  Parents of children with ADHD who participated in the research via Balans were not reimbursed. Respondents in the control group were reimbursed for participating, since this is common practice in this kind of population research. Both samples were not made aware that Janssen was the founder of the study to avoid bias in any way.  Promotor prof. dr. J.K. Buitelaar (BIG-nummers 09020377201 and 89020377216) is Professor of Psychiatry and Child- and Adolescent Psychiatry at Radboud University and head of Karakter Child and Adolescent Psychiatry University Centre. He was not reimbursed for his work related to this PhD thesis. Jan Buitelaar has been in the past 3 years a consultant to/member of advisory board and/or speaker for Janssen BV, Eli Lilly, Roche, Lundbeck, Medice, Shire, and Servier. He is not an employee or stock shareholder of any of these companies. 
He has no other financial or material support, including expert testimony, patents, 
and royalties. Prof. dr. J.K. Buitelaar has registered his financial relationships in the Dutch Healthcare Transparency Register (DHTR) (www.transparantieregister.nl). 
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The DHTR is established by physicians, healthcare providers and - institutions and companies with the aim of being transparent concerning the cooperation between healthcare parties. Further information on Dutch regulations on PhD studies and funding for universities can be found in the law on higher education (wetten.overheid.nl/BWBR0005682/2016-01-01).  Co-supervisor dr. L. Hakkaart-van Roijen from the institute of Medical Technology Assessment (iMTA) of the Erasmus University Rotterdam received reimbursement for time invested, in accordance with iMTA’s standard agreement 
for external PhD students. She was invited by prof. dr. J.K. Buitelaar to join the 
project based on her expertise on QoL and societal cost assessment in general and 
for ADHD specifically. The study protocols for data collection of both samples as well as the questionnaires for both the ADHD sample and for population controls were drafted in cooperation between all supervisors and A. van der Kolk. The 
questionnaires were built from three existing questionnaires. Information on these questionnaires and manuals can be found at www.kidscreen.de, www.euroqol.org 
and www.imta.nl. L. Hakkaart-van Roijen has no further conflict of interest.  Co-supervisor dr. M. van Agthoven was an employee of Janssen-Cilag BV until September 2014 and did not receive any additional remuneration for his involvement in this PhD thesis. M. van Agthoven worked for Gilead Sciences from October 2014 until June 2016. This company is not involved in psychiatry. His co-supervision from October 2014 until June 2016 has happened fully in leisure time. From July 2016 onwards M. van Agthoven works at Janssen-Cilag BV. The members of the manuscriptcommittee that evaluated this thesis, prof. 
dr. B.G.M. van Engelen, dr. E.M.M. Adang and prof. dr. F. Boer have no conflicts of interests to declare. 
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APPENDIX 2 
LETTER ATTACHED TO THE MAGAZINE OF THE ASSOCIATION BALANS
Rotterdam, september 2010Betreft: onderzoek naar ADHD
Geachte mevrouw/heer,
Het institute for Medical Technology Assessment (iMTA) aan de Erasmus Universiteit Rotterdam voert een onderzoek uit naar de gevolgen van ADHD. Hierbij wordt gekeken naar de kosten van behandeling en naar de kwaliteit van leven van kinderen met ADHD en hun ouders/verzorgers (hierna ouders). Deze informatie vormt een waardevolle aanvulling op de huidige kennis over ADHD en de impact op kinderen en hun ouders. 
Voor dit onderzoek vragen wij de medewerking van ouders van kinderen tussen de 8 en 18 jaar oud met de diagnose ADHD. Graag zouden wij de vragen stellen aan de ouder die het meest betrokken is bij de zorg voor het kind (of de kinderen) met ADHD. Als u dit wilt doen dan stellen wij dat zeer op prijs. 
Via onderstaande link komt u op een website waarop de vragen staan. Met behulp van de code kunt u inloggen op de site. Het invullen van de vragen zal ongeveer 20 minuten duren. De resultaten worden anoniem verwerkt en kunnen dus niet met u of met uw kind(eren) in verband gebracht worden. 
De vragenlijst bestaat uit twee delen: Deel I heeft betrekking op uw kind en bevat o.a. vragen over de hoeveelheid contacten met hulpverleners, school en de kwaliteit van leven van uw kind. Deel II heeft betrekking op de ouder die het grootste deel van de dag de zorg voor het kind draagt. De vragen in dit deel hebben betrekking op zorggebruik, werk en kwaliteit van leven van de ouder. Er staat per pagina vermeld of de vragen over het kind of over de ouder gaan.Link: www.adhdonderzoek-imta.nl 
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(U kunt dit intypen in de balk bovenin het scherm van de zoekmachine 
op uw computer). Inlogcode is: A2m8B21Kp
De vragenlijst is beschikbaar tot 1 oktober 2010. 
Bij voorbaat hartelijk dank voor uw deelname en voor uw tijd. Uw informatie zal in belangrijke mate bijdragen aan de vergroting van kennis over en beter inzicht in de impact van ADHD. Hiervan kan gebruik gemaakt worden om het omgaan met ADHD voor betrokkenen te optimaliseren.
Met vriendelijke groet, 
Clazien BouwmansInstitute for Medical Technology Assessment aan de Erasmus Universiteit Rotterdam
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SUMMARY
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder in children and adolescents (hereafter referred to as child/children) and is highly persistent into adult age. The worldwide-pooled prevalence of ADHD in children is 5.3% and comorbidity is often present. Gene-environment interactions appear to be the main aetiological mechanism underlying ADHD. As with virtually all psychiatric disorders, no diagnostic tests are available to establish the diagnosis and therefore the diagnosis of ADHD is based on a combination of behavioral 
symptoms. The most often used classification system worldwide is the Diagnostic and Statistical Manual for Mental Disorders (DSM). 
ADHD is often topic of debate, especially in the light of a rising incidence which seems to distract from the public health and societal implications. Many studies on the impact of various aspects of ADHD are available, but the impact was not studied in an integrated manner. Especially in case of health policy making and health care provision it is essential to understand the overall burden of ADHD based on a societal perspective (direct and indirect non-medical costs and direct medical costs) to be able to provide appropriate interventions. When studying the burden of ADHD it is important to take quality of life (QoL) of the child and the parent and societal costs into account. In clinical practice, ADHD symptom reduction is one of the goals of treatment followed by improvement of functioning in important life domains. Guidelines describe the pivotal role of medication in the 
management of ADHD with unanimous recommendations for stimulants as first-line pharmacotherapy.  Studies show that without treatment, children with ADHD 
experience poorer outcomes in most life areas. Also, continued and compliant treatment results in improved functioning compared to treatment discontinuation or non-compliance (not following the treatment regimen as prescribed by the doctor). Moreover, the problem of non-compliance is described as an obstacle in ADHD treatment. For this study it was deemed necessary to include both short-term (symptoms) and long-term (functioning) effects of treatment to capture 
all relevant aspects of the burden of suboptimal treatment use. A pre-defined 
definition to operationalize both the concept of compliance and functioning is used to study the effects of suboptimal treatment use: ‘response to treatment’. 
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The overall problem statement of the thesis is ‘What is the individual, interpersonal 
and societal impact of ADHD in terms of quality of life and societal costs related 
to response to treatment? ’. The emphasis is placed on the role of response to ADHD treatment as it is considered relevant to show what the effect of optimal pharmacological treatment is for patients and society.
The thesis is divided into three parts, each part of the thesis highlighting the burden of ADHD, either focusing on the measurement of QoL, presenting QoL and societal cost data, providing literature-based evidence or comparing ADHD data to population controls.
Part I, ‘Quality of life’, explores two QoL instruments for use in ADHD studies and presents QoL data for ADHD. Chapter 2 specifically focuses on the validity and responsiveness of the generic preference-based EuroQol-5 dimension instrument (EQ-5D) and the generic QoL questionnaire KIDSCREEN-10 (KS-10) in children with ADHD. This chapter presents that QoL can be accurately measured using these instruments in an ADHD sample. The two instruments are complementary as they measure different constructs of QoL. EQ-5D is an appropriate instrument 
for measuring QoL in children if needed to calculate utilities; when more specific information is requested for clinical use there can be a preference for KS-10. 
Chapter 3 shows that QoL according to EQ-5D and KS-10 is significantly lower for children who are non-responders to ADHD treatment compared to responders to ADHD treatment; the QoL of parents shows the same trend implying the relevance of family involvement in the treatment pathway. The association between 
treatment response and children’s QoL is significantly influenced by age category, having a sibling with ADHD, and presence of comorbidity.
Part II, ‘Societal costs’, describes societal cost data related to ADHD and provides insight in factors associated with educational and academic performance in children with ADHD. Chapter 4 reports on the association between societal costs and treatment response in children with ADHD and their parents. The study shows that monthly costs for children with ADHD are much higher for non-responders to treatment compared to responders and the same trend applies to their parents. 
Chapter 5 focuses on a specific part of ADHD burden and studies factors associated 
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with ADHD and educational and academic performance via a systematic literature review. The main source of educational challenges seems to be related to the inattentive symptoms of ADHD. Educational outcomes are shown to be improved using small group work, learning via a computer-based service and as a result of coaching and pharmacological treatment. 
Part III, ‘Comparison of an ADHD sample and population controls’, shows data of the ADHD sample as presented in part I and II compared to population controls to further identify the burden of ADHD. Chapter 6 shows that significantly higher monthly societal costs are reported for children with ADHD and their parents vs. population controls. The higher costs in the ADHD sample are primarily related to the children’s doctor consultations, children’s training, children’s coaching at school and parent’s productivity losses (absence and absenteeism). Further, QoL 
in both children with ADHD and their parents is significantly comprised compared to population controls. The lower QoL in children with ADHD is mainly associated 
with internalizing problems such as sadness and anxiety and is associated with the QoL of their parents. 
The main conclusion of this thesis based on the different chapters is conclusive in one direction: the individual, interpersonal and societal impact of ADHD is high. The lower QoL in children with ADHD is mainly associated with internalizing problems and is associated with the QoL of their parents. Future studies, including cost-effectiveness studies and systematic literature reviews, should focus on interventions aimed to improve response to treatment in order to limit ADHD burden as well as focus on topics that improve educational performance in children 
with ADHD. Next, the anamnesis by the physician (diagnostic interview and history 
taking) could be extended by use of the KS-10 or EQ-5D as part of the clinical 
assessment providing more insight in the specific elements impacted by ADHD. Patients and parents should be involved in decision making and in shaping new initiatives in ADHD care. Further, a relevant task for patient associations would 
be to share scientific evidence on ADHD in the public domain to place the societal discussions into perspective. This study adds to current literature on real-life cost and QoL in ADHD patients, which is amongst others of fundamental importance for future cost-effectiveness analyses in order to aid reimbursement decisions. 
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With respect to media reporting, it is relevant to share scientific evidence in the public domain in an accurate and appropriate manner. Media should offer balanced stories that lead to in-depth discussions where different standpoints are accepted. This could contribute to less opposing opinions towards ADHD and its treatment, which might reduce stigmatization and accompanied troubles for children with ADHD and their environment. 
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SAMENVATTING
Attention Deficit Hyperactivity Disorder (ADHD) is een neurobiologische ontwikkelingsstoornis bij kinderen en adolescenten (hierna vermeld als kind/kinderen) en houdt vaak aan tot in de volwassen leeftijd. De wereldwijde prevalentie van ADHD bij kinderen is 5.3% en kinderen met ADHD hebben vaak comorbide stoornissen. Het onderliggende etiologische mechanisme van ADHD lijkt een interactie tussen genen en omgeving te zijn. Zoals bij de meeste phychiatrische stoornissen is er bij ADHD geen diagnostische test beschikbaar op basis waarvan de diagnose is vast te stellen. De diagnose ADHD wordt dan ook vastgesteld op basis van het combineren van verschillende gedragssymptomen. 
Het meest gebruikte systeem voor classificatie van psychiatrische stoornissen wereldwijd is de ‘Diagnostic and Statistical Manual for Mental Disorders’ (DSM). 
ADHD wordt veel besproken, met name als het gaat om een stijging in prevalentie. Deze focus lijkt af te leiden van het publieke gezondheidsprobleem en de sociale 
gevolgen van ADHD. Er zijn al vele studies verricht naar specifieke aspecten van ADHD, maar de impact van ADHD is nog niet op een geïntegreerde wijze onderzocht. Vooral bij beleidsvraagstukken in de gezondheidszorg is het van belang om een goed inzicht te hebben in de totale impact van ADHD gebaseerd op het maatschappelijk perspectief (directe en indirecte niet-medische kosten en directe medische kosten) om de juiste interventies aan te bieden. Bij het in kaart brengen van de impact van ADHD is het belangrijk om de kwaliteit van leven (kvl) van het kind en de ouder in kaart te brengen alsmede de maatschappelijke kosten die met ADHD gepaard gaan. In de klinische praktijk is het reduceren van de symptomen van ADHD een belangrijk doel, gevolgd door verbetering van het functioneren van het kind in verschillende levensdomeinen. Richtlijnen beschrijven de centrale rol van medicatie in de behandeling van ADHD waarbij een unanieme aanbeveling wordt gegeven voor stimulantia als eerstelijns farmacotherapie. Studies laten zien dat zonder goede behandeling kinderen met ADHD een minder goed functioneren in verschillende domeinen van hun leven ervaren. Daarnaast is ook een continue behandeling samen met het nauwkeurig opvolgen van een voorgeschreven behandeling (compliance) van belang om een goed functioneren te bereiken. Wanneer de behandeling wordt onderbroken 
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of er wordt niet nauwkeurig opgevolgd wat er door de arts is voorgeschreven (non-compliance) neemt het functioneren af. Het probleem van non-compliance is dan ook beschreven als een obstakel in de behandeling van ADHD. In deze studie wordt het van belang geacht om zowel de effecten van behandeling op de korte termijn (symptomen) als op de langere termijn (functioneren) mee te nemen om een goed beeld te kunnen schetsen van de gevolgen van een 
sub-optimale behandeling. Een voorafgedefinieerde beschrijving waarin de concepten compliance en functioneren worden geoperationaliseerd is gebruikt: ‘behandelrespons’. De algemene onderzoeksvraag van deze thesis is ‘Wat is de 
individuele, interpersoonlijke en maatschappelijke impact van ADHD uitgedrukt in 
kwaliteit van leven en maatschappelijke kosten gerelateerd aan de behandelrespons? ’. De nadruk is gelegd op het belang van behandelrespons bij de behandeling van ADHD omdat het van belang wordt geacht aan te tonen wat het effect is van een optimale medicamenteuze behandeling voor patiënten en de maatschappij.
De thesis is opgedeeld in drie delen waarbij elk deel een aspect van de impact van ADHD belicht, hetzij met een focus op het meten van kvl, het presenteren van kvl data en data over maatschappelijke kosten, een beschrijving van de literatuur of door vergelijken van data van een groep met ADHD met een groep uit de algemene bevolking.
Deel I, ‘Kwaliteit van leven’, onderzoekt twee instrumenten om de kvl bij ADHD te meten en presenteert gegevens over de kvl bij ADHD. Hoofdstuk 2 gaat specifiek in op de validiteit en responsiviteit van het algemene EuroQol-5 instrument (EQ-5D) waarbij de score omgezet kan worden in een waardering van de kvl. Daarnaast is gekeken naar de algemene kvl vragenlijst KIDSCREEN-10 (KS-10) bij kinderen met ADHD. Dit hoofdstuk presenteert dat kvl in een groep kinderen met ADHD valide gemeten kan worden met beide instrumenten. De instrumenten zijn aanvullend op elkaar aangezien ze verschillende constructen van kvl meten. Wanneer het nodig is om utiliteiten te meten is de EQ-5D een geschikt instrument, wanneer 
er meer specifieke gegevens nodig zijn over de kvl kan er een voorkeur zijn voor de KS-10. Hoofdstuk 3 laat zien dat op basis van de EQ-5D en KS-10 de kvl van 
kinderen zonder behandelrespons significant lager is dan van kinderen met een behandelrespons; de kvl van de ouders laat dezelfde trend zien en geeft daarmee 
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aan dat het relevant is om ook de familie in het behandeltraject te betrekken. 
De associatie tussen behandelrespons en de kvl van kinderen wordt significant beïnvloed door leeftijdsgroep, het hebben van een broer of zus met ADHD en de aanwezigheid van comorbiditeit. 
Deel II, ‘Maatschappelijke kosten’, beschrijft de maatschappelijke kosten gerelateerd aan ADHD en biedt inzicht in factoren die geassocieerd zijn met prestaties van kinderen op school. Hoofdstuk 4 rapporteert over de associatie tussen maatschappelijke kosten en behandelrespons bij kinderen met ADHD en hun ouders. De studie laat zien dat de totale maandelijkse kosten van kinderen met ADHD veel hoger zijn bij kinderen zonder behandelrespons (non-responders) vergeleken met kinderen met een behandelrespons en deze zelfde trend gaat op voor de ouders van deze kinderen. Hoofdstuk 5 kijkt naar een specifiek deel van de impact van ADHD, namelijk de factoren die samenhangen met resultaten op school op basis van een systematische literatuurstudie. De voornaamste oorzaak van het onderpresteren op school lijkt gerelateerd te zijn aan de symptomen van aandachtstekort van ADHD. De schoolresultaten lijken te verbeteren door het werken in kleine groepen, leren via een computerprogramma en door toedoen van coaching en het gebruik van farmacotherapie.  
Deel III, ‘Vergelijking van een ADHD groep met een controlegroep’, laat data zien van een groep kinderen met ADHD zoals gepresenteerd in deel I en II en deze data wordt vergeleken met een controlegroep om de impact van ADHD verder te onderzoeken. Hoofdstuk 6 laat zien dat de maandelijkse kosten van kinderen 
met ADHD en hun ouders significant hoger zijn vergeleken met de controlegroep. De hogere kosten zijn voornamelijk gerelateerd aan doktersbezoeken van kinderen, training en coaching van kinderen en productiviteitskosten van ouders (afwezigheid en absenteïsme). Verder is de kvl van kinderen met ADHD en hun 
ouders significant lager dan die van de controlegroep. De lagere kvl bij kinderen met ADHD is vooral geassocieerd met internaliserende problemen zoals verdriet en angst en is tevens geassocieerd met de kvl van hun ouders. 
De hoofdconclusie van deze thesis op basis van de verschillende hoofdstukken 
wijst overtuigend in één richting: de individuele, interpersoonlijke en maat-
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schappelijke impact van ADHD is hoog. De lagere kvl van kinderen met ADHD is hoofdzakelijk geassocieerd met internaliserende problemen en is geassocieerd met de kvl van hun ouders. Toekomstige studies, inclusief kosteneffectiviteitsstudies en literatuuronderzoeken, zouden zich moeten focussen op interventies die tot doel hebben de behandelrespons te vergroten met als doel de impact van ADHD te verkleinen. Tevens zouden toekomstige studies zich moeten richten op onderwerpen die de schoolprestaties van kinderen met ADHD kunnen verbeteren. De anamnese van de arts (het diagnostisch interview) kan worden uitgebreid 
met de KS-10 of EQ-5D zodat er meer inzicht ontstaat in de specifieke elementen die worden beïnvloed door ADHD. Kinderen met ADHD en hun ouders moeten worden betrokken bij besluitvorming rondom zorg en andere initiatieven rondom ADHD. Verder is een belangrijke taak van patiëntenorganisaties om wetenschappelijke kennis op een juiste wijze in het publiek domein te brengen zodat de maatschappelijke discussie in perspectief wordt geplaatst. Deze studie draagt bij aan de bestaande literatuur over de kosten en kvl van kinderen met ADHD in de praktijk. Deze data is onder andere van fundamenteel belang voor toekomstige gezondheidseconomische analysis en pakketbeslissingen. De data over ADHD die wordt gepresenteerd in de media moet gebalanceerd zijn zodat ze tot goede discussie kunnen leiden waarin verschillende standpunten naar voren komen. Dit kan bijdragen aan een situatie waarin sprake is van minder stigmatisering van kinderen met ADHD en hun omgeving.
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DANKWOORD 
Het doel van dit boekje was vooral om de impact van ADHD op het individu, gezin en de maatschappij helder te maken, en om daarbij zorgvuldig te beschrijven dat een zeer gedegen assessment van ervaren problemen geboden is. Iedereen heeft een mening over ADHD, zowel professionals als leken. Deze mening is vaak gebaseerd op beperkte informatie of op krantenkoppen die meestal op een wijze geformuleerd worden zodat het lezers zal trekken en daarmee vaak een negatieve toon hebben. Lastig, want het maakt je soms toch aan het twijfelen. Mensen vinden ook altijd iets en daarbij gaat op dat internet en TV veel bijdragen aan het uitdragen 
van visies die veelal aan het einde van een spectrum liggen (extreem voor of 
extreem tegen). Echt weten welke kanten er aan een verhaal zitten is er vaak niet bij, maar de tweet is er al wel uit. 
 De term ‘PhD’ staat voor Doctor of Philosophy afkomstig van het Griekse woord ‘philosophia’ wat letterlijk betekent ‘liefde voor wijsheid’. In Nederland wordt meestal gekozen voor Dr. voor een naam. Voor mij gaat op dat ik die liefde wel ervaar, maar dat ik vooral het gebruik van deze kennis relevant vindt. Wel lastig soms, want meestal draagt een studie slechts een klein deel aan de gehele kennis bij, dus ook mijn studie gaat niet de wereld veranderen. Maar hopelijk draagt deze kennis iets bij voor kinderen met ADHD om hun mogelijkheden optimaal te kunnen benutten. Het afronden van een proefschrift zou verder het bewijs zijn dat je in staat bent zelfstandig een onderzoek uit te voeren, het behalen van de zogeheten ‘proeve van bekwaamheid’. Naar mijn mening kan niemand geheel zelfstandig onderzoek doen. Een eindresultaat is volgens mij altijd iets wat uit gezamenlijkheid ontstaan is. Juist dit overleggen, feedback vragen, zoeken naar verbetering en nieuwe ideeën toelaten zorgt ervoor dat een eindproduct een gebalanceerd geheel wordt. Als je enkel alleen blijft nadenken zorgt dat net als bij ‘wie is de mol’ voor een tunnelvisie en ga je je slechts richten op zaken die aansluiten bij wat je al denkt. Sowieso blijft te allen tijde de vraag wat de waarheid is. Tijdens 
mijn opleiding Gezondheidswetenschappen volgde ik het vak wetenschapsfilosofie. Een fantastisch vak dat wat mij betreft meer wetenschappers moeten volgen om open te blijven staan voor meer dan enkel p-waarden. Vanuit dit idee was 
het ook fijn om dit boekje te schrijven terwijl ik ook werkte bij Janssen en dus meekreeg hoe bepaalde discussies in de praktijk vorm kregen. Janssen heeft mij 
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de kans geboden voor een langdurig ontwikkelingstraject waarin ik verschillende vaardigheden kon opdoen en waarvan ik nu kan vieren dat dit project met succes is afgerond! 
Respondenten en vereniging Balans: Allereerst veel dank aan de ouders die de moeite hebben genomen om een zeer lange vragenlijst in te vullen. Ik stond echt versteld van het aantal reacties. Zonder data geen analyse, dus heel hartelijk dank! Voor mij gaf deze hoge response de toewijding aan van de ouders om een bijdrage te kunnen leveren aan kennis over de aandoening van hun kinderen en de wens om het omgaan met ADHD te optimaliseren. Zonder Balans was de studieopzet niet mogelijk geweest, dus ook veel dank voor het mede mogelijk maken van deze promotie.
Prof. dr. J.K. Buitelaar, Jan: Graag wil ik professor Buitelaar hartelijk danken voor 
het feit dat hij dit traject met mij in wilde gaan. Een eer om met deze expert te mogen werken en kennis mee te krijgen van de vele jaren ervaring op het gebied van ADHD. De bijeenkomsten waren helder en gezellig. De feedback die ik van u ontving over bepaalde onderwerpen uit het nieuws getuigden van bijzonder veel kennis van zaken en van een genuanceerde visie. Dank voor de blijvende positieve insteek en opleiding in hoe het nu echt in zijn werk gaat in de wondere wereld van het publiceren. Ook daarin was steeds de nuance aanwezig bij bijvoorbeeld mijn vraag of ik al een mail kon sturen hoe het nu stond met mijn indiening: ‘sommige 
editors zijn snel, voor anderen kan een vriendelijke aansporing geen kwaad’. Ook leuk was uw reactie na publicatie van mijn eerste paper als eerste auteur ‘altijd iets 
om trots op te zijn, je zelf in druk te zien!’. Een conclusie die kan worden getrokken over de beschrijving van de geschiedenis van ADHD is dat men spreekt over kinderen met een achterblijvende ontwikkeling van het karakter in plaats van het verstand. Des te mooier om te promoveren bij een professor die werkzaam is bij een centrum met deze naam. Daarbij ook dank aan Bregje van Uden en Nadine Schalk van Karakter voor het altijd vriendelijk beantwoorden van mijn vragen en het organiseren van de afspraken. 
Michel: Hoe het allemaal begonnen is, op 5 juni 2009 toen in mijn hometown het idee ontstond peer-reviewed artikelen te schrijven. Opvolgend ons bezoek aan de 
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Kapittelweg in Nijmegen waar we naar buiten liepen en ik nog aan je vroeg: ‘Maar… 
begrijp ik nu goed dat ik ga promoveren?’. Tjah, dat begreep ik goed. Nog niet helemaal beseffend welke voeten het allemaal in de aarde zou hebben. Onder andere op pad naar Venetië (ik herhaal, Venetië) naar onze nieuwe vriend Massimo om mijn eerste poster te presenteren op het congres Costs and Assessment in Psychiatry van het International Center of Mental Health Policy and Economics. Wat doe je dan? Natuurlijk, lego poppetjes op bruggen zetten en foto’s maken! Mensen die keken er vreemd van op (en wel een beetje terecht natuurlijk). De poppetjes hebben uiteindelijk de kaft niet gehaald, maar ik heb er wel goede herinneringen aan. Ook in het begin, toen ik dit hele project nog steeds als grap omschreef, had en hield jij er vertrouwen in dat het goed ging komen. Het is een heel leerproces geweest waarin we veelal de humor konden blijven zien, ook na afwijzing nummer 7. Met het analyseren van de data was het naast serieus ook gezellig. Collega’s waren zelfs meerdere malen in de veronderstelling dat wij computerspelletjes aan het spelen waren, edoch (zeg ik dat eigenlijk vaak?) het enige programma dat openstond was toch echt SPSS. SPSS en statistiek, zaken die voor jou peanuts waren, maar waar ik stress van kreeg. Des te leuker om te merken dat ik nu zelf ga denken: laat ik dat eens even uitrekenen J. Uiteraard bel ik je daarna alsnog, maar een kniesoor die daar op let. Dat komt natuurlijk deels door de simpele uitleg die jij kan geven, over bijvoorbeeld een regressieanalyse: ‘Het 
doel zou kunnen zijn om een voorspelling te maken over de lengte van vrouwen en 
het aantal dates dat ze heeft per maand’. Nu met mijn eigen slides over het relatief risico, odds-ratio en construct validiteit krijg ik een stuk minder stress; ik zoek het op (en heb meteen lol door voorbeelden met hond-poes-konijn). Nog steeds 
blijf ik schrijven 10x leuker vinden dan SPSS, dus dankjewel voor het geduld en 
het keer op keer uitleggen dat ‘split file’ en ‘select cases’ echt andere dingen zijn en hulp in het weekend met suggesties als ‘het begint met een t en het eindigt op 
test’. Gelukkig heeft SPSS wel ook nog humor met het aanmaken van dummies waarbij ik dan moest denken aan de vrolijke doosjes met roze, oranje of gele snoepjes. Het ging bij het analyseren steeds om de hamvraag (die bleek te komen van de NCRV de quiz ‘Mastklimmen’); wat wil je weten? We zijn gedurende het traject meerdere malen Hothoiaanse taferelen tegen gekomen, maakten we veel gebruik van het onvolprezen notepad, vele zeurneuzen (een woord dat je niet zo vaak hoort), slap geleuter, soepkippen, viel er wel eens iemand uit een lift (het 
239
Dankwoord
zogeheten lift-incident), kregen we luie mails die over de schutting werden gepleurd, en allerhande prietpraat; waarom dat erbij hoort, dat weet niemand. Ook moesten we vaak lang wachten op feedback en ging ik mails sturen aan het editorial bureau met de strekking “Since we are very curious on the progress, 
especially myself” J. Ook waren er wel eens misverstanden toen ik in een TC vol met collega’s enthousiast riep: ‘Michel en ik werken bij mij thuis aan mijn promotie….’. Anyways… In ditzelfde kader stuurde ik jou een linkje met Fokke en Sukke over ADHD, maar dan moet die link natuurlijk wel op het juiste plaatje openen…! Je 
profiel met nummer 46 (René weet dan genoeg) botste soms met mijn 148. 
Gelukkig hebben phdcomics.com en de modern talking megamix het regelmatig kunnen relativeren en vooral de 100.000 kattenplaatjes die over en weer gegaan zijn (want real men love cats). Bij het sturen van een plaatje van buurhond Ollie was je reactie dan ook onverbetelijk ‘Gatsie, een hond!!!’. Daarnaast vele goede en slechte grappen over ‘baby changing’, ‘friends of Bill W.’, knorretje, mails over het verschil tussen Michel en andere mensen op tijdstip 7:39, wát Wildi? met dank aan Karin, solliciteren met een das (HAHAHAHAHAHAHA), een review ala het lokale suffertje, gesprekken over Iwaaaan op vakantie, in te kleuren vakjes met 
bruin (TE flauw), krantenknipsels uit de wakkerste krant van Nederland met als titel ‘wat is een kattenleven waard? en daarbij i.p.v QALY verwijzen naar HALY en KALY’, Dr. G.H. Koek en Dr. J.W. Kruimel die een kamer delen, en nog veel meer. Verder veel glazen tonic, appelsap (altijd goed), thee (rooibos vs. earl grey), bier en wijn die zouden volgen. Overdoen zou ik het nooit, blij zijn dat ik het heb meegemaakt: zeker! Gelukkig zijn er uiteindelijke vele prachtwerkjes verschenen al was het soms moeilijk, zoals bij JCPP in 2012 ‘Boeh... meteen afgewezen!!’. Op welke locaties hebben we aan onze prachtartikelen gewerkt waar je mij als levende Tom-Tom telefonisch naartoe kon begeleiden in vaak mijn toenmalige Japanse allemansvriendje (hierbij zie ik uiteraard een plaatje van stationsgebied Amsterdam voor me met plaatje van een wc)? In elk geval in Venetië (naar de odd-size), Berlijn, Madrid, Sweet Lake City (met Snuf en in het wanstaltige NH aan de Danny Kayelaan), heel vaak Utrecht city (o.a. aan mijn keukentafel in Oudwijk met Kris de poes, bij BCN en bij Buurten met rietjesappelsap), Berkel en Rodenrijs, Amsterdam, Wiesbaden, Dordrecht, heel vaak Rotterdam (iMTA, bij de gansjes & Inntel (om 18.26), bij restaurant Water waar kapsalon echt op de kaart stond en we Astrid in real life hebben gezien – het blijft jammer dat we (nog) niet op TV 
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mochten bij 2 voor 12, maar wat niet is kan nog komen!), Vught (De Rosier met stempelkaart), Groningen (in B&B Het Paleis), Den Haag (helaas zonder Edith en Mark), Praag (alwaar wij ISPOR board of directors werden én waar ik een discussie 
had met de toen voor mij onbekende Niek Klazinga J), Nijmegen (Karakter), 
Maastricht (waar de titel tot stand kwam in café de Poshoorn), Leidschendam, Capelle aan de IJssel, Amstelveen (De witte bergen), Gorinchem (met vrolijke verjaardagsparty), Eemnes, Breda (good old Mastbosch ‘aha, de mensen van de appelsap’), Ulvenhout, Oisterwijk, Oosterhout, Tilburg (211a), Beerse, Sprang-
Capelle, Amersfoort en dan mis ik er vast nog een paar. Jammer dat het kattencafé Amsterdam nog niet bestond. De kroketten van Annie zijn onvergetelijk, het eten in BCN Utrecht wil ik niet zo nodig herinneren, maar Venetië was dan weer fantastisch! En alle keren dat jij ineens de slappe lach kreeg en dan weer ‘ojee, 
vreselijk’ zei, hoe leuk is dat! Dankjewel voor je doorzettingsvermogen en enthousiasme (Wooooowwwww!! - GEWELDIG - SUPER - Greeeeeeaaaaaattttt!!! – GOED BEZIG phdtje!!!) en elke keer ‘suc6 of ssssssuuuuuuuccccccceeeeessssss!’ wensen, zelfs als we artikelen moesten gaan lezen over daytime sleepiness, jij bleef vrolijk - Of course!! Je bent een LV-RD-88 en natuurlijk soms een beetje een 77-ZR-PT, en dan werd ik gillend gek van de ‘hierbij in rood mijn comments’ of ‘nog 
wat extra puntjes’ of een hele specifieke voorkeur voor het woord nonetheless. Maar dat heb je toch nodig om ergens te komen, want ‘stiekem zijn dit dan toch 
wat reviewer comments waar we best blij mee mogen zijn!’ en waren er niet voor 
niet document titels als ‘20140904 Integratie data Balans en Gfk Mitchel is een held’. Je had leraar willen worden, wat ook soms nog wel eens om de hoek kwam kijken met opmerkingen over het verschil tussen de Germaanse taal en de Angelsaksische taal (???!). Fijn om nu in het WE niet meer aan de PhD te typen of naar Zoetermeer te moeten om data analyses te doen. Want AM is van PhD2Be nu 
toch echt PhD Anne-Mary: I like. Hoewel een PhD een tiny, insignificant step for mankind is, is het zoals jij vaak zegt: een giant leap voor Michel en Annemarie. Je hebt in 2014 nog eens gedroomd dat mijn PhD klaar was en ik Ahoy had afgehuurd voor mijn feestje. Dat laatste was een beetje te gortig, maar we hadden al vele malen afgesproken dat we veel drank willen als het klaar zijn, en zeker na deze laatste hick-up die niemand voor mogelijk had gehouden, maar: we kunnen, yessssss!
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Leona: Super dat jij als Associate professor health economics and health technology assessment mijn copromotor wilde zijn. Mijn eerste artikel over ADHD dat ik van Michel kreeg was jouw artikel uit 2007. Heel leuk dat we nu samen op de opvolgende papers staan en we na bijna 8 jaar een nieuw stukje bijdragen aan de kennis over deze burden of illness. Dankjewel voor de vele reviews van mijn teksten en de bijeenkomsten in Utrecht. Het is jouw kracht om bij de materie te blijven en je niet af te laten lijden voor wetenschappelijk niet-onderbouwde standpunten die helaas wel de krant halen. Het is inderdaad zonde van je tijd om te investeren in meningen die als basis een onderbuik gevoel hebben en die tevens de werkelijkheid van patiënten en naasten ontkennen. Dank voor deze visie. 
Clazien: Vanaf het eerste moment betrokken bij het inzichtelijk maken van de kosten die horen bij ADHD, eerst nog op basis van literatuur, daarna op basis van het data-onderzoek. Bijzonder dat jij samen met Leona en Saskia de Nederlandse kostenhandleiding hebt geschreven die gebruikt is voor deze studie. Daarnaast heb jij de contacten gehad met ouders van kinderen met ADHD die een vraag hadden, uiteindelijk toch het meest belangrijk, want dat zijn de mensen waar we deze studie voor hebben uitgevoerd. Daarnaast staat het paper over de EQ-5D en KIDSCREEN zowaar op een Wikipedia. Dankjewel voor de samenwerking en geniet van het thuis zijn nu. Saskia: Nog een van de auteurs van de kostenhandleiding. Deze kostenhandleiding kon ook gebruikt worden bij het opzetten van de aanpassing van het Health Economics model. Een aantal indieningen later ligt er een prachtig stuk met een mooie groep auteurs. Je hebt hiervoor vele avonden en weekenden doorgewerkt, ook al was je al begonnen met een nieuwe studie psychologie. Jij ook succes met de afronding van je eigen boekje en in elk geval dank voor de samenwerking voor het mijne! Susan: Inhoud is het meest belangrijk, maar het moet er ook wel aantrekkelijk uitzien en daar kwam jij voor om de hoek kijken. Ik ben heel blij met hoe het boekje is geworden, precies de uitstraling die ik zocht!
Janssen-Cilag BV: Janssen laat zich leiden door sociale en maatschappelijke verantwoordelijkheden. Vanuit deze visie heb ik de mogelijkheid gekregen om 
onderzoek te doen naar de gevolgen van ADHD. Ik dank Janssen voor de financiële steun die ik heb gekregen om dit project te kunnen volbrengen met daarbij veel mentale ondersteuning die nodig was om mijn werk en deze PhD te kunnen combineren. 
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Anneke, niet helemaal sinds het begin, maar al lange tijd kamergenoten bij Janssen. 
Eén van de mensen die eenzelfde werkopvatting heeft als ik en die me soms met 
één vraag aan het denken kan zetten: ‘Annemarie, is dit nou wel zo verstandig?’. We hebben menig levensles gedeeld, waaronder “The more you see, the less you 
know. The less you find out as you go. I knew much more then than I do now” van jouw grote helden van U2. Je zei daarbij dat als je heel jong bent, je heel goed denkt te weten hoe alles zit, naarmate je ouder wordt en steeds meer weet wordt alles steeds grijzer. En onze conclusie is daarmee ook dat we milder worden en vaker kunnen denken: ‘zij doen het blijkbaar zo’. Bedankt voor het luisteren, het meedenken en je opbeurende mails! Silvia, je hebt me erg geholpen met je oneliners en opbeurende teksten. Je bent vanaf 2012 mijn coach in het kader van timemanagement, maar de gesprekken die we hebben zijn veel meer dan enkel mijn werk in goede banen leiden. Ik heb veel gehad aan de zinnen ‘Wil je gelijk 
of wil je geluk’ en ‘Groeien gaat nu eenmaal gepaard met pijntjes’. Je eerlijke en daarmee ook confronterende feedback vind ik super, het komt altijd uit een goed 
hart. Deze mail was ook een fijne: ‘Basje gaat trotst zijn joh! En je paps ook! En je 
mams, vanwaar ook ze je haar kracht en liefde en wijsheid stuurt, OOK’!. Dankjewel dat je er altijd in geloofd hebt dat ik het zou redden en dat je met me mee wilde denken hoe ik niet enkel mezelf, maar ook anderen hiervan kon overtuigen. Je tomeloze energie werkt aanstekelijk! Annekes en Sil, jullie samen zijn het perfecte duo om mij morele bijstand te verlenen en mijn zenuwen in bedwang te houden op de dag van mijn verdediging. Daarnaast bleken jullie ook tijdens het moeilijke einde van dit traject geschikte ondersteuners om te zorgen dat ik niet op zou geven en zou blijven geloven in de goede opzet van het onderzoek en de relevantie van de gepresenteerde uitkomsten.
Susan, al in 2014 spraken we voor het eerst af, omdat ik niet te laat wilde starten met de opmaak van het boekje (deels ook omdat me dat het leukste onderdeel 
leek!). Het heeft lang geduurd, maar we zijn er! Het was fijn om af en toe de danseres erbij te pakken en me voor te stellen dat ze op de omslag stond, want dat droeg erg bij aan het volhouden van dit bizarre einde van vele jaren promoveren. Sowieso leuk om je te leren kennen en erg leuk om een beetje mee te volgen hoe het gaat met je bedrijf en welke opdrachten je aan het doen bent.
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De liefste papa, van de Meene school in Zelhem naar het Ulenhof College in Doetinchem en toen helemaal naar Maastricht. Als afsluiter van mijn studie in Maastricht ook nog 3 maanden Soedan. En wat ik dan het allerleukste vind is dat jij de eerste bent die zegt: ‘Ik kom langs!’. De beste tijd daar was met jou en tante Manny. Wel even slikken toen jullie weer weggingen, maar het onthaal op 
Schiphol was daardoor nog fijner. Een kleine periode Nienhuis in Zelhem waar ik bij jou terecht kon in huis. Daarna ging ik naar Utrecht, vervolgens kwam de baan in Tilburg die in het begin niet altijd even gemakkelijk was, en jawel, er ging ook nog gepromoveerd worden. Je conclusie was wel vaker dat ik teveel wilde. Gelukkig kon ik altijd bij jou op de bank terecht voor wijze vaderlijke adviezen waaronder ‘wat je wilt dat kun je’ en ‘het is de kunst jezelf te blijven’. Voor jou was het niet altijd helemaal helder waar ik qua onderwerp mee bezig was, maar je bent er trots op. Zonder opleiding en ondersteuning van thuis was dit niks geworden, dus dankjewel! We zeiden het al na Soedan: ‘Nu kan ik alles’. Ook toen was ik superblij dat het voorbij was en tevens superblij dat ik het had meegemaakt. Dat is ook nu weer zo. Soms is het niet zo makkelijk, maar samen komen we er wel. Twee vierdaagses hebben dat ook laten zien, ‘kom op Annie, we gaan weer’. Dit grote werk heeft ook weer meegegeven de zaken stap voor stap aan te pakken en steeds te genieten van wat je al wel bereikt hebt: houd goede moed! Hans&Nancy en Marjan&Geert, dank dat ik altijd bij jullie terecht kan. Hans, jij hebt al vele praktische tips gegeven voor mijn leven überhaupt en Marjan, de dagjes sauna ter ontspanning zijn altijd welkom! Fijn dat er uitbreiding van de familie is met Noa&Kiki en Taro&Izar. Toke, alweer een hele tijd van de partij en daar ben ik erg blij mee. Dankjewel voor je hartelijkheid en interesse in wat ik aan het schrijven was. Mia, ook jij zo trots als een pauw! Een belangrijke bijdrage is natuurlijk het bestaan van Bas, maar jouw enthousiasme en trots waren niet minder relevant. Hoe onwerkelijk dat jij in november geheel onverwacht overleden bent. We missen je enorm, dag lieve Mia. Van Joost&Aletta houd ik de belangrijke tips ‘Mind your own business’ goed in gedachten en kom ik af en toe katten knuffelen ter ontspanning. Tante Manny, ook steeds geïnteresseerd en betrokken. Gedurende de jaren vele activiteiten ondernomen samen en bij ons in huis is gemiddeld alles óf van papa gekregen óf van tante Manny en mag Bas het dus niet wegdoen J. Je motto ‘gaat het niet zoals het moet, dan moet het maar zoals het gaat’ blijft een nuttige om in gedachten te houden, ook bij projecten zoals deze.  Oma, we hebben 
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het niet zozeer over mijn proefschrift, maar vaak aan de hand van foto's komen er mooie verhalen over hoe het leven vroeger was. De bezoekjes zijn altijd plezierig. 
Tante Margreet, fijn dat we contact hebben en af en toe een dagje afspreken om bij te kletsen over het leven en de familie.
Joost: De bouwsteen van het hele project. Zoals je weet was je sheet met je hele uitwerking van het idee ‘het in kaart brengen van de invloed van ADHD’ nogal overweldigend. Ik kwam koud van de universiteit en toen kwam er een wervelwind van ideeën op me af. Dankzij jouw idee ligt dit boekje er, dankjewel! 
Eliane: Natuurlijk superleuk, iemand die gaat promoveren. Maar er worden vrij snel vragen gesteld over ADHD en temeer in relatie met de farmaceutische industrie. Dan komt er een radio programma en dan mag jij antwoorden verzinnen. Dank daarvoor! En dank dat je vanaf het begin enthousiast bent geweest over dit traject en de uitvoering ervan en meedenken over ‘hoe de hazen lopen’. Onze eerste ontmoeting was natuurlijk top en bij aardbeientaart kan ik enkel nog aan jou denken, jummie! Daarnaast was jij mede organisator van ‘de 5 juni bijeenkomst’ waar het uiteindelijk allemaal begonnen is. Baudowine: Wij zijn vele keren op 
pad geweest naar experts op het gebied van ADHD om te kijken of onze zoektocht in de literatuur naar de impact overeenkwam met de ervaringen in de praktijk; beide in onze hybride Honda. Heel leuk om te beleven en je hebt me daarmee ook meteen wegwijs gemaakt bij Janssen. Deelname aan het trio ‘BAM’ was ook een feest. De organisatie rondom de onderzoeksopzet was zonder jouw contacten niet gelukt. De samenwerking met Balans is hierin cruciaal geweest, na het uitpluizen van de verschillende mogelijkheden om een grote groep ouders van kinderen 
met ADHD in 1x te bereiken bleek dit de enige mogelijkheid en die is gelukt. Heel veel dank voor je hulp, enthousiasme en doorzettingsvermogen! Kathleen: Over doorzettingsvermogen gesproken, dan hebben we hier nog een goed voorbeeld! De vragenlijst moest geprogrammeerd worden en dat heeft veel meer voeten in de aarde dan je zou verwachten. Maar dankzij jou is dat fantastisch gelukt! Zo werd dankzij jouw speurwerk de functionaliteit gevonden om het opnemen van het IP-
adres uit te schakelen, werd de domeinnaam goed overgedragen en heb je wel 20x getest of de vragen nu echt goed stonden in Survey Monkey. Super bedankt voor je belangrijke bijdrage en betrokkenheid. Sjaak: Een kleine, maar heel belangrijke bijdrage. Op aanraden van Silvia ben ik nog eens met je gaan praten aangezien 
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ook jij een promotietraject had doorlopen tijdens je loopbaan. Begin januari 2014 
zaten we aan de koffie op de tweede verdieping in het leuke koffiehoekje. Jij hebt toen gezegd dat je om de vaart erin te houden had afgesproken met je gezin dat je zaterdagmorgen en zondagmorgen aan de slag ging. Je werkte dan van 8.00 tot 12.00, niet korter en niet langer. Dit bleek de gouden tip om het vol te kunnen houden, ook als de zon scheen. Daarnaast super om met iemand te kunnen werken die opgenomen is in het World Book of Hope! 
Stefan, Mieke, Liesbeth, Wendy, Heleen, Andrea, Joost, Hugo, Johan, Tom 
en nog vele collega’s. Vooral de afwisseling en de gezelligheid met jullie was belangrijk om de PhD te kunnen handelen. Het ontvangen van mails over vrouwen die minder vet verbranden als ze stress hebben, marktplaatsbestellingen doen, mails met ‘hoi super kanjer’, voeteren over ‘die kuttekop‘, leesvoer voor bij of in het 
haardvuur, delen van goed nieuws (mijn oor is open!), tips om een extra half uur uit te trekken om je weg te vinden in de metropool van het zuiden (Wagenberg), waardering voor post van Piet, Leonidas, bespreken van kunst van die andere Annemarie van der Kolk, levensvragen (hoe zou een duif nu naar huis vliegen?), 
HEMAR EMEA meetings én feestje met de look-a-like van Johan, verhalen over de 
Killer Kleuter van hondje Diva, weddenschappen voor flessen wijn, foto’s van witte bonen in tomatensaus, bijeenkomsten met slechts saaie mannen in grijze pakken, lol met de A’tjes, foto’s van Lola en Joris, plaatjes van Swift, gespreken over ome Jan, foefelen en rommelen, het bespreken van de vraag wat nu eigenlijk een separatist is, support voor de alcohol loze maand, het bespreken van het liefdesleven van Gordon, 
en niet te vergeten een heerlijke eindejaars afsluiting 2014 in Den Haag. Specifiek Smees, dank voor je praktische kijk op de wereld en de les dat het belangrijk is om thuis aardig gevonden te worden, maar dat het op kantoor gaat om resultaat. ‘Als 
dat in een vriendelijke sfeer kan is het mooi, maar dat is niet noodzakelijk’. Verder heeft de instelling dat we uiteindelijk met de beschikbare tijd de juiste afwegingen moeten maken geholpen en de conclusie die je al in mei 2014 trok ‘Dat gaat ons 
zeker lukken!’, die is uitgekomen!
Marieke, dankjewel dat je mijn vriendin bent en dat ik altijd bij jou op de bank kon en kan crashen als dat even nodig is om een avondje te maisen. Samen in Utrecht bevalt me heel goed! Jacobien, met jou begonnen in de wieg en nog vaak samen op pad. Fijn dat er altijd iemand is die mijn hele leven kent, mama heeft gekend en zelf 
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ook ondernemend is met het behalen van een studie naast werk en gezin. Heel fijn dat we nog steeds contact hebben! Jacobien, al vanaf de wieg samen, leuk is dat! Heel leuk dat wij nog steeds met elkaar in contact zijn en leuke uitstapjes maken! 
Mieke, dagjes sauna ter ontspanning waren noodzakelijk om de ontspannenheid te bewaren. Ook bezoekjes aan Haps en papa Theo als ook weekendjes Londen hebben hun bijdrage geleverd. Had jij nou kunnen denken tijdens onze Azië rondreis dat ik nog eens zou promoveren? Dat had de waarzegster op Khao San Road niet voorspeld J Maya, heel fijn dat we zo vaak ‘ja’ hebben gezegd en veel leuke activiteiten hebben beleefd in de PhD-jaren. En onvergetelijk natuurlijk dat we Mark tegenkwamen dankzij de NS kortingsbonnen! Toch al de tweede keer dat ik dankzij de NS een leuke man tegenkom. Anne, veel meegemaakt met jou! Het moet soms uit onze tenen komen om door te zetten, maar het lukt. Ik ben heel blij dat we vriendinnen zijn en je interesse hebt in mijn verhalen. Samen met Maya zijn we de museumclub, ik hoop dat we die nog lang in ere zullen houden! Lizanne, mede-PhD’er! Als een van de weinigen snapte je echt hoeveel moeite en tijd het kost om dit voor elkaar te krijgen en die wist wat discussies over parametrische danwel non-parametrische toetsen inhouden. Jij had in 2014 al een mooi boekje 
klaar en dat zette mij weer aan tot extra acties. Dank voor je betrokkenheid! 
Pleunie, dankzij jou vele ontspannende activiteiten ondernomen. We hebben een leuke tijd gehad in Breda en nog steeds in Utrecht city. Fijn dat je altijd in bent voor een spontaan ligconcert of iets anders om uit te proberen! Lineke, vanaf dag 1 van onze studie kennen we elkaar en wat leuk dat we nog steeds vriendinnen zijn! Je bent iemand waarbij ik geheel mezelf kan zijn en kan vertellen wat de twijfels zijn die er op dat moment leven. Op nog vele leuke activiteiten, ook al moeten we nu ATWT missen en doen we nu veel nuttigere dingen met ons leven. Sera, ook jou ken ik van onderwijsgroep 1 in Maastricht. Ook al wonen we nu ver uit elkaar, het contact blijft goed. Je bent ondernemend en gaat je angsten niet uit de weg, dat stimuleert mij ook weer om uitdagingen op te blijven zoeken. Yvette, na onze Soedanese avonturen nog steeds contact, leuk is dat. Je reist nog steeds graag en veel, maar gelukkig heb je als basis Den Haag gekozen en kom ik graag klussen met daarna uitrusten op het strand. Sandra, ja, eindelijk, je kunt een jurkje gaan kopen J. Heel leuk dat wij elkaar zijn tegengekomen ook al werkten we niet eens echt samen. Waar we ook zijn, lekker in je oversized tuin, op kantoor, achter een slagboom, of in een sauna waar bikini-dag is, altijd gezellig. Evelien, boeiend 
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om over je belevenissen als huisarts te praten, een wereld waarin de praktijk 
voorkomt waar ik vaker in theorie over bezig ben. Het is altijd fijn om aan de Röntgenlaan te komen en gezellig dat de mannen goed aansluiten in grappen – hoe meer bier hoe groter de lach J. Nienke, een doorvrager die kan doordringen tot de dingen waar ik graag overheen praat. Geïnteresseerd en beschikbaar voor kopjes thee en levenslessen. Nu lekker genieten in Curaçao en aan de slag met je eigen bedrijf. Daphne, jij bleef maar trots op mijn acties. Als het niet mijn huis was mét verbouwing dan zeker wel de PhD waar je met regelmaat naar hebt geïnformeerd; 
fijn met jou. Cornélie, ook jij bent gepromoveerd en kon daar mooie verhalen over vertellen. Ik heb weliswaar nog geen Penny fotostrip, maar dit boekje komt al wel een beetje in de buurt. Ria, Resi, Heleen en Hanny: wat leuk dat we na 3 jaar nog steeds om de zoveel tijd samenkomen in Bastacosi. Fijne avonden! 
Mijn lieve Bas! Je hebt niet het hele traject meegemaakt, maar stapte in op 28 april 2013. Het blijft een mega romantisch verhaal en ik denk nog vaak aan Koninginnedag/Koningsdag 2013 in Amsterdam; hoeveel toeval kun je hebben. Maar zoals je wel vaker zegt ‘vraag niet hoe het kan, maar profiteer ervan’. Je hebt de belangrijkste periode meegemaakt waarin ik naar een hogere versnelling schakelde en de publicaties echt tot een einde moesten komen. In die tijd hebben we mijn huis verbouwd en zijn we daar samen gaan wonen. Superspannend (voor mij dan J), maar het is een heel goede beslissing gebleken. Ik vind je de 
allerliefste, allerknapste, allerstoerste en allerleukste! Wat hebben we het fijn 
samen en wat fijn dat we altijd lol hebben, ook (en misschien wel vooral) bij de ‘oepsie’ momenten. Interessant ook dat jij in staat was lol te halen uit de saaie SPSS variabele SEKSEK. Dankjewel dat je me keer op keer vroeg als ik aan het werk was ‘dit is toch wel voor je PhD he?’. Je hebt me goed geholpen en vond het prima dat ik op zaterdag en zondagochtend ging typen al dacht je eerst even ‘gloep’. Wakker worden naast jouw vrolijke hoofd was zeker behulpzaam. Ik deed en doe mijn best nog meer zorgen mee te geven aan de vuilnisman en me een beetje van jouw evenwichtigheid eigen te maken. We kunnen nu het boekje af is nog meer genieten 
in ons fijne huis en ontspannen op de bank in slaap vallen (oh, heb jij het einde 
ook gemist?), ons vol in gaan zetten voor The Finest Vintage, nieuwe dansmoves ontwikkelen tijdens gala’s van Sirene, rondhangen in de e-type center, uit eten bij de HEMA en Utrechts Royaal, wonen op de Oudegracht, onze eigen lama, naar de 
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Parade, vreemde katten redden op straat, naar RTL Late Night, genieten op vrij dag, kijken naar fathertje Brown of Scotts & Bayleys, veeeeel water drinken als we thuis komen uit de stad, oppassen op Ollie, weekendjes naar Londen, Ripley de pipley of Harrogate, met onze toet in de zon zitten, kinderboerderijen bezoeken, de eerste prijs behalen bij het klassiekerweekend Ameland, een vaarbewijs halen, vakantie op Schiermonnikoog, nog meer Utregse kroegen ontdekken, rondrijden in mijn Porsche en jouw Bugatti (die uiteraard in de huiskamer staat) en niet te vergeten met de Morris (issie al af????). Sowieso gaan we nog vaker op pad om 
gebakjes te eten en koffie te drinken, mét een koekje! Joepie!


Hij liep daar in de stad 
's Avonds laat 
Plotseling aan de overkant 
Zag hij ze staan 
Iemand riep "Je hoort niet bij ons" 
Mes, steek, pijn 
Denk goed na aan welke kant je staat 
Denk niet wit, denk niet zwart 
Denk niet zwart-wit 
Denk niet wit, denk niet zwart 
Denk niet zwart-wit 
Maar in de kleur van je hart 
Maar in de kleur van je hart 
Donker was de straat 
Op weg naar het plein 
Een taxi, het is te laat 
Het is voorbij 
Wie wil er bloed op de achterbank 
Van de werkelijkheid 
Denk goed na aan welke kant je staat 
Denk niet wit, denk niet zwart 
Denk niet zwart-wit 
Denk niet wit, denk niet zwart 
Denk niet zwart-wit 
Maar in de kleur van je hart 
Maar in de kleur van je hart 
Frank Boeijen - Zwart-wit

A. van der Kolk
A. van der K
olk
EIG
H
T D
AYS A W
EEK
EIGHT DAYS A WEEK
The individual, interpersonal and societ
al impact of ADHD in terms
of quality of life and societal costs relat
ed to response to treatment
